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2Chairman's Introduction
Interest in research seems to be at an all-time high. Applications 
for RCS fellowships are increasing and the clinical trials 
initiative continues to develop. The National Institute for Health 
Research (NIHR) call for surgical trials resulted in nearly £28 
million being awarded. Much of this expansion in research 
activity reflects the growing enthusiasm among the trainee 
collaboratives that exist now on either a regional or national 
basis in virtually every surgical specialty. The 5 surgical trials 
centres have all made significant progress and along with the 15 
surgical specialty leads (almost every specialty has one), there is 
every sign that more new surgical trials are likely to be initiated 
in 2015 and beyond.
This expansion inevitably makes demands of the Research 
Committee and the Development Office to find the necessary 
funds to support this increased activity. Martyn Coomer and 
Johnny Fountain continue to promote all aspects of research, 
encouraging financial contributions through research evenings 
with potential donors across the UK. The College is grateful to 
them for the many evenings given up for fundraising, and to 
our research fellows who make presentations at these events. 
New funds this year include specific donations for research in 
obesity (The David Johnston Research Award) and surgical 
simulation (The Dinwoodie Charitable Company) along 
with partnership funding involving the British Association 
of Paediatric Surgeons, the National Joint Registry, the 
Circulation Foundation and the British Association of Plastic, 
Reconstructive and Aesthetic Surgeons. Once again there have 
been increased donations from Freemasonry and the Dunhill 
Medical Trust, two of our longest-standing and most generous 
benefactors.
To date we have concentrated on our research fellowships as a 
means of helping trainees achieve more substantial sources of 
funding towards an appropriate higher degree, and the clinical 
research initiative has focused on the development of clinical 
trials mainly to encourage surgical leadership for randomised 
controlled studies. Regarding research fellowships, the scheme 
is clearly successful. Two Fulbright fellowships to undertake 
research at the MD Anderson Cancer Center in Houston and 
Harvard University, Boston were awarded this year. Virtually 
every trainee who has received an RCS fellowship has gone on to 
achieve further funding. Some 40% of awards have resulted in 
a PhD. The clinical trials initiative has resulted in 15 new trials 
in surgery being added to the NIHR portfolio in the last year. 
These success stories do, however, have inevitable consequences 
that need to be addressed.
The increasing interest in undertaking research as part of 
surgical training creates a number of practical difficulties. 
While some trainees may choose to undertake research during 
core training, most request ‘out-of-programme’ time during 
specialist training. Increasingly, trainees are encouraged to 
undertake PhD as the higher degree. This may be problematic if 
large numbers of trainees within a discipline opt for this, within 
the current training system. While all surgeons benefit from 
exposure to research, some will enjoy the rigour of a PhD while 
others are more likely to be suited by a more clearly defined 
programme of shorter duration. There are practical solutions, 
but these require liaison between training committees, trusts 
and universities to accommodate trainees undertaking research 
to do on-call rotas. This would help those still in clinical training 
to gain greater experience of elective surgery as they could 
be freed from excessive on-call commitments and eliminate 
contrived rotas that limit day-time continuity of care. Some on-
call work, shared by trainees doing research, would allow them 
to maintain their clinical skills.
The success of the clinical trials initiative has accelerated the 
next stage of our research development programme. The 
introduction of new technologies, translational studies that 
bring laboratory based work to the bedside and bringing novel 
devices through to clinical application are all research areas that 
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3precede the randomised trial. In addition, studies that explore 
the utility of diagnostic tests or evaluate prognostic factors are 
not tested in randomised trials. Surgeons are involved in all 
of these studies. The introduction of new technologies and 
novel devices are particularly problematic and many good ideas 
founder in a plethora of regulatory processes and difficulties 
accessing the correct funding stream. To address this, the 
College has proposed a technology evaluation programme 
that will work in a similar way to the clinical research initiative. 
Collaborations with existing and new partner organisations 
(NCRI, NICE, MHRA, ABHI, CRUK, MRC, IDEAL) will 
result in a common portal of entry for the introduction of new 
devices and technologies. By using the expertise of the existing 
trials centres and specialty leads, it is hoped that this route 
can provide a rapid and informed opinion regarding the need 
for a new device or technology, the degree of interest in its 
development and future use, and how it can be evaluated. Ideas 
that seem worthwhile can then be taken forward with more 
detailed proposals. Some may be industry funded, others will 
require grant support, but the system should be more efficient 
than the current situation.
It seems that we are entering a period where a culture of 
research as part of the surgeon’s role is becoming more widely 
accepted. The College recognises the need to provide education 
for young researchers so that an understanding of clinical 
research methodology and participation in clinical trials, are 
seen as essential elements of training rather than optional 
extras. The training programme in trauma and orthopaedics 
now includes these elements within the curriculum and it is 
likely that other specialties will follow. A number of training days 
devoted to these areas have been organised by the trials units, 
for trainees at core and specialist levels this year. It is planned to 
make this training available nationally over the next 18 months. 
An important, yet often poorly appreciated element in the 
development of a clinical research proposal is formulating 
the right question and how best to answer it. This is heavily 
dependent on careful evaluation of existing evidence in a 
systematic fashion. In conjunction with the Clinical Effectiveness 
Unit, an Evidence Synthesis programme has been initiated to 
teach new investigators how to undertake this process correctly. 
Currently five systematic reviews are under way, covering topics 
in maxillofacial, ENT, hand, upper GI and neurosurgical 
disciplines.
What next? The momentum achieved by the clinical trials 
initiative must be maintained. Not all specialties began from 
the same point in terms of an existing or previous research 
culture, but there is an expectation that no specialty will fail to 
have a reasonable portfolio of trials in the future. We aspire to 
a situation where any patient attending a surgical clinic should 
have access to a study if they wish to participate in research. 
The success of the trials initiative, and the proposals to create 
a research pipeline from the laboratory through novel devices 
and technologies to randomised trials, has created interest 
across Europe. We believe that there are great advantages in 
an international approach to research, particularly for clinical 
trials. Hopefully, there will be news from our efforts in that 
area in 12 months. In the meantime, research will remain at 
the forefront of College strategy. The College acknowledges 
that these developments owe much to the drive and enthusiasm 
of our Director of Research, Professor Dion Morton, as well as 
the individuals from our partner organisations who provide 
oversight through the Clinical Research Initiative Steering 
Committee. Last, but by no means least, Sarah King and her 
team, who under the direction of Martyn Coomer, provide all of 
the administrative support to turn these plans into reality.
I’m sure all members of the surgical research community would 
join me in congratulating Norman Williams on being awarded a 
Knighthood in the recent New Years Honours.
An important,yet often poorly appreciated element 
in the development of a clinical research proposal is 
formulating the right question and how best to answer it. 
Fellowships are awarded to subscribing fellows or 
members of the College in a training post, or trainees 
who have passed the MCQ papers and will sit the final 
MRCS examination at this College. All applications 
are rigorously assessed by a panel of experts to 
ensure that the research, surgeon, supervisor and 
facilities are of a high standard, and that the proposed 
work will be valid, beneficial and original. The 
fellowships cover salary, on-costs and some running 
expenses. Fellows may study any aspect of surgery 
or surgical care including basic science, diagnosis, 
treatment, surgical technology, logistics or audit. 
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6Expanding the organ donor pool: 
preventing brain death induced kidney injury 
Kidney transplantation has been one of the medical success 
stories of the last half-century. It is the treatment of choice 
for patients with end-stage renal failure, offering both an 
improvement in their quality of life and also extending 
life expectancy. For example, a patient on dialysis will visit 
hospitals 3 to 4 times a week for several hours. A transplant 
offers freedom from visiting hospital and allows patients to 
return to work and to lead a normal life.
However, the major challenge in transplantation is the 
expanding waiting list, which now means that 1 in 3 patients 
will either become too unwell or die while awaiting a 
life-saving transplant. To address this transplant, centres 
are turning to donors who previously would not have 
been considered suitable for transplant, including older 
donors with more medical problems. In addition, despite 
improvements in immunosuppression (drugs used to prevent 
rejection of organs), the length of time a kidney works for 
after transplantation has not improved in the past decade. 
The aim of my research is to improve the quality and protect 
kidneys from braindead organ donors (our major source 
of kidneys for transplantation), thereby making previously 
untransplantable kidneys transplantable and to allow the kidneys 
to work for longer after transplant. Using a rat model of brain 
death, I have been characterising what molecules change 
in the kidney as a consequence of brain death process. The 
results have indicated that the way that energy production 
and metabolism occurs in kidney cells is drastically altered, 
leading to them being more prone to damage, even before 
the organs are removed for transplantation.
This has led to further work to determine if we can protect 
FELLOWSHIP/SPONSOR
Philip King Research Fellowship
SUPERVISORS
Professor Rutger Ploeg, Professor Christopher 
Pugh and Professor Susan Fuggle 
SITE OF WORK 
Old Road Campus, University of Oxford
PUBLICATIONS 
1. Akhtar MZ, Sutherland AI, Huang H, 
Ploeg RJ, Pugh CW. The role of hypoxia-
inducible factors in organ donation and 
transplantation: the current perspective 
and future opportunities. American 
Journal of Transplantation. 2014.
2. Rebolledo R, Liu B, Akhtar MZ, Ottens 
PJ, Zhang J, Ploeg RJ, Leuvenink HG. 
Prednisolone has distinct effects on the 
kidney and liver of brain dead rats. Journal 
of Translational Medicine. 2014.  
PRESENTATIONS:
1. World Transplant Congress, San 
Francisco, USA, 2014.
2. International Meeting on Ischemia 
Reperfusion Injury, Poitiers, France, 2014.
Further fundrasing
Medical Research Council for two years.
the kidneys by using novel drugs. This is a very new area of 
research that has real potential to result in expanding the 
number of kidneys available for transplantation. There is also 
a possibility that by protecting the kidneys at an early stage, 
we can make kidneys work for longer.
1 out of 3 patients will either die or become too unwell to receive a life-saving organ transplant while on the waiting list.
Mohammed 
Zeeshan Akhtar
Operating with a cardiothoracic surgeon and a urological surgeon to remove a renal tumour 
extending into the inferior vena cava and right atrium.
The Consortium on Organ Preservation includes Professor Sir Peter Morris, Professor Rutger 
Ploeg, Professor Jaques Pirenne, Professor Tom Minor and Professor Andrea Paul.
7Incidence and mechanisms of cerebral ischaemia 
following transcatheter aortic valve implantation 
compared with surgical aortic valve replacement
FELLOWSHIP/SPONSOR
Hong Kong Freemasons’ Fund for Surgical 
Research
SUPERVISOR
Professor Marjan Jahangiri and Professor 
Hugh Markus
SITE OF WORK 
St George’s University of London
PUBLICATIONS 
1. European Association of Cardiothoracic 
Surgery Annual Meeting 2013, Vienna, 
Austria
2. Society of Cardiothoracic Surgery in Great 
Britain & Ireland Annual Meeting 2014, 
Edinburgh, 
PRIZES
Ronald Edwards Prize, Best Oral Scientific 
Presentation, Society of Cardiothoracic 
Surgery in Great Britain and Ireland Annual 
Meeting 2014, Edinburgh.
PRESENTATIONS:
1. European Association of Cardiothoracic 
Surgery Annual Meeting 2013, Vienna, 
Austria
2.  Society of Cardiothoracic Surgery in Great 
Britain & Ireland Annual Meeting 2014, 
Edinburgh,
Further fundrasing
Medtronic for 2 years.
Transcatheter Aortic Valve Implantation (TAVI) is now 
considered standard of care in inoperable patients with 
severe aortic stenosis and as an alternative to aortic valve 
replacement (AVR) in those deemed high risk for surgery. 
However, neurological injury is significantly higher in 
patients undergoing TAVI compared with AVR. Different 
mechanisms have been proposed to account for this injury, 
mainly cerebral embolisation (particles that get dislodged to 
the brain) and hypoperfusion. The primary aim of this study 
was to compare the potential mechanisms of neurological 
injury following TAVI and AVR.
127 high-risk patients with severe aortic stenosis were 
recruited into the study, 85 of whom underwent TAVI and 
42 underwent AVR. A range of outcomes were measured 
to assess cerebral embolism, cerebral oxygen saturation, 
cerebral lesions and cognitive function using transcranial 
Doppler, cerebral oximeter, MRI and neurocognitive 
assessment to give comprehensive profile of cerebral health.
We have shown that the number of cerebral emboli did 
not differ significantly between TAVI and AVR. There was 
no difference between the two groups in the incidence of 
cerebral desaturation. The cerebral desaturation during 
TAVI is mild and lasts for a short period of time with no effect 
on neurological outcomes. There was also no significant 
difference in the acute cerebral ischaemic lesions detected 
on MRI between TAVI and AVR. Interestingly, the majority 
of the lesions detected in our study resolved at three months 
follow-up scan. We have also shown that both groups showed 
better neurocognitive function at three months.
Our findings indicate that the incidence and mechanisms of 
neurological injury in patients undergoing TAVI are similar 
to those undergoing AVR. We suggest that less emphasis 
should be placed on the increased neurological injury 
associated with TAVI compared with AVR and, therefore, 
TAVI may be offered to moderate risk patients with severe 
aortic stenosis.
Aortic valve narrowing is a common form of heart valve disease affecting up to 10% of people over age 75.
Aiman 
Alassar
Aiman in theatre getting ready to perform neurological monitoring
8Cancer causes more than one in four of all deaths in the UK. 
Often surgery offers the only cure; however, surgery may not 
be possible if the cancer has spread to other organs. This 
applies to many solid tumours, including breast, lung and 
prostate cancer.
Angiopoietin-2 (Ang2) is emerging as a key molecule 
in the growth and spread of cancer. Studies have found 
that blocking Ang2 can decrease the size and spread of 
cancer, as well as improve other conditions such as chronic 
inflammation and sepsis. A specific Ang2 blocker that could 
be administered to patients with minimal potentially harmful 
side effects does not exist yet.
Our study used computer modelling and a novel technique 
that accelerates the process of evolution to develop a drug 
that blocks Ang2. Using these methods a new drug was 
created called R3 which blocks Ang2 specifically.
Further attempts were made to improve R3 by making subtle 
alterations to it to better understand how it works. R3 was 
also combined with a potent detector of inflammation called 
Vascular Endothelial Growth Factor Receptor 1 (VEGFR1), 
which increases R3’s efficacy and ability to target areas of 
inflammation and new blood vessel formation such as in cancer.
Test tube experiments have shown R3 to be effective and 
work has now begun on animal models of disease. Future 
work will concentrate on testing this new drug’s ability to 
reduce inflammation and disruption of blood vessels as 
well as understanding how it works. Improvements in our 
understanding will help improve the health outcomes of future 
patients. We now have the first Ang2 specific trap, which could 
benefit the elderly suffering from advanced inoperable cancer, 
chronic wounds and sepsis.
Structure-function insights into the 
Angiopoietin-Tie2 system
FELLOWSHIP/SPONSOR
Joint RCS/Dunhill Medical Trust Fellowship
SUPERVISOR
Professor Nicholas Brindle
SITE OF WORK 
University of Leicester
PRESENTATIONS
1. The European Society of Translational 
Medicine 2013
2. The European Society of Plastic and 
Aesthetic Surgeons 2014Djalil 
Baiou
Deaths from cancer rise with increasing age and the majority of cancer deaths occur in those aged over 65 (77%). 
The research lab team at University of Leicester Djalil in Clinic
9The aim of our work is to advance the understanding of 
the mechanism of chronic sinusitis and ultimately drive the 
development of new sinusitis therapies in place of surgical 
procedures.
Nasal and sinus cells were harvested from participants 
undergoing operations for chronic sinusitis. Comparator 
healthy control cells were also isolated from participants 
undergoing keyhole pituitary gland surgery (a gland on the 
base of the brain) via the nose. Epithelial (nasal lining) cells 
and fibroblast 
(supporting 
framework) 
cells were 
collected 
and grown 
in laboratory 
tissue culture 
conditions. 
Their identity 
was carefully 
characterised 
and verified 
using 
molecular 
biological 
techniques. 
Cells were 
stimulated 
with known 
environmental 
causes of 
sinusitis 
including viruses, bacteria and oxidative stress particles. The 
inflammation response was studied in detail.
We have established and validated a cellular model to study 
the inflammatory relationship between two key cell types in 
the nose and sinuses. We have shown in sinusitis patients’ 
cells for the first time that nasal surface (epithelial) cells 
can activate supporting fibroblasts. We think that these 
fibroblasts then promote further inflammation. These 
activated fibroblasts may be the key step when a patient starts 
to develop chronic sinusitis. Our model of the epithelial and 
fibroblast cell interactions allows me to go on to investigate 
how environmental insults may lead to the development of 
chronic sinusitis within my PhD fellowship.
The disease mechanisms of chronic rhinosinusitis have not 
been widely studied. This is probably reflected in the lack of 
new medical treatments for chronic rhinosinusitis during the 
past few decades. This RCS project will continue to develop 
following the award of a Wellcome Trust Research Training 
Fellowship for the next three years.
Our longer-term plan is to continue the project thereafter, 
with the ultimate aim of delivering clinical trials of novel 
therapies as an alternative to surgery for patients. The 
position of the nose and sinuses places them as ideal 
candidates for the development of locally applied medicines, 
and thus also avoid the problems of oral steroids or 
antibiotics, which are the current best available treatments.
Sinonasal epithelial innate immune signalling in 
chronic rhinosinusitis
FELLOWSHIP/SPONSOR
Shears Foundation Northern Fellowship
SUPERVISORS
Professors Janet Wilson, Andrew Fisher and Derek Mann
SITE OF WORK 
Institute of Cellular Medicine, Newcastle University Medical School
PUBLICATIONS 
1. Stephen Ball, Anthony De Soyza, Andrew Fisher, Derek Mann, 
Janet Wilson. Airway remodelling in chronic rhinosinusitis; 
is epithelial – fibroblast signalling to blame? The Journal of 
Laryngology and Otology. 2013. 
2. Stephen Ball, Anthony De Soyza, Andrew Fisher, Derek Mann, 
Janet Wilson. Are pro-inflammatory fibroblasts the driving 
force in chronic rhinosinusitis? Clinical Otolaryngology 2012; 
37: 1–2.
PRESENTATIONS
1.  Airway remodelling in chronic rhinosinusitis; is epithelial – 
fibroblast signalling to blame? Royal Society of Medicine, 
Section of Laryngology and Rhinology. London, February 2013.
2.  Are pro-inflammatory fibroblasts the driving force in chronic 
rhinosinusitis? British Academic Conference in Otolaryngology, 
Glasgow, 2012. 
PRIZES
1.  Royal Society of Medicine, Section of Laryngology and 
Rhinology. Annual short paper prize. February 2013.
FURTHER FUNDING
Wellcome Trust Clinical Research Training Fellowship for three 
years
Stephen 
Ball
Chronic rhinosinusitis is one of our commonest conditions, affecting up to 12.5% of adults. Its disease mechanism is 
not understood and current medicines often fail, requiring surgical treatment.
Stephen with his supervisor Professor Janet Wilson in theatre 
recruiting research participants
10
Understanding how cancer arises and continues to grow 
ignoring normal cellular control signals is therefore 
fundamentally important to our understanding of this disease 
process and will lead to novel future treatments. When cells 
divide they copy and separate their genetic material, DNA, 
exactly between the two daughter cells. This process of cell 
division is precisely controlled by protein kinases, which act as 
molecular switches ensuring the proper order of cell division. 
When this process goes wrong, cells can end up with the 
wrong number of chromosomes (aneuploidy), which is one of 
the hallmarks of cancer.
The Aurora Family of kinases is one of the major kinase 
families controlling this process. My project has characterised 
how Aurora kinase B is regulated in time and place during 
the various stages of the cell cycle using state-of-the-art 
biochemistry and molecular biology techniques including 
advanced microscopy, mass spectroscopy, and protein 
biochemistry. This has identified other proteins that interact 
with and are crucial for regulating the temporo-spatial 
activity of Aurora kinase B. These new interacting proteins 
are themselves potential drug targets that may be important 
in killing cancer. I have demonstrated that inhibiting Aurora 
kinase B, either directly or indirectly by targeting the proteins 
involved in its regulation, results in the controlled cell death 
(apoptosis) of cancer cells. This demonstrates that targeting 
this pathway may become a new approach to killing cancer.
Future work building on my project is ongoing. This will 
further characterise the molecular pathway and validate the 
interacting proteins involved as potential new drug targets to 
treat cancer.
The role of the Aurora family kinases in the 
regulation of the cell-cycle and tumourigenesis
FELLOWSHIP/SPONSOR
Freemasons’ Fund for Surgical Research
SUPERVISOR
Professor Francis Barr
SITE OF WORK 
Cancer Research Centre University of Liverpool and 
Department of Biochemistry University of Oxford
PUBLICATIONS 
1.  Nunes Bastos R, Ghandi SP, Baron RD, Gruneburg U, 
Nigg EA, Barr FA. Aurora B suppresses microtubule 
dynamics and limits central spindle size by locally 
activating KIF4A. J. Cell Biol. 2013;202(4):605-21.
2.  Hammond D, Zeng K, Espert A, Bastos RN, Baron RD, 
Gruneberg U, Barr FA. Melanoma-associated mutations 
in protein phosphatase 6 cause chromosome instability 
and DNA damage owing to dysregulated Aurora-A. J 
Cell Sci. 2013;126(Pt 15):3429-40.
PRESENTATIONS
1. Baron RD, Nunes-Bastos R, Neoptolemos JP, Barr FA. 
United we stand, divided we fall – targeting mitosis to 
promote apoptosis. Invited Oral Presentation. CRUK 
Fellows Meeting. London. November 2012.
2. Baron RD, Nunes-Bastos R, Neoptolemos JP, Barr FA. 
Dissecting the role of Aurora B in the regulation of cell 
cycle progression. Invited Oral Presentation. CRUK 
Centre Meeting, Liverpool. May 2012.
Further fundrasing
Cancer Research UK Fellowship for three years 
Ryan 
David Baron
One in three people will die from cancer with one new person diagnosed every two minutes.
Starting the race for life at 
Aintree Racecourse
Laboratory tour with Amanda Harrington, a local model, 
columnist and star of Desperate Scousewives
Research team featured in the 
Journal of Cell Biology editorial 
review of our recent paper, 
taken in the state of the art 
New Biochemistry Department, 
University of Oxford. Left to 
right: Sapan Ghandi, Ricardo 
Nunes-Bastos, Ryan Baron and 
Professor Francis Barr.
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Bowel cancer is the fourth most common cancer in the 
United Kingdom. Surgical removal of the tumour is the 
primary treatment; chemotherapy, however, is also used 
in more advanced disease, albeit with variable success 
and significant side effects. The discovery of new agents 
effective against bowel cancer is therefore highly desirable.
Iron is crucial for the normal growth and function of cells. 
Insufficient iron results in anaemia; too much, however, 
can lead to ill health. Of note, there is now increasing 
evidence linking excess iron to cancer. This is not entirely 
surprising, given the plethora of processes iron is essential 
for, including DNA synthesis and ATP (energy) generation 
– both activities that are increased in cancer. A strategy to 
starve tumours of iron could thus serve as a novel therapy 
for the treatment of bowel cancer.
Iron chelators (drugs that remove iron from the body) 
are already used for the treatment of conditions such as 
β-thalassaemia. Our group has previously demonstrated 
that these agents are effective in laboratory models of 
oesophageal cancer. Their usefulness in treating bowel 
cancer, however, has never been assessed and thus the 
aim of this research has been to investigate whether iron 
chelators may offer an effective treatment.
My research has demonstrated that iron chelators display 
significant anti-cancer properties in laboratory models of 
bowel cancer. The drugs inhibit iron uptake and storage 
within colorectal cancer cells, which significantly reduces 
their viability and growth. Of note, iron chelators inhibit 
cells that are resistant to conventional chemotherapy. 
Their efficacy may 
also be increased 
by the presence 
of certain genetic 
mutations common 
in colorectal 
tumours (eg APC). 
Iron chelation may 
therefore serve as a 
‘targeted therapy,’ 
reducing side 
effects in normal 
cells.
It is now hoped a clinical trial of iron chelation therapy may 
take place within 1 to 2 years.
Iron chelators: The next generation of anti-
neoplastic agents in colorectal cancer?
FELLOWSHIP/SPONSOR
H&S Charitable Trust
SUPERVISORS
Chris Tselepis and Professor Derek Alderson
SITE OF WORK 
School of Cancer Sciences, University of Birmingham
PUBLICATIONS 
Bedford MR, Ford SJ, Horniblow RD et al. Iron 
chelators in the treatment of cancer: A new role for 
Deferasirox? Journal of Clinical Pharmacology 2013; 
53: 885–891.
PRESENTATIONS
1. Bedford MR, Evans S, Radulescu S et al. Iron 
chelation as a novel strategy for the treatment 
of colorectal adenocarcinoma. Accepted for 
oral presentation at the Society of Academic 
and Research Surgery (SARS) annual meeting 
(Durham), January 2015.
2. Evans S, Bedford MR, Lal N et al. Iron metabolism 
in colorectal adenocarcinoma: A novel therapeutic 
target? Accepted for oral presentation at the 
Society of Academic and Research Surgery 
(SARS) annual meeting (Durham), January 2015.
Matthew 
Robert 
Bedford
More than 40,000 new people are diagnosed with colorectal cancer in the UK each year and the disease is responsible 
for almost 16,000 deaths annually. This research demonstrates that iron metabolism represents a promising therapeutic 
target in the treatment of this common cancer.
Matthew at work in the laboratory
Matthew outside the Queen Elizabeth Hospital Birmingham
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Many orthopaedic implants are made from titanium (Ti) as 
the patient’s own bone joins onto Ti via the body’s natural 
healing processes. In some cases the patient’s bone fails 
to join strongly to the Ti, so the implant works loose. This 
requires revision surgery that has worse results for patients 
than initial surgery.
Research in our laboratory has found a naturally occurring 
fatty molecule called lysophosphatidic acid (LPA) that 
enhances maturation of human bone-forming cells 
(osteoblasts). Therefore we bonded LPA to Ti to see if this 
was better than ‘naked’ Ti in supporting osteoblast growth.
The aim of this research is to develop ‘next-generation’ 
implants via the direct bonding of LPA to Ti with a view to 
improving overall implant longevity.
Work with human bone marrow stem cells (hBMSCs) 
sourced from patients undergoing total hip replacement, 
showed LPA-modified Ti did promote the development 
of osteoblasts from stem cells, which should improve the 
bond between bone and metal. We also found that LPA co-
operates with and does not antagonise local growth factors, 
which is encouraging for how LPA-modified Ti may work in 
humans.
Infection can affect one in every hundred joint 
replacements and complicate one in ten revision operations. 
These infections are difficult to treat and often lead to 
removal of the implant and many weeks of antibiotics. LPA 
has been shown to slow the growth of some bacteria, and we 
found LPA-modified Ti also has antibacterial effects.
Worldwide, 
many research 
groups are bio-
functionalising 
implants 
with other 
growth factors. 
However, LPA 
is much smaller 
than these 
other growth 
factors so we can achieve a greater surface coverage, and it is 
also significantly cheaper. 
Our research continues to further develop LPA-modified Ti as 
a surface that may increase implant survival and prevent the 
need for revision surgery for many patients.
Enhancing host cell responses via 
biofunctionalisation of orthopaedic titanium
FELLOWSHIP/SPONSOR
RCS Research Fellowship supported by the Cutner Legacy
SUPERVISORS
Jason Mansell and Professor Ashley Blom
SITE OF WORK 
Avon Orthopaedic Centre
PUBLICATIONS 
1.  Blackburn J, Mansell JP. The Emerging Role of 
Lysophosphatidic acid (LPA) in skeletal biology. Bone 
2012; 50: 756–762.
2.  Mansell JP,  Blackburn J. Lysophosphatidic acid, human 
osteoblast formation, maturation and the role of 1α,25-
dihydroxyvitamin D3 (calcitriol). Biochim Biophys Acta 
2013; 1831: 105–108.
PRESENTATIONS
1. Lysophosphatidic acid (LPA)-funtionalised titanium: a 
superior implant material for supporting human osteoblast 
differentiation, European Orthopaedic Research Society 
(EORS) Meeting, Amsterdam, 27-28 Sept 2012
2. Effect of local and systemic growth factors on the human 
osteoblast response to Lysophosphatidic acid and vitamin 
D3. Society of Academic & Research Surgery (SARS) 
Annual Meeting, Royal Society of Medicine, London. 9–10 
Jan 2013.
PRIZES 
1.  Stefan and Anna Galeski Fellowship 2013
2.  European Orthopaedic Research Society (EORS) Exchange 
Travel Grant, December 2012.
Julia 
Blackburn
More than 160,000 total hip and knee replacements are performed each year in the UK, but 10% of these implants will 
fail owing to loosening at the interface of metal and bone.
Julia teaching at a basic surgical skills workshop in Rio de Janeiro
Julia teaching at a basic surgical skills workshop in Rio de Janeiro
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Gastroschisis is a belly wall defect arising during pregnancy 
resulting in bowel lying outside the abdomen in contact with 
irritant amniotic fluid. At birth the bowel is inflamed and 
sluggish resulting in poor oral feeding requiring drip feeds. 
However, the cause of sluggish bowels is poorly understood.
Previous research has shown that the amniotic fluid of fetal 
gastroschisis is inflamed and the pacemaker of the bowel – the 
interstitial cells of Cajal (ICC) – are underdeveloped in the 
bowel wall of gastroschisis babies. It is thought reduction of 
bowel wall inflammation will enable normal ICC development.
My objectives are to better understand the development of 
ICC in gastroschisis and develop a fetal therapy to improve gut 
function before birth.
Within the laboratory, I have developed techniques to 
accurately quantify ICC and other specialised nerve cells/
inflammatory cells in mouse and human bowel wall. This is 
being applied to my ongoing investigations (continuing for 
a further two years) in a gastroschisis genetic mouse model. 
Using this model I am performing a variety of fetal in-utero 
interventions to alter the levels of bowel inflammation to 
determine the effect of inflammation on ICC development 
and gut physiology. Additionally, I am analysing bowel wall 
ICC/neuronal development in human gastroschisis involving 
the largest series of archived gut specimens to date.
Finally, I have performed a retrospective review of 246 
patients to determine whether sluggish bowels are simply 
linked to the duration of amniotic fluid exposure. However, 
my findings showed that the greater the gestational age at 
birth the less time the baby needed to reach full oral feeding. 
Suggesting the cause of sluggish bowels is more multifactorial 
than just amniotic fluid exposure.
If I show an in-utero intervention to be successful at 
improving ICC development and bowel physiology then I 
could soon be translating this research into a clinical trial.
Investigation of the pathophysiology and in-utero 
treatment of gastroschisis-related gut dysfunction
FELLOWSHIP/SPONSOR
Joint RCS/British Association of Paediatric 
Surgeons Research Fellowship
SUPERVISOR
Dr Simon Eaton
SITE OF WORK 
Paediatric Surgery Unit, Institute of Child 
Health, UCL
PUBLICATIONS
1. Carnaghan H, Pereira S, James 
CP, Charlesworth PB, Ghionzoli M, 
Mohamed E, Cross KMK, Kiely E, Patel 
S, Desai A, Nicolaides K, Curry JI, Ade-
Ajayi N, De Coppi P, Davenport M, David 
AL, Pierro A, Eaton S. Is early delivery 
beneficial in gastroschisis? Journal of 
Pediatric Surgery. in press.
2. Carnaghan H, Roberts T, Savery D et 
al. Novel exomphalos genetic mouse 
model: The importance of accurate 
phenotypic classification. Journal 
of Pediatric Surgery 2013; 48: 
2,036–2,042.
PRESENTATIONS
1. Carnaghan H, Pereira S, James 
CP, Charlesworth PB, Ghionzoli M, 
Mohamed E, Cross KMK, Kiely E, Patel 
S, Desai A, Nicolaides K, Curry JI, 
Ade-Ajayi N, De Coppi P, Davenport M, 
David AL, Pierro A, Eaton S. Is early 
delivery beneficial in gastroschisis? 
American Academy of Pediatrics 
National Conference and Exhibition, 
Orlando, USA, Oct 2013.
2.  Carnaghan H, Roberts T, Savery D 
et al. Novel exomphalos genetic 
mouse model: The importance of 
accurate phenotypic classification. 
Joint European Paediatric Surgeons’ 
Association/British Association of 
Paediatric Surgeons Annual Paediatric 
Surgery Congress, June 2012.
Further fundrasing
Welcome Trust Research Training 
Fellowship for 2 years
PRIZES
First Prize in the Year 2 Category, 
UCL Institute of Child Health Poster 
Competition 2013.
Helen 
Carnaghan
43% of gastroschisis babies fall into the category of type two intestinal failure (> 28 days of drip feeds).
Helen next to her winning poster Helen working in the laboratory
Helen outside the world-renowned UCL, Institute of Child Health
Julia teaching at a basic surgical skills workshop in Rio de Janeiro
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Implant spine surgery for optimising management following 
spinal cord injury and spinal degenerative change is on the 
increase. Spinal cord injury is estimated to occur in 2,500 
people (mostly under 30 years of age) in the UK every year, 
with an approximated lifetime healthcare cost of up to £1 
million per patient. Such complex cases will increasingly need 
urgent surgery with the recent publication of research showing 
significant gains from early operative intervention.
Support from the College has allowed me to undertake 
my AO North America-approved clinical spinal training 
fellowship programme at the centre that led the above trial. 
The placement also provides a unique opportunity to further 
my experience of some of the latest minimally invasive spinal 
surgery techniques and spinal deformity, as well as treatment 
of spinal cord injury patients and its complications including 
syringomyelia. Surgical techniques learnt included using new 
technology like CT guided (O-Arm) intraoperative spinal 
navigation, which allows surgeons to take real-time CT scans 
during the operation and accurately guide spinal surgery and 
implant positioning. This significantly increases patient safety 
and allows 
more complex 
procedures to be 
undertaken, like 
en bloc resection 
of tumours, 
which has been 
shown to lead to 
longer survival in 
tumour patients.
Further clinical research during my fellowship is aimed at 
determining the best surgical management of degenerative 
spinal disease from mal-alignment of the lower spine called 
Spondylolisthesis. Tradition fusion spine surgery for this 
condition carries greater risks and is more expensive. It 
also predisposes patients to developing later complications 
called Adjacent Segment Disease. My work builds on the 
continuing work of the spine research programme and 
scientifically details the benefit of minimally invasive spine 
surgery in these patients. Such surgery not only allows 
patients to go home on the same day of the operation, but 
altogether avoids fusion operations (in certain types of 
spondylolisthesis) thus minimising risks, optimising costs 
and improving outcomes.
Reference
1. Fehlings MG, Vaccaro A, Wilson JR, Singh A, W Cadotte D, Harrop JS et al. Early versus delayed 
decompression for traumatic cervical spinal cord injury: results of the surgical timing in acute 
spinal cord injury study (STASCIS). PLoS ONE. 2012; 7:e32037.
Minimally invasive spine and spinal cord injury 
surgery - improving indications and outcomes
FELLOWSHIP/SPONSOR
Harry Morton Fellowship
SUPERVISORS
Professor M Fehlings, R Rampersaud and S Lewis
SITE OF WORK 
Krembil Neurosciences Centre, Toronto Western Hospital, 
Canada
PUBLICATIONS 
Chaudhary BR, Fehlings MG. Adult-Onset Syringomyelia 
– From theory to practice and beyond. World Neurosurg 
2014: S1878-8750(14)00754-2.
PRESENTATIONS
1.  Minimally invasive decompression in focal 
lumbar spinal stenosis with or without stable 
spondylolisthesis. Comparative outcomes and 
re-operation rates at two years and beyond. Society 
for Minimally Invasive Spine Surgery Global Forum, 
Miami, USA. September 2014.
2.  Two-year comparative outcomes of minimally 
invasive decompression in focal lumbar spinal 
stenosis – AO Spine North America Fellows Forum, 
Banff, Canada. March 2014
Bedansh 
Roy 
Chaudhary
The need for spine surgery is exponentially increasing and assessing treatments is vital to deliver optimal patient and 
healthcare resource benefits
O-Arm and navigation equipment used in the OR to provide 
surgical guidance
Reviewing a patient who had surgery around the base 
of the brain four days earlier
Roy with one of his mentors, Dr 
Stephen Lewis, outside the SickKids 
Hospital in Toronto
15
Cancer is one of Britain’s biggest killers. Bladder cancer in 
particular is debilitating, expensive to treat and associated with 
a high morbidity and mortality.
The normal human cell provides an environment for genes 
to be made into proteins used to promote and maintain our 
survival. A key step is to take the mRNA (a complimentary 
product of DNA) out of the nucleus and into the cytoplasm 
to be made into a protein. To facilitate this process there are 
exporter proteins that provide taxi-rides for mRNA to optimise 
this transport.
There is a number of key exporter proteins already identified 
and at baseline we knew that the most canonical exporter was 
at low levels in some cancer cells. Hence, our project aims were 
to identify alternative means of mRNA transport used by these 
cancer cells, which we demonstrated using techniques such as 
western blotting and polymerase chain reactions.
We sought to evaluate the 
range of cancers that use 
these alternative transport 
mechanisms and to 
interrogate the biological 
mechanisms that trigger 
the switch from normal to 
alternative RNA transport 
and to test whether these 
alternative pathways could be 
exploited to kill cancer cells 
selectively.
We performed a screen to 
see if we could artificially knock these alternative pathways 
out of cancer cells and thus induce cell death, and this proved 
successful. This provides hope that these pathways could be used 
as drug targets.
We also performed studies such as immunohistochemistry and 
polymerase chain reactions to see if the levels of these exported 
proteins could be detected in tissues and/or urine and serum 
samples of patients to provide a platform for a diagnostic tool. 
This work remains in progress. This would be invaluable to 
help clinicians decide on the best course of action for patients 
diagnosed with cancer and may lead to more ‘tailored’ bladder 
cancer (and wider) investigations and treatments.
So far this work has 
led to the discovery 
of a new exporter 
protein and we 
have found that 
a wide range of 
cancers are using 
alternative RNA 
export mechanisms, 
which we have gone 
on to characterise. 
We may also have identified one of the ways in which a cell with 
damaged DNA ‘switches off’ the usual RNA exporter.
This research builds upon work established in the Wilson 
laboratory and other laboratories worldwide that specialise in 
these processes. Our work furthers knowledge of the cellular 
process involved in mRNA export in cancer and is being put 
forward as a PhD thesis.
mRNA export and cancer
FELLOWSHIP/SPONSOR
Joint Wellcome Trust/RCS Research 
Fellowship
SUPERVISOR
Professor Stuart Wilson and Professor James 
Catto
SITE OF WORK 
University of Sheffield
PUBLICATIONS 
1. Viphakone N, Hautbergue GM, Walsh 
M, Chang CT, Holland A, Folco EG, Reed 
R, Wilson SA. TREX exposes the RNA-
binding domain of Nxf1 to enable mRNA 
export. Nat Commun 2012; 3: 1,006.
2. Hautbergue GM, Hung ML, Walsh MJ, 
Snijders AP, Chang CT, Jones R, Ponting 
CP, Dickman MJ, Wilson SA. UIF, a 
New mRNA export adaptor that works 
together with REF/ALY, requires FACT for 
recruitment to mRNA. Curr Biol 2009; 19: 
1,918–1,924. 
PRESENTATIONS
RNA Society Conference, June 2014, 
Quebec, Canada.
Further fundrasing
The Wellcome Trust for three years
Bladder cancer is the most expensive to treat and undertake surveillance on. In the USA it costs between $90,000 and 
$200,000 per patient from diagnosis to death.
Marcus 
George Kwesi 
Cumberbatch
Marcus in Wilson laboratory with colleagues
Marcus sat at Davinci Robot with supervisor 
Professor Jim Catto
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Current treatment regimens for head and neck cancer (HNC) 
involve surgery and radiotherapy ± chemotherapy. However, 
despite recent advances five-year survival rates have remained 
static over the past 20 years – particularly in Human Papilloma 
Virus (HPV)-negative disease.
Insulin-like Growth Factor (IGF) is a protein, which stimulates the 
growth and development of cells, and is thought to be important 
in the development of several common cancers including HNC. 
This project aims to investigate whether blocking the action of 
IGF could reduce the survival of cancer cells and provide new 
treatment options in head and neck cancer.
Using tissue from 190 HNC samples I have demonstrated that 
the IGF receptor is over-expressed in HNC, compared to normal 
tissue, and that this is particularly true in HPV-negative tumours.
In addition, I have demonstrated that blocking the IGF 
receptor in HNC cells that are growing in the laboratory 
significantly reduces the survival of cancer cells. When IGF 
blocking drugs are used in combination with radiotherapy this 
enhances the ‘cell killing’ effect of radiotherapy.
Future research will focus on identifying ‘biomarkers’ which 
predict the response of tumours to IGF blocking drugs.
My research findings to date suggest that IGF plays an 
important role in the biology of HNC, particularly in HPV-
negative disease, and that using IGF blocking drugs in this 
context may provide an attractive new therapeutic target. 
Ultimately I hope this research will form the basis for a clinical 
trial investigating the combination of IGF receptor-blocking 
drugs with current treatment regimens in head and neck 
cancer patients.
Investigating the role of the IGF axis in Head and 
Neck cancer
FELLOWSHIP/SPONSOR
The Dr Shapurji H Modi Memorial Research Fellowship
SUPERVISOR
Valentine Macaulay
SITE OF WORK 
John Radcliffe Hospital, Oxford
PRESENTATIONS
1.  Investigating the role of the IGF axis in Head and Neck cancer. British Association of Head and 
Neck Oncologists (BAHNO). April 2013.
2.  Investigating the role of the IGF axis in Head and Neck cancer. Oxford Cancer Research Centre 
Symposium. April 2013.
Further fundrasing
Heads Up and the Oracle Cancer Trust for one year
Head and neck cancer is the sixth most common cancer in the UK and two thirds of patients present with advanced disease.
Oliver 
Thomas Dale
Oliver gaining consent to use patient tissue for research purposes
Laboratory-based research into the IGF receptor in Head and Neck cancer
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Cancer kills 150,000 people in the UK each year. After 
surgical removal of cancerous tumors, plastic surgical 
reconstruction may involve moving tissue from a different 
anatomical location to reconstruct the defect. For example, 
after mastectomy for breast cancer, tissue is frequently 
moved from the abdomen to reconstruct a breast. This 
tissue is termed a ‘free flap’. Currently, a free flap has no 
oncological benefit to protect against cancer recurrence, and 
provides reconstruction only. Scientific evidence suggests 
free flap tissue may be primed to release proteins to the local 
environment with anti-cancer properties.
This international research collaboration between Stanford 
University and University College London aims to genetically 
alter reconstructive tissue to release proteins with anti-
cancer properties and prevent cancer recurrence at the exact 
anatomical location of the initial tumour. To achieve this 
goal, our initial experiments have confirmed:
1. Cancer eradication via 
a therapeutic protein
2. Successful delivery of 
the gene encoding the 
therapeutic protein to 
the cells of the free flap 
and subsequent release of 
the therapeutic protein
3. A contemporary means 
of joining blood vessels 
during reconstructive 
surgery.
Future translational benefits from this research includes 
developing a free flap for patients with cancer that reduces the 
risk of recurrent disease, thus increasing quality and duration 
of life by offering a potential cure to a patient’s initial cancer in 
a single oncological and reconstructive operation immediately 
after diagnosis.
Therapeutic flaps for reconstructive surgery 
after cancer
FELLOWSHIP/SPONSOR
RCS Fulbright Scholar Award
SUPERVISOR
Professor A O Grobbelaar
SITE OF WORK 
Stanford University, USA
PUBLICATIONS 
Davis CR, Rappleye CT, Than P, 
Whitmore AJ, Maan ZN, Rodrigues 
M, Bishop SN, Ghali S, Grobbelaar 
AO, Gurtner GC. Sutureless 
microvascular anastomosis for 
clinical application using Poloxamer 
188 as an optimal transient 
thermoreversible stent. Journal of 
the American College of Surgeons 
219:S89. 
PRESENTATIONS
1. Davis CR, Rappleye CT, Than 
P, Whitmore AJ, Maan ZN, 
Rodrigues M, Bishop SN, Ghali 
S, Grobbelaar AO, Gurtner 
GC. Sutureless microvascular 
anastomosis for clinical 
application using poloxamer 
188 as an optimal transient 
thermoreversible stent. American 
College of Surgeons – 100th 
Annual Clinical Congress. October 
2014, San Francisco, CA, USA.
2. Davis CR. Can plastic surgery 
cure cancer? Fulbright Visiting 
Scholars Research Presentations. 
March 2014, University of 
California, San Francisco, USA.
Prize
Stanford University School of 
Medicine 7th Annual Plastic Surgery 
Research Symposium (Stanford 
University, USA) Co-author of Best 
Basic Science Paper.
Christopher 
Davis
Cancer recurs in up to one in three unfortunate patients, despite optimal combinations of surgery, chemotherapy and 
radiotherapy. Can therapeutic reconstructive surgery prevent cancer returning?
Rodin Sculpture Garden, Stanford UniversityResearch dissemination at Downing Street
Stanford University Campus Google Inc, Mountain View, California
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perform both open 
and laparoscopic 
surgery, complex 
reoperative surgery 
and observe less 
common procedures 
such as the Koch 
pouch formation and 
rectourethral fistula 
repair.
As well as increasing 
my operative 
experience, I 
attended clinics and 
multidisciplinary 
team meetings, 
performed 
endoscopy, joined 
ward rounds and had 
on call commitments.
My time working in Toronto gave me more than just the 
operative experience that I was expecting. It gave me an insight 
into complex decision-making and teamworking and also the 
opportunity to work in a different healthcare system. It also gave 
me the chance to witness a different surgical training program 
and to see how the surgeons in Toronto are training surgeons 
over a shorter timeframe than in the UK.
Since returning to the UK I have started work as a consultant 
general and colorectal surgeon and I am certain that I am a 
better surgeon as a result of this post-CCT fellowship.
I trained in general 
and colorectal surgery 
in the UK but was 
keen to undertake a 
post-CCT fellowship 
in colorectal 
surgery so that I 
had a greater level 
of experience and 
expertise with which 
to treat my patients 
on commencing as a 
Consultant Surgeon. 
The American Society 
of Colon and Rectal 
Surgeons recognises a 
number of colorectal 
surgery residency 
programs, including 
at the University of 
Toronto. Having 
visited the surgeons 
at the University of Toronto I was offered a place on their 
residency program for 1 year.
I spent the year working at Mount Sinai and St Michael’s 
Hospitals, both located in downtown Toronto. I had the 
opportunity to be involved in the management of a high volume 
of patients with colorectal malignancy and inflammatory 
bowel disease. Working at specialist centres gave me a chance 
to greatly increase my colorectal experience, particularly of 
patients with complex inflammatory bowel disease and those 
requiring pelvic pouch surgery. I had the opportunity to 
Post-CCT Colorectal Fellowship in Toronto
FELLOWSHIP/SPONSOR
Harry Morton Fellowship supported by H&S Charitable Trust
SUPERVISORS
Robin Mcleod and Helen Macrae
SITE OF WORK 
Mount Sinai and St Michael’s Hospitals, Canada
Nicola 
Jayne Eardley
To learn about pouch surgery, in particular laparoscopic pouch formation and various aspects of surgery related to 
Crohn’s disease
Nicola being presented with a piece of artwork by a patient 
in appreciation of the hard work of the team during his 
cancer treatment
Mount Sinai hospital
St Michael’s hospital
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I am enrolled in the General Surgery training programme 
at the University of Toronto, Canada, and have completed 
the third postgraduate training year (PGY3). I came to study 
at the University of Cambridge to do oesophageal cancer 
research in Professor Rebecca Fitzgerald’s lab with a CRUK 
Cambridge Cancer Centre Clinical Fellowship.
Oesophageal adenocarcinoma is a cancer of the oesophagus 
that is becoming increasingly common in the Western 
world, with a six-fold increase over the past three decades. 
This disease has a poor overall survival rate (<20%) 
unless detected and treated at an early stage. Oesophageal 
adenocarcinoma has a known precursor lesion called 
Barrett’s oesophagus, which is associated with chronic acid 
reflux and inflammation. However, little is known about the 
relationship between inflammation in Barrett’s oesophagus 
and the oesophageal microbiome (ie all bacterial species in 
the oesophagus).
My PhD research aims 
to characterise the 
composition of the 
oesophageal microbiome 
at different stages 
of progression from 
Barrett’s oesophagus 
to cancer. To do this 
we are using different 
methods of sampling the 
microbiome, including 
the novel Cytosponge™ 
(Barrett’s oesophagus Screening Trial, Fitzgerald lab). The 
Cytosponge™ consists of a spherical mesh compressed within 
a gelatine capsule and attached to a string. Once swallowed, 
the capsule dissolves and the Cytosponge™ expands in the 
patient’s stomach. After five minutes, the Cytosponge™ can be 
withdrawn on a string through the patient’s mouth, collecting 
cells and bacteria along the entire oesophagus.
A pilot study has already been performed to confirm whether 
it is possible to analyse tiny amounts of DNA from bacteria 
in the oesophagus using a technique called 16S rRNA gene 
sequencing. The purpose of this technique is to identify 
and classify the different species of bacteria. The next step 
is to complete a larger study (>300 samples) to investigate 
whether there is any difference in bacterial species along the 
progression sequence from Barrett’s oesophagus to cancer. 
Discovering whether alterations in the microbiome have any 
functional role in the development of oesophageal cancer is 
clinically important, because it may improve detection of early 
cancers and guide possible therapies (such as antibiotics or 
probiotics) for these patients.
Daffolyn examining bacteria colonies grown in Petri dishes, trying to isolate colonies that contain 
her gene of interest
Daffolyn visualising her gene of interest, which has 
been successfully cloned in seven bacteria colonies
Characterisation of the oesophageal 
microbiome and its functional relevance in 
oesophageal cancer
FELLOWSHIP/SPONSOR
Harry Morton Fellowship
SUPERVISOR
Rebecca C Fitzgerald
SITE OF WORK 
Hutchison/MRC Cancer Unit, University of Cambridge
PUBLICATIONS 
D Fels Elliott, Fitzgerald RC. Molecular markers for Barrett’s oesophagus and its progression to cancer. 
Current Opinion Gastroenterology 2013; 29: 437–445.
FURTHER FUNDING
Cambridge Cancer Centre Clinical Research Fellowship (Cancer Research UK) for three years 
Daffolyn 
Rachael 
Fels Elliott
There has been a six-fold increase in oesophageal cancer in the United Kingdom during the past three decades, and the 
reason behind this increase has not yet been discovered.
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There are 
1.2 million 
deaths from 
Road Traffic 
Accidents 
worldwide 
and 5,400 
deaths each 
year from 
trauma in 
England. 
This dwarfs 
the 40,000 
severely 
injured 
people 
surviving 
trauma in 
England.  
With the 
recent 
advances 
in military trauma care and the setting up of civilian trauma 
centres improving survival, it was time to investigate how to 
improve the survivors’ recovery.
We set up a study that would examine how the body responds to 
and recovers from trauma.
In 100 severely traumatised patients, half military and half 
civilian, we collected blood and urine from injury and at 
periodic intervals for 6 months. We also measured muscle loss 
using ultrasound. In blood, we measured hormones (substances 
which control organ systems) that are released under stress and 
also those that build muscle (steroids).
The military injuries were inflicted by bullet or bomb whereas 
the civilian injuries were mainly road-traffic accidents. Stress 
hormone levels were high during the first 6 weeks and the 
anabolic steroid hormones were very low and took several weeks 
to recover. Muscle loss was 22% on average and reached its 
lowest point by 6 weeks. We measured the body’s ability to fight 
infection and this was lowest at two weeks following injury.
We found a clear imbalance between the stress hormones 
and steroids that is associated with severe muscle loss and the 
ability to fight infection. DHEA is one of these hormones that 
may reverse this 
imbalance. Our next 
steps are to set up a 
trial to supplement 
this naturally 
occurring hormone 
in the severely injured 
that may improve 
survival but, almost 
more importantly, 
improve recovery and 
return more injured 
to independent 
living will reduce the 
costly burden of care 
to families and the 
country alike.
The endocrine response to severe trauma: the 
steroids and immunity from injury to rehabilitation 
(SIR) study
FELLOWSHIP/SPONSOR
Joint RCS/Military Research Fellowship
SUPERVISORS
Professors Janet Lord, Wiebka Arlt, Julian Bion and Mark 
Midwinter
SITE OF WORK 
NIHR Surgical Reconstruction and Microbiology Research Centre, 
Birmingham
PUBLICATIONS 
Two papers are currently in draft around the neutrophil 
function after major trauma and the endocrine response to 
severe trauma.
PRESENTATIONS
1. Mark Foster, Taylor A, Hill N, Staruch R, O’Neil D, Bion J. 
The endocrine response to severe trauma: the steroids and 
immunity from injury to rehabilitation (SIR) study. 2013. 
Endocrine Society 2013 – San Francisco.
2.  Mark Foster, Angela Taylor, Neil Hill, Rob Staruch, Donna 
M. O’Neil, Julian F Bion, Stephen Young, Mark Midwinter, 
Joanne Fallowfield, Janet Lord, Wiebke Arlt.  The endocrine 
response to severe trauma. British Endocrine Society 2014.
PrizeS
Best Registrar Presentation, Travelling Surgical Society, 
Birmingham 2013.
FURTHER FUNDING
The National Institute for Health Research Surgical 
Reconstruction and Microbiology Research Centre (NIHR 
SRMRC), Royal Centre for Defence Medicine, Drummond 
Foundation, Wellcome Trust Birmingham CRF for 
consumables, research staff and laboratory support.
Mark 
Anthony 
Foster
Severely traumatised patients lose more than 20% of their muscle thickness by 6 weeks after injury
Mark measuring recovery
Mark in trauma surgery
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Vascularized composite 
allotransplantation (VCA), 
most commonly hand or face 
transplantation, can replace 
any tissue deficit with ‘like for 
like’ tissue achieving optimal 
functional and aesthetic 
results. Patients who have 
suffered hand amputation 
can become independently 
self-caring, patients living 
in social isolation owing to 
facial disfigurement can 
return to normal function.
Injuries that are 
unreconstructible using 
current gold-standard 
techniques can be treated 
by this method; however, 
life-long immunosuppression 
that confers morbidity and 
mortality to VCA recipients 
is required to support a graft 
that improves quality of life 
but is not lifesaving.
The aim of this research 
is to investigate strategies 
that can reduce the systemic 
toxicity associated with 
immunosuppression by 
pre-treating the 
graft ex vivo prior to 
transplantation.
To date I have 
developed the world’s 
first orthotopic model 
of hand transplantation 
in swine to enable gold-standard evaluation VCA immunology in 
a translatable model. Unlike all other models of VCA it comprises 
all relevant tissue types and enables the evaluation of nerve 
regeneration, tendon and bone healing and functional recovery.
Experiments using this model and our previously described 
model of gracilis musculocutaneous flap transplantation have 
demonstrated the ability of hydrogen sulphide, an ex vivo 
hyperbaric warm perfusion device and topically delivered 
immunosuppressive agents (using drug eluting microparticles) 
to delay the onset of acute rejection. The homology between 
humans and swine enables these results to be translated into 
clinical trials.
Projects are ongoing, with current protocols evaluating enzyme-
activated drug eluting hydrogels, delivering immunosuppressive 
agents.
The RESTOR project is a long-term endeavour with particular 
focus on the reconstructive benefits to service personnel injured 
in recent conflicts. This has yielded a cadre of patients with 
devastating extremity and maxillofacial injuries, who have very 
high reconstructive demands and expectations based on their 
high levels of pre-morbid function and young age.
Targeted graft specific therapy delays 
acute rejection in vascularised composite 
allotransplantation
FELLOWSHIP/SPONSOR
Joint RCS/Military Research Fellowship
SUPERVISOR
Lt Col M R Davis MD USAF MC
SITE OF WORK 
United States Army Institute of Surgical Research, San 
Antonio, Texas
PUBLICATIONS 
1. C Villamaria, C A Fries, J R Spencer, M Roth, 
M Davis. Hydrogen sulphide mitigates ischemia 
reperfusion injury in a porcine model of vascularised 
composite allotransplantation. Ann Plas Surg 2014; 
72: 594–598.
2. Villamaria CY, Rasmussen TE, Spencer JR, Patel 
S, Davis MR. Microvascular porcine model for 
the optimisation of vascularised composite tissue 
transplantation. J Surg Res 2012; 178: 452 –459.
PRESENTATIONS
1.  Military Health Systems Research Symposium, Fort 
Lauderdale, Florida, August 2014.
2.  Association of Trauma and Military Surgery (ATMS), 
Harrogate, April 2014.
PRIZES
The Richard Wiseman Medal, for best podium presentation 
of original research at ATMS 2014.
Charles 
Anton 
Fries
Half of upper limb amputees do not use their prosthetic limb as it does not provide adequate function
Charles operating in the tented field hospital 
Afghanistan
Charles presenting at the MHSRS meeting
Charles on patrol in Afghanistan
Charles at an outreach clinic in Afghanistan
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In the past decade more than 2.6 billion people have become 
casualties of disasters. Mass casualties following disasters are 
characterised by a quantity of severely injured patients that 
can rapidly overwhelm available medical resources. Bleeding 
due to trauma causes almost 50% of deaths in the first 24 
hours following injury and is the leading preventable cause 
of death in this population. These casualties require urgent 
operations and large volumes of blood to survive, which can 
lead to rapid exhaustion of hospital blood supplies.
The objective of this research project is to increase our 
understanding of how blood is consumed in mass casualty 
events and investigate a method for improving blood 
planning for events, which could reduce future disaster-
associated mortality.
Following an extensive 100-year worldwide review of blood 
use in mass 
casualty 
events, I have 
developed 
the first 
computer-
based 
simulation 
model of 
a hospital 
blood system 
during a 
disaster. The 
computer 
model has been designed with software commonly used in 
industry to optimise system outputs and improve efficiency.
Application of this technology in medical disaster planning 
allows the investigation and experimentation of blood 
provision under the surge conditions of a mass casualty event, 
across a range of scenarios and hospital constraints. The 
results will identify system bottlenecks, and help develop best-
practice guidelines for managing bleeding casualties using 
a more time, resource and financially efficient method, than 
could be achieved through real-life simulation experiments.
Results from the development stage of the model have already 
been used in the public service; assisting emergency planners 
in ensuring adequate blood supplies were available to meet 
the expected demands of a disaster during the 2012 Olympic 
Games. The results from the current experimentation phase 
will hopefully further add to our understanding and improve 
policymaking for optimal blood provision in future events.
Optimal use of transfusion resources in trauma 
surgery and mass casualty events
FELLOWSHIP/SPONSOR
RCS Research Fellowship with the support of the Rosetrees 
Trust
SUPERVISORS
Professor Karim Brohi and Lieutenant Colonel Nigel Tai
SITE OF WORK 
The Blizard Institute, Queen Mary University of London
PUBLICATIONS 
1. Glasgow S, Davenport R, Perkins Z, Tai N, Brohi K. 
A comprehensive review of blood product use in civilian 
mass casualty events, Journal of Trauma-Injury, Infection 
and Critical Care 2013; 75: 468–474.
2. Glasgow SM, Allard S, Doughty H, Spreadborough P, 
Watkins E. Blood and bombs: the demand and use of 
blood following the London Bombings of 7 July 2005. 
Transfus Med 2012; 22: 244–250.
PRESENTATIONS
1. World Trauma Congress – The impact of damage control 
resuscitation on blood provision for mass casualties. Rio 
de Janeiro, Brazil, August 2012.
2.  Annual Meeting of The Society of Academic and Research 
Surgery – A 100-year review of blood use in civilian mass 
casualty events. London, UK. January 2013.
PrizeS
President’s Poster Prize Winner, Annual Meeting of SARS, 
Royal Society of Medicine, London January 2013.
FURTHER FUNDING
The National Institute of Health Research for one year.
Simon 
Glasgow
Disaster-related deaths have risen 23% in the past decade, with more than one million lives lost. Bleeding is the leading 
preventable cause of death in these mass casualty events.
The trauma science exhibit Simon helped develop alongside his research to teach children
Simon in action, teaching children how bleeding is controlled in theatre
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The challenge in the management of oral epithelial dysplasia 
(OED) lies in identification of patients in whom the risk of 
progression to oral cancer is high. OED often presents as white 
or red patches in the mouth.
Diagnosis and grading 
of severity (mild, 
moderate or severe) 
requires a biopsy. 
Known risk factors for 
transformation to oral 
cancer include the size 
and appearance, but 
the importance of site 
of lesion in the mouth, 
grade of dysplasia and exposure to environmental carcinogens 
remains controversial.
Patients with a diagnosis of OED were recruited to an 
observational study in a specialist oral dysplasia clinic. Clinical, 
histopathological and risk factor data were recorded at baseline 
and one of three clinical endpoints were determined for each 
patient: transformation to oral cancer and non-transforming/
stable OED.
An estimated 22% of patients underwent malignant 
transformation within 5 years, with significant predictors being: 
non-smoking status (seven-fold risk compared to non-smokers), 
site (lesions on the sides of tongue are four times more likely 
to be become cancerous), non-homogeneous appearance (red 
or red-white lesions), high histological grade and size of lesion 
>200mm2. Gender, age, number of lesions and alcohol history 
did not predict for malignant transformation.
Although a number of these clinical determinants 
have previously been associated with higher malignant 
transformation in OED, the high-risk nature of lesions in non-
smokers is of particular note and requires a greater emphasis 
and recognition among clinicians dealing with OED. It suggests 
that patients, with non-smoking OED should be treated more 
aggressively.
One possible hypothesis is that patients with non-smoking OED 
might have defective repair mechanism for endogenous DNA 
damage, leading to cancerous progression. Archival tissue from 
a selection of this group of patients was analysed for expression 
of the FANC-D2 protein, which is crucial in DNA damage repair. 
Preliminary findings have indicated that the FANC-D2 is under-
expressed in OED that transformed to oral cancer and thus 
could help identify higher-risk OED in the future.
Molecular and clinical determinants of 
malignant progression in oral dysplasia
FELLOWSHIP/SPONSOR
RCS Research Fellowship
SUPERVISORS
JB Wilson, Professor RJ Shaw and JM Risk
SITE OF WORK 
University of Liverpool
PUBLICATIONS 
1. Ho MW, Field EA, Field JK, Risk JM, Rajlawat BP, Rogers 
SN, Steele JC, Triantafyllou A, Woolgar JA, Lowe D, Shaw 
RJ. Outcomes of oral squamous cell carcinoma arising from 
oral epithelial dysplasia: rationale for monitoring premalignant 
oral lesions in a multidisciplinary clinic. Br J Oral Maxillofac 
Surg 2013; 51: 594–599. 
2. Ho MW, Risk JM, Woolgar JA, Field EA, Field JK, Steele JC, 
Rajlawat BP, Triantafyllou A, Rogers SN, Lowe D, Shaw RJ. 
The clinical determinants of malignant transformation in oral 
epithelial dysplasia. Oral Oncol 2012; 48: 969–976.
PRESENTATIONS
1.  American Head and Neck Society: 8th International Conference 
for Head and Neck Cancer, Toronto – July 2012.
2.  British Association of Oral and Maxillofacial Surgeons Annual 
Scientific Meeting, London – June 2012.
PRIZES
British Society of Oral Medicine Annual Meeting 2012 – Poster Prize
FURTHER FUNDING
BAOMS/FSRF Fellowship 2013 and FDS Small Grant Award 2013 
for 3 years
Michael 
Wing 
Sung Ho
Oral dysplasia in non-smokers is seven times more likely to progress to oral cancer compared with smokers.
Michael working in an operating theatre with colleagues
Michael performing microvascular anastomosis for free 
tissue transfer reconstructive head and neck surgery
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I was based at the tertiary centre of Toronto Western Hospital 
where I rotated through placements including complex spinal 
tumours, advanced minimal access spine surgery, complex 
paediatric and adult deformity and intradural spinal surgery. I 
gained excellent surgical techniques through clinical practice 
and by attending numerous internal and external advanced 
cutting-edge AOSpine North America cadaver-based courses 
with world-leading faculty to acquire new and consolidate 
surgical techniques used.
I took part in one of the largest prospective multi-centre 
global studies ever to be undertaken on the management of 
cervical spondylotic myelopathy. I presented findings of the 
study at five international conferences, I won best abstract, 
best presentation and top research abstract, and three of my 
manuscripts are under preparation, with one submitted for 
publication.
After completing this fellowship I have learned essential skills 
and strategies to avoid complications and I am better equipped 
to practise evidence-based advance spinal surgery. I have 
been inspired to develop a fellowship incorporating the best 
elements of my Canadian fellowship within the NHS for future 
trainees from the UK and aboard.
I believe that the knowledge I gained and the skills that I 
developed, in addition to the networks I established, will 
positively influence the management of my future patients and 
my career for a long time to come.
Spinal Fellowship at University of Toronto
FELLOWSHIP/SPONSOR
Harry Morton Fellowship
SUPERVISOR
Professor M G Fehlings
SITE OF WORK 
Toronto Western Hospital, Canada
PRESENTATIONS
1. Surgical outcome of CSM management – 
Canadian Spine Society meeting, Lake Louise, 
Canada.
2.  Management of CSM outcome of 479 patients, 
Society of British Neurosurgeons, Autumn 
meeting, Coventry, England.
PrizeS
1. Best presentation – AONA 12th Annual Forum, 
Banff, Canada.
2.  Winner of Best International Fellow – AANS/CNS 
Crockard International Fellowship Award.
3.  Fellows/resident prize for the 2014 Cervical Spine 
Research Society (CSRS) in Orlando.
FURTHER FUNDING
HCA (Hospital Corporation of America) Scholarship, as 
a single payment.Ahmed 
Ibrahim
I was provided with an unparalleled research opportunity under the supervision of the inspiring Professor Fehlings.
Ahmed with Professor Fehlings in Banff Ahmed with Professor FehlingsAhmed with other fellows
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Ulcerative colitis (UC) is 
a common inflammatory 
disease of the large bowel, 
affecting young males and 
females equally. Bowel 
cancer risk in patients 
with chronic UC is 
heightened compared with 
the general population. 
Death from UC-cancer is 
disproportionately high, 
despite intensive endoscopic 
surveillance programmes.
This project aimed to 
examine DNA changes 
from bowel tissue taken 
from patients with UC and UC-cancers. It aimed to identify 
early DNA changes that corresponded to an individual’s risk of 
bowel cancer.
UC bowel tissue taken during surgery or endoscopy was 
processed and DNA was extracted. Using a series of laboratory 
techniques, DNA changes called ‘methylation’ were measured 
in a panel of genes responsible for cancer and cell growth. This 
is particularly useful as DNA methylation changes occur early 
before a cancer has developed.
The results showed that two genes in particular, called sFRP2 
and sFRP4, were more methylated in UC-cancer compared 
with someone who had UC but no cancer. Furthermore, sFRP2 
was more methylated in early cancer compared with advanced 
UC-cancer. This would suggest that the methylation status of 
sFRP2 could help identify UC patients at high risk of developing 
bowel cancer. A DNA-based test could be useful in the future as 
an adjunct to surveillance endoscopy.
This research will be followed up in a large-scale trial (funded by 
the NIHR), which will aim to identify further genes that can be 
used as markers of cancer risk in patients with chronic UC.
Patients with UC 
have an extremely 
poor quality of 
life. Some of 
the associated 
symptoms include 
bloody diarrhoea, 
abdominal pain, 
weight loss and 
faecal urgency. 
These can have 
negative influences 
on relationships, 
job prospects and general well-being. Heightened bowel 
cancer risk adds to the burden of misery, which involves yearly 
endoscopies. Despite these, up to half of cancers develop in UC 
patients on surveillance. This suggests that the need to develop 
more accurate methods of predicting and detecting bowel cancer 
in UC are pressing.
This would serve as a huge benefit as patients would know 
their individual cancer risk. This would lower the number and 
frequency of endoscopies in patients deemed low risk and would 
promote early surgery or therapy in those patients at high risk for 
bowel cancer.
Enhanced surveillance for ulcerative 
colitis-associated bowel cancer
FELLOWSHIP/SPONSOR
RCS Research Fellowship with the support of the Rosetrees Trust
SUPERVISORS
Glenn Matthew and Professor Dion Morton
SITE OF WORK 
School of Cancer Sciences, University of Birmingham
PUBLICATIONS 
Iqbal F, Tannahill L, Leong K, Caldwell GC, Wei W, Roelund K, Matthews G, Keolvraa S, Morton DG. Identification of novel 
candidate tumours suppressor genes in early colorectal tumourigenesis. Journal of Colorectal Disease 2012; 14: 14.
PRESENTATIONS
Association of Coloproctology of Great Britain and Ireland Conference, Dublin, July 2012.
PRIZES
First Place, University of Birmingham Research Poster Conference, July 2012.
Fareed 
Iqbal
There is a ten-fold increased lifetime risk of bowel cancer in patients with ulcerative colitis.
Fareed performing an endoscopy of a patient 
with ulcerative colitis
Fareed removing a colon cancer in theatre from a patient with 
ulcerative colitis
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Dupuytren’s disease causes the fingers to curl into the palm, 
leading to severe impairment of hand function. Patients with 
advanced disease are most commonly treated by surgical 
excision of the diseased tissues. This requires extensive 
postoperative rehabilitation for three months.
The cell that produces the matrix, and is responsible for 
contraction in Dupuytren’s disease, is the myofibroblast. 
Our group recently reported that the locally secreted 
pro-inflammatory cytokine, TNF, specifically controls the 
development of myofibroblasts in Dupuytren’s disease. During 
the past year I have been investigating the TNF signalling 
pathways in Dupuytren’s disease and the mechanisms 
underlying persistence of the localised inflammation. 
My studies have been based on human tissues using 
techniques including cell culture, flow cytometry, RT-PCR, 
Western blotting, ELISA, Mesoscale Discovery, MTT assays, 
transfection, culture forced monitor, immunofluorescence 
and various histological techniques, as well as an ex vivo assay. 
There is currently 
no approved 
treatment to prevent 
the progression 
of early disease 
or recurrence 
following surgery. 
Achieving my 
research objectives 
will aid the 
development of 
new drug-based 
therapies to treat 
this disabling and chronic condition of the hand.
Musculoskeletal fibrotic disorders related to Dupuytren’s 
disease include frozen shoulder and periarticular fibrosis, which 
together affect approximately five per cent of the general UK 
population. Their common pathological link is the persistence 
of myofibroblasts. The findings from my study may therefore 
translate to other localised musculoskeletal fibrotic conditions.
There is an urgent unmet need to develop targeted therapies to 
prevent progression of the early stages of Dupuytren’s disease 
and prevent recurrence following surgery of this extremely 
common and disabling disorder.
Academic surgery is waning and few practising surgeons have 
the skills in the fields of molecular and cell biology. The RCS 
research fellowship has helped to fund a year of my DPhil 
research project and allowed me to gain the skills required to 
effectively join the next generation of surgeon scientists.
Targeting inflammatory pathways in 
Dupuytren's disease
FELLOWSHIP/SPONSOR
Blond McIndoe Research Fellowship
SUPERVISORS
Professor Jagdeep Nanachahal and Kim Midwood
SITE OF WORK 
Kennedy Institute of Rheumatology, Nuffield Department of 
Orthopaedics, Rheumatology and Musculoskeletal Sciences, 
University of Oxford
PUBLICATIONS
1. Verhoekx JS, Verjee LS, Izadi D, Chan JK, Nicolaidou V, 
Davidson D, Midwood KS, Nanchahal J. Isometric contraction 
of Dupuytren’s myofibroblasts is inhibited by blocking 
intercellular junctions. J Invest Dermatol. May 7 2013.
2.  Verjee LS, Verhoekx JS, Chan JK, Krausgruber T, Nicolaidou 
V, Izadi D, Davidson D, Feldmann M, Midwood KS, Nanchahal 
J. Unraveling the signaling pathways promoting fibrosis in 
Dupuytren’s disease reveals TNF as a therapeutic target.” 
Proc Natl Acad Sci USA. 2013; 110: E928–937.
PRESENTATIONS
1. The British Association of Plastic Reconstructive and Aesthetic 
Surgeons and Irish Association of Plastic Surgeons Winter 
Scientific Meeting, Dublin, Ireland, November 2013.
2.  British Society for Surgery of the Hand/British Association 
of Hand Therapists Combined Autumn Scientific Meeting, 
London, UK, October 2013.
FURTHER FUNDING
1. Kennedy Trust Funded Fellowship for 18 months.
2. RCSEd Small Project Grant for 1 year.
David 
Izadi
Dupuytren’s disease is a common disorder affecting 4% of the general UK population, and up to 20% of patients over 60 
years in Scotland. 20% develop complications and 10% of patients develop recurrence at 3 years. The direct cost of surgery 
to the NHS is £60m per annum.
David examining a patient with Dupuytren’s diseaseDavid disaggregating Dupuytren’s tissue for cell culture
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(TR040303), which is known to block the MPTP in other cell 
types, on pancreatic cells.
Experiments were conducted using the most modern 
equipment with high-powered microscopes that show 
changes in living cells, including human cells – given freely 
and willingly by pancreas patients – to evaluate effect of 
TR040303 on mitochondrial function and cell death in 
response to pancreatic toxins. Once the protective effects of 
the drug were established on cells, TR040303 was tested in 
three different models of experimental acute pancreatitis and 
it reduced the severity of disease.
These findings 
can be translated 
into a clinical trial 
and hence provide 
an opportunity to 
treat patients with 
acute pancreatitis. 
As MPTP opening 
is implicated in 
other diseases like 
cardiovascular 
and neurological 
disorders, our 
research can 
potentially help 
people with other diseases and facilitate research in other 
areas of science as well. Further research can be undertaken 
to dissect the exact mechanism of action of TR040303 and 
how it modulates the opening of MPTP.
Acute pancreatitis is a common, serious illness where the 
pancreas becomes inflamed in a short period of time. One 
in five people with pancreatitis develop a severe form of 
the disease that may need intensive care and treatment in 
hospital for several months – chronic ill health or even death 
can result. Unfortunately there is no specific treatment for 
this disease thus far. This research project tested a new drug 
that can be used to treat acute pancreatitis.
Our team has discovered that there is a special channel 
(mitochondrial permeability transition pore – MPTP) in 
cells, which if kept open is harmful to the pancreas. Opening 
of the MPTP damages cells by injuring the parts of cells 
called mitochondria, which use the fuel from food to make 
energy. Blocking this bad channel protects the mitochondria 
and prevents cellular damage. We tested a new drug 
Evaluating TR040303 as a potential treatment of 
necrotizing pancreatitis
FELLOWSHIP/SPONSOR
RCS Research Fellowship with support from the Surgical 
Rsearch Fund
SUPERVISOR
Professor Robert Sutton
SITE OF WORK 
NIHR Liverpool Pancreas Biomedical Research Unit
PRESENTATIONS
1.  TRO40303 reduces mitochondrial injury and 
ameliorates experimental AP. American Pancreatic 
Association meeting, November 2013, Miami, USA, 
and 39th annual meeting of Pancreatic Society of Great 
Britain and Ireland, December 2013, Liverpool, UK. 
2.  TRO40303 reduces mitochondrial injury in response 
to fatty acid ethyl esters and ameliorates alcoholic 
pancreatitis. Japanese & American Pancreatic 
Association Meeting, November 2014, Hawaii, USA
PRIZES
1.  Winner of the Lord Smith prize for best oral 
presentation, 39th annual meeting of Pancreatic Society 
of Great Britain and Ireland, December 2013
2.  Young investigator award & travel fellowship, 
presentation at the annual American Pancreatic 
Association meeting, November 2013
FURTHER FUNDING
CORE for three years
Muhammad 
Ahsan Javed
One in five people with pancreatitis develop a severe form of the disease but there is still no targeted therapy for acute pancreatitis.
Fresh normal human pancreas tissue being retrieved in theatre
Macroscopic appearance of normal human pancreas tissue
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Chronic Pancreatitis (CP) is a debilitating disease caused by 
acinar cell damage and fibrosis of the pancreas, affecting nearly 
1 in every 10,000 people. The disease leads to malabsorption, 
malnutrition, diabetes mellitus and increased risk of pancreatic 
cancer, but probably most significantly for the patients, severe 
chronic abdominal pain. There is little treatment.
Alcohol is a common cause but only the minority of those who 
drink to excess develop the disease, although the reason is 
unknown. Liverpool researchers have discovered that pancreatitis 
can be caused by a product of non-oxidative metabolism 
of alcohol. The majority of people get rid of alcohol by 
oxidation. We propose that there are differences in the genes 
related to alcohol metabolism, which may increase non-
oxidative products in some people, leading to CP.
To explore this, I set up a biobank to collect blood samples 
from patients with a history of alcohol excess, both with a 
good history of CP and those who are otherwise healthy. 
Using DNA extracted from the blood samples, I isolated 
the protein-coding region of 60 genes 
related to the metabolism of alcohol, 
using a technique called sequence 
capture.
I sequenced isolated DNA from 
102 cases and matched controls, 
using techniques (Next Generation 
Sequencing) that have only recently 
become available on this scale.
This has highlighted 24 different 
variations that are statistically different 
in frequency between the two groups. 
Although I have finished my formal 
research time, work is ongoing with the 
NIHR Liverpool Pancreas Biomedical 
Research Unit to validate these 
differences in a second population of 
patients, and once this is complete we 
can examine the way in which these 
different genes contribute to CP.
The role of alcohol metabolism in the development 
of chronic pancreatitis
FELLOWSHIP/SPONSOR
RCS Research Fellowship supported by the Harold Bridges 
Legacy
SUPERVISOR
Professor Robert Sutton
SITE OF WORK 
NIHR Liverpool Pancreas Biomedical Research Unit
PUBLICATIONS
1. DC Whitcomb, J LaRusch, AM Krasinskas, L Klei, JP 
Smith, RE Brand, JP Neoptolemos, MM Lerch, M Tector, 
BS Sandhu, NM Guda, L Orlichenko, Alzheimer’s Disease 
Genetics Consortium. S Alkaade, S T Amann, MA 
Anderson, J Baillie, PA Banks, D Conwell, GA Coté, PB 
Cotton, J DiSario, LA Farrer, CE Forsmark, M Johnstone, 
TB Gardner, A Gelrud et al. Common genetic variants in 
the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-
related and sporadic pancreatitis. Nature Genetics 
2012.
2.  Nicholson JA, Johnstone M, Greenhalf W. Divisum may 
be preserving pancreatic function in CFTR patients – but 
at a cost. Am J Gastroenterol 2012; 107: 1,758–1,759.
PRESENTATIONS
1. Pancreatic Society GB&I, Liverpool 2013. Carboxyl-ester 
lipase variable tandem repeat and its relationship to 
alcohol induced pancreatitis.
2.  Pancreatic Society GB&I, Liverpool 2013. The diagnosis 
of chronic pancreatitis: a systematic review.
PrizeS
Winning team – NIHR Experimental Medicine Doctoral 
Research Training Camp 2013.
Marianne
Johnstone
Chronic pancreatitis has a prevalence of approximately 70 per 100,000 population in the UK. It is not clear why certain 
individuals develop the disease, while the majority of people with equivalent exposure to risk factors do not.
Marianne preparing DNA in the lab ready for sequencing Post-sequencing analysis of data
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Women undergoing mastectomy commonly require 
postoperative radiotherapy, which is harmful to the 
reconstructive free flaps used for breast reconstruction. 
Irradiation of free flaps leads to contracture, volume 
loss and often requires further surgical procedures to 
correct. Therefore, when radiotherapy is anticipated breast 
reconstruction is delayed until after it has been delivered. 
Consequently, patients require multiple operations, a 
longer cumulative hospital stay and may have to live with a 
mastectomy deformity for a period before reconstruction can 
be performed. The over-arching goal of this work is to allow 
women undergoing mastectomy to have an immediate breast 
reconstruction at the time of their mastectomy, irrespective 
of their need for postoperative radiotherapy.
The aim of this project was to radioprotect reconstructive 
flaps using a virally delivered gene therapy strategy. 
Specifically, flaps were treated with viral particles carrying 
radioprotective genes by delivering them through the blood 
vessels of the flap in the interval in which it is detached from 
the body’s circulation. Once administered, the circulation is 
re-established by stitching the blood vessels of the flap to the 
systemic circulation.
So far, this project has developed and validated a novel 
model of flap irradiation and shown that radioprotective 
viral therapy reduces both contracture and volume loss 
after irradiation. Importantly, it achieves this without 
compromising the oncological efficacy of the radiotherapy 
itself against any residual cancerous disease.
This therapeutic modality (free-flap gene therapy) represents 
a highly novel opportunity for clinical translation and, 
indeed, the research programme at the Institute of Cancer 
Research and The Royal Marsden Hospital is currently the 
only one of its kind in the United Kingdom. The programme 
of work in this field is ongoing and aims, ultimately, to allow 
women undergoing mastectomy to have earlier, and more 
durable, breast reconstructions.
The radioprotection of free flaps using virally 
delivered gene therapies
FELLOWSHIP/SPONSOR
RCS Research Fellowship with the support of the Blond 
McIndoe Fund
SUPERVISORS
Professor Kevin J Harrington and Mr Paul A Harris
SITE OF WORK 
Institute of Cancer Research, Fulham Road, London
PRESENTATIONS
1.  British Association of Plastic, Reconstructive and 
Aesthetic Surgeons (BAPRAS) Winter Meeting. 
December 2013. Dublin, Republic of Ireland (invited 
lecture).
2.  National Cancer Research Institute (NCRI) Annual 
Conference. January 2013. Liverpool, England.
PUBLICATIONS
Seth R, Khan AA et al. Targeted gene delivery by free 
tissue transfer in oncoplastic reconstruction. Lancet 
Oncology 2012; 13: 392–402.
PRIZES
Paton Massor Memorial Fund, BAPRAS, 2011.
FURTHER FUNDING
1. The Wellcome Trust
2. British Association of Plastic, Reconstructive and 
Aesthetic Surgeons (BAPRAS)
3. Masons Medical Research Foundation for 24 months.Aadil 
Ali Khan
Almost half of all women undergoing mastectomy and breast reconstruction will require radiotherapy after surgery.
Aadil planning laboratory experiments with a scientific colleague. Discussing patient care with Mr Paul Harris (left) and Professor 
Kevin Harrington (right)
Presenting on free flap gene therapy techniques at the annual “Pint 
of Science” festival 2014 with Professor Kevin Harrington (right).
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Traumatic brain injuries (TBI) still claim the highest toll in 
terms of lost lives and disability for those under the age of 40. 
Treatment aims to control raised pressure within the head and 
maintain adequate blood flow to the brain. Despite optimal 
clinical management, about 10%–15% of patients require 
advanced therapies – such as a decompressive craniectomy or 
barbiturate coma – in order to control life-threatening rises in 
the pressure.
This project aimed to examine whether obstruction of the 
large veins inside the head – named intracranial venous 
sinuses – occurs following TBI. To do this, we screened TBI 
patients with a novel form of computed tomography (CT) 
scanning named CT venography, which 
provides detailed three-dimensional images 
of the venous sinuses. The pressure, brain 
oxygenation and biochemistry were also 
continuously monitored in those patients 
who were treated in the Neurocritical Care 
Unit.
Our results have shown that about one-
third of the patients who have a severe 
TBI and a skull fracture develop venous 
sinus obstruction. Importantly, we have 
found that patients with obstructed venous 
sinuses seem to develop more frequently 
life-threatening rises in the pressure within 
the head. In some cases, not even advanced 
therapies were able to avert a fatal outcome. 
We have also observed that obstructed 
venous sinuses can sometimes have long-
term effects such as severe headaches on patients who have 
otherwise gone on to make a good recovery after a severe TBI.
Previous work from our unit in patients suffering from 
another condition – named pseudotumour cerebri – that leads 
to high pressure within the head has shown that quite a few 
have obstructed venous sinuses. A novel treatment that was 
pioneered in Cambridge about ten years ago is the insertion 
of a stent to hold the vein open. As a result of this, the 
pressure is reduced and the patient’s symptoms improve. The 
current project, which builds on past research, is paving the 
way for a prospective study that will evaluate whether stenting 
is effective and safe following severe TBI.
Traumatic brain injury: the role of veins
FELLOWSHIP/SPONSOR
Freemasons’ Fund for Surgical 
Research with support from the 
Rosetrees Trust
SUPERVISOR
Professor Peter J Hutchinson
SITE OF WORK 
Division of Neurosurgery, 
Addenbrooke’s Hospital and University 
of Cambridge
PUBLICATIONS
1. Kolias AG, Kirkpatrick PJ, Hutchinson 
PJ. Decompressive craniectomy: 
past, present and future. Nat Rev 
Neurol 2013; 9: 405–415.
2.  Kolias AG, Guilfoyle MR, Helmy 
A, Allanson J, Hutchinson PJ. 
Traumatic brain injury in adults. 
Pract Neurol 2013; 13: 228–235.
PRESENTATIONS
1. Post-traumatic Venous Outflow 
Obstruction: the Effects 
on Intracranial Pressure, 
Cerebrovascular Pressure 
Reactivity and Outcome. 15th 
International Conference on 
Intracranial Pressure and Brain 
Monitoring, Singapore, 2013.
2.  The utility of CT Venography in 
patients with Traumatic Brain 
Injury. International Brain Injury 
Association’s 9th World Congress 
on Brain Injury, Edinburgh, 2012.
PrizeS
1. Best poster presentation at the 
9th World Congress on Brain 
Injury 2012.
2. Junior doctor ‘Teacher of the Year’ 
award, East of England Deanery 
2012.
FURTHER FUNDING
Raymond and Beverly Sackler 
Studentship (2011–2014) for 3 years
Angelos 
G Kolias
One in three patients who have a severe traumatic brain injury and a skull fracture develop blockage of the large veins 
inside the head.
Angelos (third from left) reviewing a patient with his colleagues in the Neurocritical Care Unit of Addenbrooke’s Hospital.
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There has been a 
growing interest 
in the use of 
stem cells to treat 
hearing loss. 
Recent work has 
shown it is possible 
to form early 
cochlear cells – the 
cells responsible 
for detecting 
sound in the ear 
– from stem cells. 
Our aim was to 
create a disease 
in a dish model of 
Usher syndrome, 
the most common 
deaf-blind 
syndrome.
 
Forming cochlear cells displaying the same disease as found in 
patients would enable us to try and manipulate and correct the 
cells using drugs or other compounds. Corrected cells could 
then be transplanted into patients potentially restoring hearing.
At the beginning of the fellowship we took skin biopsies from 
adult Usher patients and are the first group to derive stem 
cells from this disease. We have shown these stem cells are 
identical to patient cells and carry the same genetic change. It 
is as if we have taken adult cells and turned back the clock to 
the embryonic stage.
Usher Syndrome 1B: A stem cell model of deafness
FELLOWSHIP/SPONSOR
The Dr Shapurji H Modi Memorial Research Fellowship
SUPERVISOR
Lyle Armstrong
SITE OF WORK 
Institute of Genetic Medicine, Newcastle University
PRESENTATIONS
Usher Syndrome 1B: A stem cell model of deafness. Deafblind Scotland Annual Conference, 5 March 2013.
PRIZES
Otology Section Matthew Yung Short Paper Prize 2013–14. Royal Society of Medicine, 7 February 2014. ‘Generation of an in vitro 
disease model of Usher syndrome 1B (USH1B) using induced pluripotent stem cells (iPSC)’.
FURTHER FUNDING
Wellcome Trust for three years
Peter 
Kullar
Currently we have limited treatment options for the 1 in 6 people in the UK with hearing loss.
We then employed a protocol to form cochlear cells from 
these stem cells. This method was based on the chemical 
environment of the developing cochlea. We can now reliably 
create cells resembling those of the early cochlea.
The fellowship gave me a solid background for seeking further 
funding from the Wellcome Trust. This grant will fund an 
allied project and work within our group to further improve 
the protocol. During the next year we hope to be able to create 
more mature cochlear cells and our five-year plan would be 
then to correct the genetic defect in these cells. These could 
then be surgically implanted into the patient’s ear and replace 
the damaged patient cells.
Presentation at Deafblind Scotland March 2013
Institute of Genetic Medicine, Newcastle University
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Although 
total knee 
replacement 
(TKR) is an 
established 
and successful 
operation 
for end-stage 
osteoarthritis, 
a substantial 
proportion of 
patients (up 
to 20%) are 
dissatisfied 
following TKR. 
Unicompartmental knee replacement (UKR) replaces only 
the diseased parts of the knee, preserving normal joint 
surfaces and ligaments, and restoring more normal knee 
function. It is a smaller operation than TKR, and has fewer 
complications, but it is more likely to need revision surgery, 
usually owing to loosening of the cement bond between the 
implant and the bone. This project involved a series of studies 
to understand why UKR has a high revision rate, and to 
identify factors that might improve this situation in terms of 
patient selection, surgical practice and implant design.
In the first part, we used data on 550,000 patients from a 
national cohort to examine outcomes in TKR and UKR. 
Using this cohort, we identified factors in terms of patient 
selection and surgical practice predisposing to poor outcomes 
after UKR. Finally, we performed studies of a new implant 
design, designed to improve bone-implant fixation. We have 
found that the new implant demonstrates improved fixation 
and is as safe and reliable as the standard implant. The new 
implant is now being introduced worldwide.
We hope this research will improve patient care in four 
areas. By providing more evidence of the advantages 
and disadvantages of UKR, surgeons and patients will be 
better-informed when choosing between TKR and UKR. 
By providing a greater understanding of the patients likely 
to fare well after UKR, patient selection for UKR should 
improve. By determining surgical factors associated with 
success, UKR provision may be concentrated in units where 
success is more likely, leading to better outcomes overall. 
Finally, as the new implant provides improved fixation, 
patients receiving UKR in the future may have more reliable 
long-term outcomes.
Understanding failure in unicompartmental knee 
replacement
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90,000 knee replacements are performed each year in England and Wales and up to 20% of patients are dissatisfied.
Alex with his supervisor Professor Murray
Alex with one of his patients
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With a growing and ageing population, the numbers of bone 
graft procedures in spinal, joint replacement and trauma surgery 
is growing exponentially. Current bone graft strategies, using 
cadaveric or synthetic bone are often unsuccessful and can transmit 
disease and be expensive. Using stem cells to create bone tissue 
from patients’ own cells for use in bone graft procedures is an 
attractive solution. This work aims to investigate cost-effective 
methods of creating bone from stem cells, and produce spherical 
beads of bone tissue for use in bone graft surgery.
Stem cells were grown on two-dimensional plates within the 
Biosystems Engineering Laboratory at Imperial College London 
and were fed various combinations of proteins that are known to 
promote bone growth from stem cells. The oxygen content of the 
atmosphere was altered to investigate if this helped bone growth. 
The addition of two proteins (BMP4 and FGF2) to the growing 
cells was found to enhance the amount of new bone produced, 
and a lower amount of oxygen in the atmosphere compounded 
further improved production. These results have confirmed 
previous reports that adding proteins can improve bone tissue 
production from stem cells, and has shown for the first time that 
low concentrations of these proteins, at low oxygen levels, enhances 
bone tissue production.
As this work progresses, bone production will be continued in 
three-dimensional beads made from hydrogels. Other cost-effective 
ways of enhancing bone production from stem cells within the 
3D bead environment will be investigated. This work is expected 
to generate personalised, biologically active bone graft implants, 
which could be used to improve the success rate for patients 
undergoing spinal, joint or trauma surgery requiring bone grafts, 
improve the pain levels experienced by many patients, and reduce 
the need for further surgery.
The production of bio-inspired, 3D mineralised 
cellular implants using induced pluripotent stem 
cells for bone tissue engineering applications
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7: 243–254.
FURTHER FUNDING
Joint RCS–Dunhill Medical Trust research fellowship for 
two years
Robert James 
MacFarlane
Up to 70% of bone grafting procedures fail within 10 years.
Robert at work in the Biosystems Engineering Laboratory, Imperial College London
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Using regulatory B cell therapy, we sought 
to address the problem of chronic allograft 
rejection and thereby improve the long-
term outcomes of transplanted organs. 
Using a mouse heart transplant model of 
chronic allograft rejection, we were able to 
demonstrate that regulatory B cell therapy 
could prolong allograft survival and ameliorate 
the development of deleterious autoantibody 
and cardiac allograft vasculopathy.
These findings corroborate the demonstration 
of increased regulatory B cell frequency in 
kidney transplant patients that show stable graft 
function in the absence of immunosuppression, 
when compared to patients requiring ongoing 
immunosuppression or undergoing chronic 
rejection.
Further work is required to understand the 
mechanism of action of regulatory B cells in 
transplantation before their introduction into 
human clinical trials, although the production 
of the cytokine interleukin-10 is thought to be 
critical.
These findings highlight the potential for 
regulatory B cells to be used as cellular 
immunotherapy in clinical transplantation, and 
could avoid the need for re-transplantation in 
a significant proportion of patients and further 
burden on an already scarce supply of organs.
Regulatory B cell therapy in transplantation
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SUPERVISOR
Gavin J Pettigrew
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Mekhola 
Mallik
Half of all solid organ transplants fail within just ten years.
This patient lost his kidney transplant after three years and had to return to dialysis. My research seeks to prevent the 
late loss of transplanted organs.
Teaching Brazilian students Basic Surgical Skills as a Stefan and 
Anna Galeski Travelling Fellow
Winner of the first Scientific Meeting of the 
Brazilian College of Surgeons and Royal College 
of Surgeons of England Research Trainee Prize
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The aim of this project was to investigate the role of bacteria 
in causing symptoms of throat inflammation.
Twenty-two patients were recruited who had severe throat 
symptoms. All patients had failed to improve despite 
strong medical therapy. Patients were investigated through 
a symptom questionnaire, standardised examination 
findings score, robust physiological tests and finally biopsies 
performed of their throat under local anaesthetic using a 
novel endoscopic technique. Biopsies were investigated by 
molecular techniques for the presence of Helicobacter Pylori.
All patients had rated their symptom burden as severe 
on a validated questionnaire and were found to have 
signs of throat inflammation on standardised endoscopic 
examination. However, no patient had acid reflux into their 
throat during physiological investigations. Thirty per cent of 
participants were found to be colonised with Helicobacter 
Pylori.
This work was undertaken to improve the treatment of 
symptoms related to throat inflammation. This condition 
causes great distress to patients, resulting in difficulty 
swallowing, breathing and speaking. Quality-of-life studies 
have shown that this condition has a large disease burden. In 
addition it is one of the commonest reasons for referral into 
the ENT team and treatment does not consistently work. This 
has led many groups to suggest the underlying mechanism of 
symptoms may not be related to reflux of acid into the throat, 
as has been traditionally held.
My preliminary findings suggest an interesting role of a 
bacteria causing throat irritation. This bacteria is already well 
known to cause inflammation in the stomach. My findings 
have prompted a collaboration with an American group and 
together we will continue to characterise the role of this 
bacterium in the throat, with the aim of finding novel ways to 
treat patients with this condition.
Investigation into the association of Helicobacter 
Pylori and laryngopharyngeal reflux
FELLOWSHIP/SPONSOR
H&S Charitable Trust Fund
SUPERVISOR
Professor Martin Birchall
SITE OF WORK 
Ear Institute, UCL, London
Nishchay 
Mehta
One in every three patients with laryngopharyngeal reflux was found to be colonised by a bacteria known to cause cancer 
when present in the stomach.
Nish taking a biopsy of the pharynx with a transnasal oesophagoscope
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has a huge advantage as there is a range of naturally occurring 
and genetically modified mouse strains that mimic human 
deafness. To date, there are very few studies of CI in mice. The 
primary aim of the project was to develop a reproducible and 
viable technique to enable long-term CI in the mouse and to 
assess the cochlea response to implantation.
Despite the technical challenges, we have developed a 
successful method for mouse CI with excellent survival 
rates to date. Analysis post-implantation showed evidence of 
greater threshold shifts in the implanted ear, but substantial 
preservation of residual hearing. There were no cases 
of profound hearing loss. Histological analysis revealed 
inflammation within the cochleae and encapsulation of the 
implant in tissue with characteristics suggestive of fibrosis. 
Research continues to more clearly define these effects on 
residual inner ear structure and function. It is hoped the 
research will help optimise surgical techniques and design 
more appropriate electrodes with regards to preserving 
hearing and therefore maximise benefits to patients. There is 
also huge interest in delivering therapeutics to the inner ear 
via CI to both preserve and enhance function. Our mouse 
model will help 
pave the way for 
this research as, 
without a suitable 
animal model, 
this will not 
become a reality.
Hearing impairment is the most common sensory disability 
in humans. In terms of treating profound sensorineural 
hearing loss, cochlear implants play a key role and are the 
most successful sensory prosthetic device developed in the 
past 40 years. One area of growing research is cochlear 
implantation (CI) in patients with residual hearing such as 
those with age-related hearing loss. To date, the benefits of 
CI in these patients have been overshadowed by the fact that 
some can lose a substantial part of their residual hearing 
in the implanted ear. This is concerning, especially as the 
underlying cause of this loss remains unclear and prompts 
questions regarding the effects of CI on inner ear structure 
and function.
Investigation of CI and the inner ear in humans is mainly 
restricted to post-mortem studies. This relative inaccessibility 
has therefore led to the development of various animal 
models, which play a key role in research. The use of mice 
Developing a mouse model of cochlear implantation
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Nina 
Mistry
Hearing impairment currently affects more than 280 million people worldwide and by 2030 the World Health 
Organization predicts there will be an estimated 14.5 million, making it one of the Top 10 disease burdens, ahead of 
conditions such as diabetes.
Nina with a patient
Nina presenting at the Association for Research in Otolaryngology
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Deep venous haemodynamics and development of a 
deep vein valve implant
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Freemasons’ Fund for Surgical Research with the 
support of the Rosetrees Trust
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Chronic venous disease affects a third of the adult population of Western Europe and the USA and costs approximately 
1%–2% of the annual healthcare budget of these countries.
Chronic venous disease is common, distressing and a significant 
cause of healthcare expense. The cause is failure of the valves 
in the superficial or deep veins of the legs. Patients with deep 
venous disease have limited options for treatment. A safe 
method of treating patients with this complex disease is needed.
The aims of this project were to make measurements around 
normal deep vein valves using ultrasound and magnetic 
resonance imaging, to develop computational and laboratory 
flow models for deep vein valves, to develop and investigate 
a new material to engineer a prototype deep vein valve 
replacement and to develop a valve for implantation into the 
deep venous system.
An observational study has been carried out evaluating 
subjects with normal deep veins with ultrasound, contrast 
enhanced ultrasound and dynamic magnetic resonance 
imaging of normal subjects. This has given the flow, velocity 
data and anatomical images required for the project.
A preliminary computational flow model has been developed 
using the data obtained from the imaging stage of the project. 
This is a two-dimensional model incorprating flexible valve 
leaflets. A laboratory model of venous function, in the form of a 
flow rig has been created.
Presently, materials and coated metal stents used in the vascular 
system have several problems. They cause clotting of blood 
and are often not compatible with blood or body systems. In 
addition, they lack the required mechanical properties. I have 
synthesised a novel material that is very compatible with blood, 
based on the material Methacrylolyoxyethyl phosphorylcholine 
(MPC). Its properties have been modified to change its 
solubility and mechanical properties.
This project aimed to guide the development of a treatment for 
patients, for whom few options are available. Chronic venous 
disease and venous ulceration are painful and debilitating, 
potentially requiring years of treatment. An effective treatment 
option that could be carried out without major surgery could result 
in ulcers healing quicker and improvements in patients’ symptoms 
and quality of life, as well as reduced costs for the NHS as a whole.
A patient having an MRI scan of the veins and valves in the leg Professor Davies and the Academic Section of Vascular Surgery Hayley presenting at the Charing Cross Symposium
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Estrogen receptor beta is an important modulator 
of prostate carcinogenesis
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Prostate cancer is the commonest cancer in men. Despite many years of research, the role of estrogen in the prostate is 
incompletely understood.
The steroid hormone  estrogen has been shown to be 
important in the development and progression of prostate 
cancer (PC). To date, the mechanisms by which estrogen 
exerts its effects in the prostate are incompletely understood. 
There are two receptors in prostate tissue that mediate 
the effects of estrogen; estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ). ERα is thought to mediate the 
‘bad’, tumour-promoting effects of estrogen, whereas ERβ 
is thought to be mostly protective and 
tumour-suppressive. However, recent 
evidence would suggest that ERβ may 
also have a harmful, tumour-promoting 
effect within the prostate. The aim of 
my research, therefore, is to improve 
understanding of the role of ERβ and to 
establish whether it represents a target for 
future treatment of PC.
The broader study of ERβ has thus 
far been hampered by problems with 
specificity of antibodies for detecting 
ERβ in tissue samples or cultured human 
cell lines. This has led to conflicting 
and confusing results in the published 
literature. My research so far has been 
focused on testing a large number of 
ERβ antibodies to ensure that I have 
a useful, accurate antibody that will 
specifically target ERβ in the samples I 
will be working with. To do this, I have 
been working in a cell line with ERβ 
expression that can be switched on or 
off with doxycycline. The result of this 
work has been that I now have three validated ERβ antibodies 
that I can confidently take forward to use for the rest of my 
research. These antibodies will be used for a wide range of 
studies on PC cell lines and human prostate tissue to assess 
if ERβ expression correlates with patient prognosis, and to 
assess the function of ERβ at a genetic level to see how it 
influences cancer development and progression.
Adam with one of his patients
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An integrated approach for individual treatment 
planning in aortic dissection
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Half of all patients with aortic dissection are dead within five years, regardless of the treatment they receive.
Aortic dissection is a life-threatening condition where a tear 
develops in the inner lining (intima) of the aorta, forming an 
additional false channel (lumen). As a result, blood flow in 
the true lumen may be compromised, affecting the viability 
of organs. Tear location and the presence of complicating 
factors (persistent chest pain due to ongoing aortic growth, 
compromised blood supply to organs and aortic rupture) largely 
dictate patient management.
Stable patients undergo regular imaging, monitoring changes in 
aortic size. Aortic growth of 0.5 cm from previous scans or a total 
aortic size of 5.5 cm, are deemed significant, requiring stent-
graft insertion. Despite best medical and surgical care, patients 
continue to have variable outcomes and those with apparently 
similar types of dissection anatomy have different long-term 
outcomes. Unsurprisingly, managing these patients is difficult.
Although false lumen haemodynamics (blood pressure, 
velocity and wall shear stress) are thought to be responsible for 
complications, no study has proven this. The aim of this project 
is to develop an entirely non-invasive, tailor-made method to 
study haemodynamics in aortic dissection using a combination 
of computed tomography (CT) and magnetic resonance (MR) 
imaging and computer simulation techniques. This will allow 
development of a patient-specific method for treatment planning, 
providing a superior modality of care.
There are two parts to this study. In the first instance, patients 
due for stent-graft insertion (due to the presence of symptoms or 
adverse features on their clinical imaging) have an aortic MRI 
prior to surgery and invasive pressure wire measurements taken 
from within the aortic true and false lumen during their surgery.
Anatomical data from the CT and physiological haemodynamic 
data (velocity) from the MRI scan is used to develop a non-
invasive simulation of aortic conditions. A comparison of invasive 
and non-invasive methods will determine validity. As a second 
stage, a follow-up study of patients using this non-invasive 
method will determine the effect of aortic haemodynamics on 
patient outcomes.
Alia and Dr Figueroa analysing simulation results
Aortic dissection models 
developed by Alia
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Vibrational spectroscopy for early diagnosis of 
Barrett's neoplasia
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The head of division is a Clinical Lead on the Barrett’s Oesophagus Surveillance Study (BOSS), the largest randomised controlled 
trial of Barrett’s surveillance worldwide, instigated and led by my MD research supervisor, and our team in Gloucester.
The Harry Morton Fellowship gave me the opportunity to 
visit McMaster University Medical Centre and the Farncombe 
Family Digestive Health Research Institute in Hamilton, 
Ontario. Farncombe has a reputation as one of the leading 
research groups in the world in gastrointestinal conditions. 
The research towards my MD has been focused on Barrett’s 
oesophagus and early oesophageal cancer: this is one of many 
areas of expertise at the Farncombe Institute.
The Farncombe Institute is composed of both clinicians 
and full-time scientists, with daily presentations of current 
research and lively discussion. It was fantastic to experience 
this integrated research environment in a centre for academic 
medicine. Members of the group have a long history of 
Barrett’s research, with particular interests in advanced 
endoscopic imaging techniques closely related to my research 
in optical diagnostics. Discussing my work with this group 
allowed me to benefit from their experience in this field.
The head of 
division is Professor 
Paul Moayyedi, 
an academic 
gastroenterologist and 
a clinical lead on the 
Barrett’s Oesophagus 
Surveillance Study 
(BOSS), the largest 
randomised controlled 
trial of Barrett’s 
surveillance worldwide, instigated and led by Professor Hugh 
Barr, my MD research supervisor, and our team in Gloucester. 
The visit provided an opportunity to discuss the BOSS trial 
in depth, and plan the 
initial output from the trial. 
This was a great learning 
experience for me to discuss 
aspects of clinical trials 
methodology and statistical 
analysis with a group of 
experts. We were then able 
to set up an international 
teleconference with key 
collaborators and share our 
thoughts on the analysis plan for the BOSS trial. As a result, we 
have recently submitted the first paper from this study.
I was also able to spend time observing endoscopy sessions and 
shadowing a senior resident during general surgical on calls at 
the nearby Juravinski Hospital (both McMaster and Juravinski 
hospitals form part of Hamilton Health Sciences). This gave 
me an insight into the Canadian healthcare system and some 
of the similarities and differences between our health services. 
Overall, this was a rich experience that provided many valuable 
lessons for my future clinical and research career.
Oliver with Professor Paul Moayyedi
Hamilton borders the Niagara Peninsula and is a short 
drive from Niagara Falls
The Toronto skyline from Lake Ontario
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Barrett's neoplasia
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Under 10% of cases of oesophageal adenocarcinoma are detected as part of current Barrett’s screening programmes.
Cancer of the 
oesophagus 
(gullet) affects 
over 8,000 
patients in the 
UK each year. 
Unfortunately, 
most patients are 
diagnosed at a late 
stage and curative 
treatment is not 
possible (only 13% 
survive 5 years from diagnosis). Early diagnosis is the key to 
enabling timely intervention and improving survival.
Barrett’s oesophagus is a pre-malignant condition which can 
sometimes progress to cancer, but most patients with the 
condition have mild symptoms of acid reflux, or no symptoms 
at all. There are an estimated one million people in the UK 
with Barrett’s oesophagus, but only 
a small minority of these will have 
their condition diagnosed.
Current screening programmes use 
endoscopy to monitor patients with 
known Barrett’s oesophagus for 
cancerous changes. Undertaking 
endoscopy as a screening tool in 
the general population would be 
expensive, invasive and impractical, 
and a number of groups have 
investigated non-endoscopic tests. 
One possibility is collecting cells 
from the 
oesophagus 
using a 
miniature 
brush, which 
is swallowed 
and then 
withdrawn. 
Microscopic 
analysis of 
oesophageal 
cells is rarely performed, lacks standardisation, and screening 
would be labour intensive and costly.
Infrared spectroscopy is an optical diagnostic technique 
that provides detailed biochemical measurements of cellular 
content. We investigated infrared spectroscopy as a method for 
accurate and automated detection of early oesophageal cancer 
in these cells.
We collected cells from the oesophagus in patients undergoing 
endoscopy. We then used infrared spectroscopy to measure 
each sample, and build classification models based on the 
known pathology of each patient. Testing our model has shown 
highly accurate identification of Barrett’s and early cancerous 
changes, suggesting great promise for this technique in 
screening for early oesophageal cancer.
Next steps will include refining the collection and 
measurement techniques for widespread use in Barrett’s 
screening, and a clinical trial testing infrared cytology 
screening against current gold-standard (endoscopy and 
biopsy).Oliver presenting work at a conference
Oliver performing an endoscopy
Oliver discussing the project with a nurse in endoscopy
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FELLOWSHIP/SPONSOR
National Joint Registry/RCS Fellowship
SUPERVISORS
Professors Paul Gregg (NJR), David Murray (Oxford) and Ashley Blom (Bristol)
SITE OF WORK 
Multiple sites including Leicester, Oxford and Bristol
PRIZES
1.  First Prize ISAR 2014 Conference, Boston: Temporal trends in Revision Total Hip Replacements.
2. Third Prize Poster presentation: ISAR 2014, Boston: The influence of femoral stem design on the incidence of periprosthetic 
fracture after hip replacement.
FURTHER FUNDING 
Gwen Fish Charitable Research Trust for up to two years
Jeya 
Palan
The National Joint Registry (NJR) for England, Wales and Northern Ireland is the largest arthroplasty registry in the 
world with ore than 1.6 million records for total hip, knee, shoulder and ankle replacements.
My fellowship year was spent on a number of research projects.
1. Service evaluation and validation of the NJR data on Oxford Medial Unicompartmental Knee Replacements. This retrospective 
radiographic study using NJR data will identify the reasons for higher and lower than expected revision rates following Oxford 
unicompartmental knee replacements (UKR). This study will identify if inappropriate surgical indication or poor surgical 
technique can explain the reasons for higher than expected revision rates.
2. Temporal trends in Revision Total Hip Replacements: an analysis of 
National Joint Registry data from 2003 to 2012. The number of revision 
total hip arthroplasties (THA) being performed is increasing, but 
little is known about any changing pattern in patient demographics 
or reasons for revision over the past decade. This study has shown 
that patient characteristics have generally remained constant over 
the past decade. There has been an increase in the number of cases 
being revised for adverse tissue reaction and unexplained pain.
3. The influence of femoral stem design on the incidence of periprosthetic fracture 
after hip replacement. A periprosthetic fracture (PPF) following a total 
hip replacement (THR) is a devastating complication associated with 
increased morbidity and mortality for the patient. Different femoral 
stem designs and type of fixation (cemented or cementless) can 
influence the risk of having a revision for a PPF.
4. Data validation in arthroplasty registries. This review highlights some 
of the key issues on data validation in arthroplasty registries and 
describes the data validation process being developed in the NJR to 
improve data capture and accuracy. This project will work together 
with the British Orthopaedic Network Environment (BONE) 
in delivering a high-quality internal audit mechanism for data 
validation in units performing hip or knee replacements.
In summary, this fellowship has enabled me to undertake further analysis 
of the NJR data that will help clinicians and patients make informed 
choices about their hip or knee replacements, identify trends in revision 
hip or knee replacement surgery and to improve the data validation 
process in the NJR.Jeya doing a total hip replacement
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Femoroacetabular impingement trial (FAIT): A multi-centre 
randomised controlled trial comparing surgical and non-
surgical management of femoroacetabular impingement
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Antony 
Palmer
The goals of treating femoroacetabular impingement are to improve patient symptoms and prevent the development of 
osteoarthritis.
Osteoarthritis is the most common joint disease worldwide, 
affecting an estimated 10% males and 18% females over 60 years 
of age. It results from the action of hostile biomechanics upon a 
susceptible joint and correction of these biomechanics may offer 
a means of disease prevention. This would represent a paradigm 
shift in osteoarthritis treatment where currently the only 
effective treatment is joint replacement for advanced disease.
Femoroacetabular impingement (FAI) is a hip condition that 
gives rise to hostile biomechanics through abnormalities 
in the shape of the femoral head-neck junction (cam 
impingement) or orientation of the acetabulum (pincer 
impingement). The consequence is pathological abutment of 
the femoral head-neck junction against the acetabular rim. 
In the short term, FAI can cause pain and disability, and in 
the long term it significantly increases the risk of developing 
osteoarthritis. Studies suggest FAI may be responsible for 
more than half of all cases of hip osteoarthritis.
There is considerable uncertainty surrounding how best to treat 
FAI. The principal two therapies adopted are physiotherapy 
and surgery. These aim to correct adverse joint biomechanics, 
either by improving core stability and movement control, or 
reshaping the hip joint. There is no long-term outcome data 
for either treatment and no study has compared their efficacy. 
This is an important area for research, given that the number of 
operations performed worldwide for this condition continues to 
rise exponentially.
In a feasibility study, we 
demonstrated equipoise 
amongst patients and 
surgeons with respect to 
FAI treatment, and used 
our findings to design a 
multi-centre randomised 
controlled trial. This ongoing 
trial compares the efficacy 
of physiotherapy with 
arthroscopic surgery for both 
improving symptoms and 
preventing osteoarthritis. 
In addition to conventional 
radiographic measures 
of osteoarthritis that only detect advanced disease, we are 
using novel markers of early degenerative change including 
physiological MRI and urinary and serum biomarkers of joint 
metabolism. These offer the potential to determine treatment 
efficacy within a short timeframe. (NCT01893034)
The study allows high-resolution assessment of joint morphology that enables diagnosis and 
monitoring of early osteoarthritis
Image of the hip revealing early osteoarthritis
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Characterisation of MicroRNAs in ulcerative 
colitis and colitis associated cancer for use as 
potential biomarkers
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The Professor Norman Williams and Ileostomy Association 
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Baljit Singh and Howard Pringle
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MicroRNA manipulation in colorectal cancer cells: from 
laboratory to clinical application. J Transl Med 2012; 20:10.
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1.  Screening of novel plasma MicroRNAs associated with 
disease progression in Ulcerative Colitis, European Union 
of Gastroenterology Week, Vienna, Austria, October, 
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2.  Colitis Associated Cancer: a UK institutions 12-year 
experience. Royal Society of Medicine, Coloproctology 
section, Geneva/Switzerland, May 2012. Oral 
Presentation.
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Maleene 
Patel
Ulcerative colitis affects 1 in every 420 people in the UK and is an established risk factor for colorectal cancer.
Ulcerative Colitis (UC) is a life-long, inflammatory condition of 
the large bowel. Patients with UC require regular colonoscopies 
to detect pre-cancerous changes known as dysplasia. The 
colonoscopic surveillance method is user dependent and can 
miss dysplastic lesions. Furthermore it is resource intensive, 
invasive and has poor patient compliance. These pitfalls fuel 
the ongoing search for alternative-screening methods that 
can accurately diagnose dysplasia or colitis-associated-cancer 
(CAC) at an early stage.
MicroRNA (miRNAs) are regulatory molecules that have been 
implicated in many pathological processes, including cancer 
development. My research aimed to establish the miRNAs 
associated with UC and assess their potential as biomarkers for 
the detection of dysplasia and CAC.
The first part of the study utilised high-throughput discovery 
technology to profile the expression of 381 miRNAs in 
archived, UC-affected colonic mucosa. Real-time quantitative 
PCR was subsequently used to validate the results in an 
independent cohort. Combining different miRNAS together in 
a panel increased the capacity of the miRNAs to differentiate 
between disease states.
In the second part of the study, blood samples were collected 
from 120 patients undergoing colonoscopic surveillance for UC. 
Blood samples were allocated into groups based on biopsy results 
(Quiescent UC, Active UC, Dysplasia and CAC). Microarray 
technology was utilised to screen for more than 750 miRNAs 
within the groups, followed by PCR validation of 27 high-priority 
miRNAs of interest. Mir-375 was one of the miRNAs found to 
distinguish CAC cases from UC cases.
This feasibility study provides proof of concept of miRNAs as 
biomarkers. Future research will extrapolate these findings to a 
larger UC population to further evaluate the selected panel of 
miRNAs. This could lead to a blood test to monitor and identify 
patients that are at risk of developing CAC. Such a test would 
reduce unnecessary colonoscopies, and improve outcomes for 
patients through prompt surgical intervention.
Maleene consenting a research patient
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Real-time imaging of the human middle ear using 
high frequency ultrasound
FELLOWSHIP/SPONSOR
Harry Morton Fellowship
SUPERVISOR
Professor Manohar Bance
SITE OF WORK 
Dalhousie University, Halifax, NS, Canada
James 
Rainsbury
High-frequency ultrasound (HFUS) allows excellent visualisation of much middle ear anatomy and pathology through an 
intact ear drum, or Tympanic Membrane (TM).
I chose Halifax for my fellowship because of the excellent 
international reputation of the unit for high-quality research in 
middle ear mechanics. Professor Bance has built up a lab that 
is supported not only by a team of biomedical engineers but 
also a ‘Fab Lab’, or fabrication lab, which is purpose built for 
precision engineering anything from piezo-electric transducers 
for experimental bone conducting hearing aids to the cutting-
edge handheld endoscopic ultrasound scanner used for my 
experiments in middle ear imaging.
Chronic middle ear disease and conductive hearing loss are 
two common problems managed by otologists. In the middle 
ear, direct visualisation of tissue or fluid, and the ability to 
evaluate the ossicles (the malleus, incus and stapes) would 
enhance the diagnosis of conductive hearing disorders and 
provide a non-surgical means of assessing the performance of 
implants used to reconstruct the ossicular chain. For imaging 
past the TM, modalities such as computed tomography are 
typically used, but these often do not provide sufficient 
resolution of structures of interest.
HFUS (>20MHz) is a relatively new area of ultrasonic imaging 
that provides an order of magnitude better resolution than 
conventional low-frequency systems. Although HFUS has 
previously been implemented in some clinical applications, such 
as intravascular and ophthalmic imaging, it has not been widely 
accepted as a diagnostic tool because commercially available 
systems have a limited depth-of-field. In low-frequency ultrasound 
systems, improvement in depth-of-field is achieved by replacing 
the single element transducer with a transducer array and an 
electronic beamformer, and there has recently been some success 
in developing high-frequency 30-50MHz array transducers and 
beamformers. This may increase the clinical utility of HFUS and 
introduce new applications such as imaging the auditory system.
This study 
investigated 
the 
capability of 
HFUS using 
a transducer 
array to 
image the 
middle 
ear in real 
time to demonstrate simulated clinical scenarios involving the 
ossicular chain, as well as measuring vibrations of TM and middle 
ear structures in response to sound stimuli.
In unfixed cadaver ears, the TM, ossicles and middle ear were all 
easily identifiable, with capabilities demonstrated for real-time 
imaging and video capture, three-dimensional reconstruction 
and vibrometry of middle ear structures. Based on these results, 
we conclude that HFUS is a relatively simple and minimally 
invasive technology with great potential to provide clinicians with 
new tools for diagnosing and monitoring middle ear pathologies.
James presenting at the RCS, 12 Sept 2014
Implanting the Bonebridge, a novel bone 
conducting hearing implant
Halifax
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Study of spermatogonia stem cell propagation prior 
to cancer treatment in a mouse model
FELLOWSHIP/SPONSOR
The Shears Northern Research Fellowship
SUPERVISORS
Professor Robert Pickard, Professor Mary Herbert and 
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SITE OF WORK 
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1. International Society For Stem Cell Research, Stem 
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2. BAUS Academic Section at SARS meeting, Robinson 
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1. North East Surgical Society – Feggetter Prize for 
Best Presentation. May 2013.
2. BAUS Academic Section at SARS meeting, 
Cambridge – Prize for presentation. January 2014.
FURTHER FUNDING 
The Urology Foundation for two yearsRaveen 
Kaur Sandher
In the UK, more than 850 boys are diagnosed with cancer every year, the treatment of which can often lead to irreversible 
infertility.
In the UK more than 850 boys are diagnosed with cancer 
annually. With improving cancer survival there has been a 
greater focus on life after cancer. Cancer treatment can have 
an irreversible effect on boys’ fertility. Treatment depletes 
the precursors to sperm, the Spermatogonial Stem Cells 
(SSCs). SSCs only develop into sperm at puberty; so freezing 
of sperm is not an option as it might be in adults. Currently 
we are not able to preserve fertility in these patients.
Exciting research has shown that by taking a testicular 
biopsy before cancer treatment, growing (culturing) the 
SSCs in a laboratory and then transplanting them back 
into the testicle can restore fertility in a mouse model. The 
published methodology for culturing SSCs was slow and 
produced a low cell number. In addition, freezing SSCs was 
extremely difficult, with many cells being non-viable upon 
warming. Therefore the aim of my research was to develop 
a rapid, reliable and reproducible method to culture and 
freeze mouse and eventually human SSCs.
In order to optimise the culture method, I decided to 
grow SSCs alongside the other supporting cells in the 
testicle. These cells are important because they release 
growth factors. By mimicking the in vivo environment I 
saw a dramatic increase in SSC number at several time-
points. Very few groups across the world have been able 
to grow human SSCs in the laboratory; however, using 
this technique I have been successful. In addition, using a 
rapid freezing method that prevents ice crystal formation 
within the cell, and therefore less cell wall disruption upon 
thawing, I have been able to demonstrate excellent viability 
rates after freezing.
In conclusion, I have 
been successful in 
maintaining long-term 
cultures of human 
SSCs. My findings 
are an important 
advancement for 
the future clinical 
application of SSCs 
restoring fertility to 
male childhood cancer 
survivors.
Spermatogonial stem cells on a confocal microscope
Raveen discussing her research project with a patient with male infertility
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Improved diagnostic outcomes in craniofacial 
surgery by use of next generation DNA sequencing
FELLOWSHIP/SPONSOR
Blond McIndoe Research Fellowship supported by the 
Rosetrees Trust
SUPERVISOR
Professor Andrew Wilkie and Steven Wall
SITE OF WORK 
Weatherall Institute of Molecular Medicine, University 
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Despite major craniofacial surgery to remodel the skull in patients with craniosynostosis to relieve raised intracranial 
pressure or deteriorating head shape, an underlying causative gene defect can only be identified in 21%–24% of cases.
Craniosynostosis is the premature fusion of growth points 
or sutures in the skull. It is relatively common, affecting 
approximately 1 in 2,200 people. This early fusion can have 
adverse effects on airway, breathing and brain development. At 
least one major surgical procedure is required to correct skull 
deformity, allow normal brain growth and prevent complications. 
Coronal synostosis is the second commonest pattern of premature 
fusion. Scientific evidence suggests it is enriched for single gene 
mutations and associated with secondary complications requiring 
further surgery.
This project used new 
DNA technology and 
advanced computational 
methods to analyse the 
fraction of the human 
genetic code that makes 
proteins. The aim was to 
search for novel disease 
genes in patients with 
bilateral coronal synostosis 
where all gene tests were 
negative. Damaging genetic 
variants shared between 
two or more patients were 
prioritised as this strategy 
previously identified a new 
disease gene and condition, 
known as TCF12-related 
craniosynostosis. During 
this project, a further novel 
disease gene (TCF20) was identified in a single patient with 
coronal synostosis and autistic spectrum disorder. As further 
patients later identified with this gene mutation had autism 
only, it is not thought to cause coronal synostosis.
Further investigation into the genetic background of TCF12-
mutation-positive individuals with or without craniofacial 
problems suggests it is important in disease development. 
Analysing parental origins in cases where TCF12 mutations arose 
as a new condition (‘de novo’) revealed a paternal origin in some 
cases and two instances of maternal origin. Sequencing DNA 
of parents of selected patients looking for de novo mutations 
revealed in one family a novel variant in MYH4, providing a new 
candidate for future studies.
Finally, lists of genes with damaging variants have been compiled 
so future researchers can continue this work to improve diagnostic 
outcomes, surgical risk stratification and genetic counselling for 
patients.
Vikram and Douglas Murray (former BAPRAS 
President) following the former’s prize-winning 
national presentation at the Tenth West Midlands 
Plastic Surgery Meeting (September 2013)
Members of the Wilkie Lab, where molecular research was conducted
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The differential expression of microRNA in 
abdominal aortic aneurysms
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Abdominal aortic aneurysms are the tenth leading cause of death in men over 65 years.
An abdominal aortic 
aneurysm (AAA) is an 
enlargement of the biggest 
blood vessel in the body. It 
typically causes no symptoms 
prior to rupturing, which 
commonly results in death. 
AAA account for 5,251 deaths 
per year in the UK. Currently 
1.8% of men aged 65 have 
an aneurysm, however the 
vast majority are small. These 
patients therefore undergo 
surveillance prior to the need 
for surgical intervention 
to decrease the chance of 
rupture.
Several studies have attempted 
to find a protein that can be 
used to detect people with 
AAA. This research combined 
data from all previous protein 
studies identifying 16 proteins 
that were increased and 2 that 
were decreased in patients 
with AAA. However, none of 
these proteins demonstrated 
sufficient sensitivity and 
specificity to be used as a 
screening tool for AAA. 
Therefore this study aimed to 
look at the expression of a new 
marker, namely microRNAs. 
MicroRNAs are small RNAs 
which are not converted into 
protein. They exert their effect 
by attaching to messenger RNA 
and causing it to be degraded, 
thereby decreasing protein 
expression. MicroRNAs are 
crucial in the regulation of 
cardiovascular disease, and 
represent novel therapeutic 
strategies to decrease AAA 
expansion.
This study identified a significant difference in expression of 
29 microRNAs in blood, 4 of which were validated in a second 
larger study in blood. One of these microRNAs was also found to 
be significantly increased in plasma, but none were found to be 
differently expressed in aortic tissue. 
The four microRNAs identified within this study were found to 
interact with several of the proteins associated with aneurysms, 
making them plausible markers of abdominal aortic aneurysms. 
However, these four miRNAs were also found to be differently 
expressed in patients with peripheral arterial disease; therefore 
they may be due to generalised atherosclerosis rather than 
specific to aneurysms.
The results of this research will help us to understand why both 
aneurysms and peripheral arterial disease occur, taking a step 
towards treating these conditions, which are a considerable 
burden in those with advanced age.
Preparing samples for microRNA analysis
Presentation at the Vascular Society of Great 
Britain and Ireland
Being awarded the British Journal of 
Surgery Prize
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Paediatric neurosurgery with special interest in 
paediatric epilepsy surgery
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Hospital for Sick Children, Toronto, Canada
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400 children per year in the UK could benefit from neurosurgery to treat epileptic seizures.
In September 
2012 I left 
London to take 
up a fellowship 
in paediatric 
neurosurgery 
at the Hospital 
for Sick 
Children 
in Toronto, 
Canada. 
Sick Kids is 
one of the 
premier paediatric neurosurgery departments worldwide 
and a significant proportion of international paediatric 
neurosurgeons have passed through their training 
programme.
I arrived to find Toronto bathed in glorious sunshine: a 
surprise given the 
stories I had heard 
of arctic winters 
and deep snow. I 
spent a year at Sick 
Kids developing 
my knowledge 
and skills. The 
fellowship covered 
all aspects 
of paediatric 
neurosurgery 
including elective 
and emergency 
cases, and inpatient and outpatient care. I have a particular 
interest in the surgical management of paediatric epilepsy 
and the exceptional strength of Sick Kids’ epilepsy surgery 
program was one of the attractions of the fellowship.
I gained experience in all aspects of the management of 
epilepsy surgery patients, including the use of magneto-
encephalography (MEG) as a technique to non-invasively 
identify seizure foci. A MEG scanner is essentially an 
extremely powerful detector of magnetic fields, able to detect 
synchronised neuronal currents and thus identify epileptic 
foci. A significant number of the surgical candidates also 
underwent placement of invasive grid and depth electrodes, 
in order to more fully characterise the seizure onset zone 
prior to resective surgery. This allowed me to learn new 
techniques in the analysis of invasive EEG.
I am returning to the UK to take up a consultant post at 
Great Ormond Street Hospital, with a subspecialty interest in 
paediatric epilepsy surgery. The techniques I have learnt at 
Sick Kids will be immensely useful in my new job. The award 
I received has 
been incredibly 
helpful in 
coping with 
the financial 
burden of my 
fellowship and 
I am extremely 
indebted for 
the assistance it 
has provided.
Martin in the OR at Sick Kids
Martin trialling the 3D operating microscope camera Martin with James Rutka in front of the cornerstone donated to Sick 
Kids by Great Ormond Street Hospital
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Exploring the immunological response to 
severe trauma and identifying potential 
treatment options
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Trauma remains one of the most frequent causes of death in those aged under 45 worldwide. It results in six million deaths 
annually worldwide. Up to a staggering 60% of patients admitted to the ICU following severe traumatic injury develop 
infectious complications. The development of sepsis in these patients is associated with a three-fold increase in mortality.
As the immediate treatment given to severely injured trauma 
patients continues to improve, more and more patients who 
previously would have died either at the scene of injury or 
shortly afterwards are now surviving. These patients require 
ongoing care in an intensive care unit (ICU) and now are 
much more likely to die from infections contracted there 
or from multi-organ failure than to die directly from their 
injuries. Frequently these are young, previously healthy people 
and it is unclear why they are so susceptible to normally 
innocuous infections.
At the Royal London Hospital our research has already 
changed the way we identify and treat the bleeding trauma 
patient. However, I am concentrating on those severely 
injured patients admitted to the ICU. Blood samples are taken 
immediately following arrival to the emergency department 
and at two later time-points. Along with other clinical 
information, we are able to explore the effects that injury and 
blood loss, as well as commonly administered treatments (such 
as blood transfusions), have on their immune systems.
As a well-functioning 
immune system is crucial to 
fight infection, we therefore 
focused on changes to this 
induced by severe trauma. 
Our experimental data 
demonstrates that within two 
hours of injury, the immune 
system is severely affected 
and is, in essence, shutting 
down. In our patients a staggering 60% of them developed 
infections during their ICU stay. 
Our experiments, which measure the activity of the immune 
response, are beginning to show us a link between severe 
traumatic injury, a defective immune system and previously 
healthy patients now at risk of developing serious infections. 
Ultimately the goal will be to develop a bedside test of the 
trauma patients’ immune system, which will identify those at 
greatest risk of infection. Then we may be in a position to treat 
these patients with novel immune therapies.
Hew in Algiers, Algeria, with some of the surgical trainees from the workshop
Hew on the Royal London Helipad overlooking 
the City of London
Hew in Algiers, Algeria, teaching a basic surgical skills workshop as a Galeski and Lawrie fellow
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Developing subspecialist skills in microsurgery, head and neck reconstruction, facial paralysis surgery  
and breast reconstruction
Microsurgery Fellowship
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William 
Arthur 
Townley
I spent a year working with Professor Stefan Hofer at the 
University Health Network in Toronto. My fellowship was 
mostly clinical, allowing me to develop subspecialist skills 
in microsurgery, head and neck reconstruction, facial 
paralysis surgery and breast reconstruction. The volume and 
complexity of work was fantastic and therefore my fellowship 
was very productive. My own interest is facial paralysis surgery, 
an area that I will be pursuing as a consultant at Guy’s and St. 
Thomas’ Hospital.
During my time in Toronto, I was able to learn much 
to facilitate running a successful facial palsy practice – 
multidisciplinary team organisation, specialist skill acquisition, 
research and patient communication.
In addition, I was able to participate in clinical research 
completing two projects, which were both presented at national 
meetings and published. The focus on clinical research at 
UHN was phenomenal and I was able to learn much in terms 
of the key factors that lead to successful research projects – 
leadership, database organisation, funding and collaboration. 
My supervisor, Stefan Hofer, was an excellent mentor, helping 
me develop clinically as a surgeon and being very supportive of 
my academic interests.
Braving a Toronto snowstorm while running between hospitals Collecting a fellowship award from Toni Zhong Team building camping trip in Killarney National Park with Stefan 
Hoferc
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Injured spinal cord pressure evaluation
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2.  International Neurotrauma Society meeting, Budapest, 
Hungary, 2014.
PrizeS
Society of British Neurological Surgeons, British Journal of 
Neurosurgery Prize, September 2013.
FURTHER FUNDING
Neurosciences Research Foundation for three years.
Melissa 
Cheng-Hwa 
Werndle
One thousand people each year, predominantly young men, survive a traumatic spinal cord injury and are left paralysed or 
wheelchair bound.
Traumatic spinal cord injuries are sudden and catastrophic 
events, with a cost to the NHS of approximately £1 billion 
per year. The management of these injuries remains highly 
variable and the current focus of treatment is on fixing and 
stabilising the bone, while largely ignoring the spinal cord. 
Developments lag decades behind brain injury research.
The aim of this study was to take well-known principles of 
brain injury management and for the first time apply them to 
the spinal cord.
We have developed a novel technique to measure spinal 
pressures in patients who had a severe traumatic spinal cord 
injury at the site of injury, which is not currently in clinical 
use. We have defined new variables called intraspinal pressure 
(ISP), and spinal cord perfusion pressure (SCPP = arterial 
blood pressure – intraspinal pressure).
We have discovered that spinal pressure is high and spinal 
cord perfusion pressure is low after traumatic injury. 
Changing blood carbon dioxide levels, administration 
of mannitol and altered doses of the anaesthetic agent 
sevoflurane had no effect on ISP or SCPP. Inotropes increased 
SCPP. By improving spinal cord perfusion pressure, we could 
improve motor-
evoked potentials 
(linked to 
improved 
leg strength 
recovery), cord 
blood flow 
and restore 
autoregulation to 
the spinal cord.
The findings 
provide proof-
of-principle 
that intraspinal 
pressure at the 
injury site can be 
safely measured 
after traumatic 
spinal cord 
injury.
Melissa with her supervisor, Professor Marios Papadopoulos, operating on a spinal 
cord-injured patient
Presenting the study findings at the EuroNeuro International 
Conference in Orlando, Florida
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Polymer-guided chondrogenesis of human 
adipose-derived perivascular stem cells
FELLOWSHIP/SPONSOR
RCS Research Fellowship
SUPERVISOR
Professor Bruno Péault
SITE OF WORK 
University of Edinburgh MRC Centre for 
Regenerative Medicine
PUBLICATIONS
1. West CC, Murray IR, González Z, 
Hindle P, Hay DC, Stewart KJ, Péault 
B. Ethical, legal and practical issues 
of establishing an adipose stem cell 
bank for research. J Plast Reconstr 
Aesthet Surg 2014; 67: 745–751.
2. Murray IR, West CC, Hardy WR, 
James AW, Park TS, Nguyen A, 
Tawonsawatruk T, Lazzari L, Soo 
C, Peault B. Natural history of 
mesenchymal stem cells, from 
vessel walls to culture vessels. 
Cellular and Molecular Life Sciences 
2014; 71: 1,353–1,374.
PRESENTATIONS
1. Adipose derived perivascular 
stem cells are a source of purified 
autologous mesenchymal stem 
cells for regenerative medicine – is 
the need for ex vivo culture over? 
European Association of Plastic 
Surgeons. Ischia, Italy. June 2014.
2.  The effects of synthetic polymer 
based biomaterials on the behaviour 
of adipose derived peri-vascular 
stem cells (PSC) in vitro. International 
Federation for Adipose Therapeutics 
and Science. New York, USA. 
November, 2013.
PRIZE
Three-minute thesis competition – 
University of Edinburgh winner, 2013.
FURTHER FUNDING 
Chief Scientist Office Clinical Academic 
Training Fellowship (three years) and 
William Rooney Plastic Surgery and 
Burns Research Trust (three years).
Christopher 
Charles 
West
One in every 4,000 children are born missing one or both of their ears
One in 4,000 children are born missing one or both of their 
ears, and the surgical technique used to reconstruct ears 
requires surgeons to remove ribs from the patient, and the 
cartilage from the ribs is used to carve a new ear. Removing 
ribs has many risks including pain, punctured lung and 
chest deformity. Patients undergoing this surgery spend 8 
hours in the operating theatre and a week recovering in 
hospital, costing the NHS £25000. Therefore, the ability 
to ‘grow’ an ear would be a major advancement both in 
patients and the NHS. The focus of my project is to identify 
the two vital ingredients required when engineering any 
solid tissue. First the correct cell type, as these are the 
building blocks, and, second, a scaffold on which they can 
grow, as this is the cement that binds the tissue together.
Mesenchymal stem cells are the cells that can generate 
cartilage and my research has shown that these cells live 
in direct relationship with the smallest of blood vessels in 
the human body. As there are blood vessels in every tissue, 
these cells can be purified from an easily accessible source – 
adipose tissue (fat). Adipose tissue is a superb source of stem 
cells as it contains significantly more cells and is much less 
painful to harvest, compared to traditional sources such as 
bone marrow.
To identify scaffolds, I used 
a special printer that prints 
tiny spots of thousands of 
individual polymers onto 
the surface of a microscope 
slide, allowing them to 
be rapidly screened. 
I have identified five 
polymers to support the 
attachment, proliferation 
and subsequent 
differentiation of the 
cells into cartilage-like 
cells. The next phase of 
this project is to combine 
the cells and polymers to 
produce three-dimensional 
pieces of cartilage for ear 
reconstruction surgery.
Chris delivering an award-winning presentation in the international 
final of the Three-Minute Thesis Competition
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Understanding axonal reinnervation of motor units
FELLOWSHIP/SPONSOR
Enid Linder Foundation Research 
Fellowship
SUPERVISORS
AO Grobbelaar, K Rolfe and 
Professor JW Lichtman
SITE OF WORK 
Harvard University, USA, and 
UCL, UK
PRESENTATIONS
1.  The Society of Neuroscience, 
New Orleans, USA.
2.  The American Association of 
Plastic Surgeons, New Orleans, 
USA.
PRIZES
1.  Grant from the Roan Trust
2.  Rosetrees Essay Prize, The 
Royal College of Surgeons of 
England
FURTHER FUNDING
The Roan Trust for two years 
and The Anton Jurgens Trust for 
one year
Alexander 
CS Woollard
20% of patients undergoing gold-standard facial reanimation surgery do not achieve a satisfactory, symmetrical smile.
Facial palsy 
is caused by 
numerous factors 
and can affect all 
age groups. Most 
patients recover 
without the 
treatment, but 
those that don’t 
spontaneously 
recover are 
left with a 
permanent 
disability. 
Speech, eating 
and eye-closure 
can all be 
affected, which 
may result in 
permanent 
damage to the 
eyes and teeth, 
and can result in awkward social interaction and can affect 
development in children.
Surgical reconstruction is an option. This involves nerve and 
muscle transfers to restore function back to normal. However, 
surgical outcomes remain variable and the cause of this 
variability is unclear. Previously, our group has proposed that 
changes in the proportion of nerves to muscle fibres after 
surgery may hold the key to how the muscle will function. Our 
current research aims to understand how nerves reform their 
connections to muscles.
This study models facial reanimation. A special coloured 
protein expressed in the nerves makes it possible to watch the 
recovering nerve as it re-grows and makes new connections 
with the muscle. The model provides information about the 
characteristics of the regenerating nerve and the patterns of 
the new connections in the muscle.
Results suggest that only about half of the nerves repopulate
the muscle; however, all of the muscle fibres make a new 
connection. This means each nerve powers twice as many 
muscle fibres than before. Previous research in this area has 
suggested that as this proportion increases the nerves can 
become over-worked and therefore ineffective. This results in 
poor functioning of the muscle.
We believe this may explain what is occurring in the facial 
palsy patients where the surgery is unsatisfactory. This will 
enable us to try and tailor reconstructions to the capacity of the 
re-growing nerve.
Alex Woollard presenting his research results at EURAPS, Italy 2014
Performing microsurgery as part of the team at The Royal Free Hospital NHS Foundation Trust
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Can you ma
ke 
We need to develop our 
surgeons through training 
and research opportunities so 
that they excel and fulfill their 
potential and provide the highest 
standards of patient care. 
To provide these opportunities the College relies almost 
exclusively on legacies, gifts and donations.
Legacies do not need to be huge sums of money to make a 
difference. A gift, whatever the amount, will help us continue 
to advance surgical standards by developing and delivering 
world-leading training and research programmes.  
To ensure that our surgeons can meet the challenges of the 
future please consider supporting the College.  
For more information or an 
informal chat about a legacy to 
the College, please contact us 
at fundraising@rcseng.ac.uk 
or call 020 7869 6086. 
The Pump Priming award is given to a limited number 
of newly appointed Consultants and Senior Lecturers 
(appointed since 2006) in surgery, who are working 
at hospitals and universities within the UK, to assist 
in the early stages of their independent research 
careers. Awards are used exclusively to support the 
award holder’s own research and not for personal 
salaries. They may be used, amongst other things, 
for small items of equipment, for consumables or for 
technical assistance. All award winners are members 
or fellows of The Royal College of Surgeons of England. 
Pump 
Priming 
Reports
Claire Hopkins 58
Carl Philpott 59
Jonathan Sutcliffe 60
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Improving outcomes from endoscopic sinus surgery
CURRENT POSITION
Consultant in Otolaryngology in Guys Hospital
TITLE OF FELLOWSHIP
PUMP PRIMING AWARD 
SITE OF WORK 
Guys & St Thomas NHS Foundation Trust 
SPECIALTY
Otolaryngology
PUBLICATIONS
1. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. 
Psychometric validity of the 22-item Sinonasal 
Outcome Test. Clin Otolaryngol 2009; 34(5): 447-54.
2. Nanayakkara J, Roberts D, Hopkins C. THe impact 
of mental health on chronic rhinosinusitis symptom 
scores.  Eur Arch ORL-NHS 2013: 270; 1361 – 4
3. Hopkins C, Rimmer J, Lund V. Does timing of surgical 
intervention in CRS impact outcomes?  - Data from the 
UK Audit of Surgery for Chronic Rhinsinusitis. Accepted 
for publication to Rhinology
4. Hopkins C, Andres P, Holy C. Does timing of surgical 
intervention in CRS impact outcomes? - Analysis of 
CPRD data. Accepted for publication to Rhinology
PRIZES
Carter A, Timms S, Hopkins C. Is man-flu really the worst? 
Women in Surgery Meeting May 2013,   Awarded best 
poster prize
Claire 
Hopkins
Chronic rhinosinusitis affects 11% of UK adults with 1 in 3 patients requiring surgery.
The aims of ongoing research are to further develop and refine a 
validated Patient Rated Outcome Measure (PROM) for chronic 
rhinosinusitis (CRS), and to use this to collect data in patients 
undergoing surgery for CRS in order to improve outcomes.
CRS 
patients 
suffer 
with nasal 
blockage, 
facial 
pain, loss 
of smell, 
chronic 
catarrh 
and sleep 
disturbance 
resulting in days off work, reduced productivity whilst at work 
and a negative impact on quality of life that has been shown 
to be greater that angina. Currently patients are treated 
medically, but roughly 1 in 3 patients require surgery to relieve 
their symptoms.
Measuring the impact on quality of life requires PROMs. 
During a Research Fellowship in the Clinical Effectiveness 
Unit at the RCS as a surgical trainee, I developed and 
validated the 22-item sinonasal outcome test (SNOT-22); this 
is now the most widely used CRS PROM internationally, and 
is recommended for future research by the European Position 
Paper on Rhinosinustis and Nasal Polyps. My current work 
builds on this preliminary research.
I have shown that the impact of symptoms and benefits 
from surgery can be modified by patient related factors. 
For example, women (surprisingly!) report higher levels of 
symptoms for the same radiological stage of CRS than men. 
Previously undiagnosed co-existing anxiety and depression are 
common amongst sufferers with CRS, and again report greater 
symptom severity for the same extent of disease. While gender 
is obviously fixed, treatment of co-existing depression may 
reduce the impact of CRS on quality of life. Identifying disease 
modifiers is essential to optimizing outcomes.
Perhaps more importantly as surgeons, we need to identify 
which aspects of our own practice determine outcome. I 
have found that timing of surgical intervention is important; 
patients undergoing surgery who have had CRS symptoms 
for more than 5 years get significantly less improvement 
than patients undergoing surgery within a year of symptom 
onset. Furthermore, improvements in symptoms are better 
maintained over 5 years in the ‘early’ group. Utilising data 
from CPRD, an administrative database in primary care, I was 
able to support these findings by showing that patients having 
‘late’ surgery have higher on-going utilization of health care 
services, with more frequent GP visits and a greater number of 
prescription. These findings have been incorporated into the 
RCS/NICE Commisioning Guidance for Rhinosinusitis. 
I am now developing this project into a large Programme 
Grant with NIHR, where we will incorporate routine eHealth 
data into a national database for sinonasal surgery, and use 
this to develop pragmatic study designs to determine the best 
treatment for this common condition.
Claire in a busy clinic
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A Feasibility study for a Randomised Controlled 
Trial of Clarithromycin for Chronic Rhinosinusitis
CURRENT POSITION
Honorary Consultant ENT Surgeon, James Paget 
University Hospital Senior Lecturer in Otorhinolaryngology 
at University of East Anglia
TITLE OF FELLOWSHIP
PUMP PRIMING AWARD 
SITE OF WORK 
James Paget University Hospital (Great Yarmouth), Guys 
& St Thomas Hospital (London), Royal Surrey County 
Hospital (Guildford), Queens Medical Centre (Nottingham), 
Freeman Hospital (Newcastle) and Queen Elizabeth 
Hospital (Birmingham).
SPECIALTY
ENT
PUBLICATIONS
1. Under submission – OTOHNS journal
2. Under submission – Int Forum Rhinol All
PRESENTATIONS
1.  Clarithromycin for Chronic Rhinosinusitis. European 
Rhinologic Society Congress (Amsterdam) June 2014 
2.  Clarithromycin for Chronic Rhinosinusitis. American 
Association of Otolaryngologists and Head and Neck 
Surgeons Annual Conference (Orlando) September 
2014
FURTHER FUNDING
RN was funded by the Bernice Bibby Trust and some of 
the equipment was paid for by the Anthony Long Trust.Carl 
Philpott
This preliminary study for antibiotics over 12 weeks in chronic sinusitis showed a recruitment rate of 83% with 76% of 
patients retained in the study and an average recruitment rate of 4.23 per month across all sites. 1 in 2 patients appeared 
to benefit with an improvement in symptoms.
The aim of this study was to assess the recruitment and retention 
of patients into a trial using long-term (12-week course) antibiotics 
to treat their chronic rhinosinusitis (long-term swelling of the nose 
and sinuses). Patients were recruited from 6 different hospitals 
and underwent a range of clinical (e.g. tests such as examination, 
scans and smell testing) and questionnaire (to assess both 
symptoms and quality of life) evaluations prior to commencing 
the antibiotic and nasal treatment. 
Patients were re-assessed at the end of the 12-week medication 
period and sent repeat questionnaires at 6 months also. Feedback 
regarding the patients’ involvement in the study was also sought.
Fifty-five patients were recruited to the study, 45 patients attended 
the 3 month visit and 41 the 6 month follow-up questionnaires. 
One patient was unable to take the medication, 4 patients suffered 
side effects (3 unable to complete the full course). Unfortunately 
there were some failings in data collection at some study sites and 
this study has highlighted some important areas for improvement 
if the study is to be repeated in the future. Fifty percent of the 
patients completing the study showed an improvement in their 
symptomatic scores at the end of the antibiotic course which was 
sustained at 6 months also.
This study has provided valuable information for an application 
to the National Institute of Health Research for a full scale trial 
where some patients will also take a placebo (medication without 
the active antibiotic) which should give definitive answers as to 
the correct course of treatment for patients with this disease. 
Although a small number of patients were included here, the 
results may suggest that half of the patients stand to benefit from 
this treatment and potentially avoid sinus surgery.Patient undergoing nasal endoscopy with image captured using the D-scope system
Patient with RN going through questionnaires
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Optimal Identification of Interstitial Cells of 
Cajal in Human Tissue
CURRENT POSITION
Consultant Paediatric Surgeon
TITLE OF FELLOWSHIP
PUMP PRIMING AWARD 
SITE OF WORK 
Faculty of Biological Sciences, 
University of Leeds and 
Department of Paediatric Surgery, 
Leeds General Infirmary
SPECIALTY
Paediatric Surgery
Jonathan 
Sutcliffe
New cell markers may advance the understanding of muscle abnormalities both within the bowel and more widely.
Jonathan demonstrating the close working relationship that is essential with the family of a patient with Hirschsprung Disease 
Smooth muscle is important for function in a range of organs including the bowel, bladder and within blood vessels. When co-ordination 
of muscles fails, patients can experience serious symptoms. In the intestine, patients can reach a point where they are unable eat and 
require long-term intravenous nutrition. If the bladder fails to empty effectively, there is an increased chance of infection and ultimately 
renal failure. Patients with spinal cord injury experience particularly troublesome symptoms due to bladder and bowel dysfunction. 
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Smooth muscle tone in blood vessels can cause problems 
in the neonatal period when vessels narrow inappropriately 
(Coarctation) or, alternatively, fail to close following birth (Patent 
Ductus Arteriosus). These conditions are common indications 
for surgery. Our understanding of the control of smooth muscle 
is limited and a clearer understanding could allow more accurate 
diagnoses and allow new treatments to be considered.
Our aim was to identify how one particular cell type, the 
Interstitial Cell of Cajal (ICC), could best be demonstrated in 
tissues. We performed a structured review of the literature to see 
how ICC had been demonstrated in the past, and tested some of 
these techniques in our laboratory to be ready to study human 
tissues reliably. We identified all 392 papers examining the role of 
ICC in human motility in a range of tissues. Although the type of 
antibody used can be seen to produce different levels of staining, 
at least 30 antibodies had been used. Because many conditions 
(57) had been studied, often with low numbers of patients and 
controls in each (on average 16 and 7 respectively), it was rare to 
find conclusive proof for any one condition.
Based on our review, we have set out to identify the best way to 
study ICC. We are now using a new antibody (PDGFa) and are 
testing it against the traditional antibody (cKit). We have used 
the antibody in the bladder in animals who had undergone 
spinal cord injury and found for the first time that the number 
of ICC stained with this antibody increases significantly. This 
finding gives new insights into how the bladder functions in these 
patients. 
Using the same antibody, another area we have been able to 
investigate for the first time has been the distribution of ICC 
in the vagina. This might be important in the development of 
treatment of children born with cloaca, a complex malformation.
We have successfully applied for ethical approval to begin to 
study ICC in human tissue, including blood vessels. Using our 
experience, we are now well placed to develop a long-term study 
of these cells.
Jonathan with his team
The surgical trials initiative
The interest generated in the first two years of this novel 
programme has exceeded expectations. The creation of five 
surgical trials centres and appointments of surgical specialty 
leads (SSLs) was completed by the end of 2014. This was 
generously supported by the Rosetrees Trust, several 
charities and many surgical specialist associations.
While the emphasis remains on the development and 
delivery of high quality randomised trials, the centres are 
involved with feasibility, pilot and safety studies as well as 
evidence synthesis. These are important preliminaries to 
full trials. The remit of the surgical trials centres therefore 
has been to support all aspects of work that might inform a 
clinical trial.
This article focuses on the views of one of our SSLs, Mr Abi 
Jain, and a trials unit co-lead, Professor Jane Blazeby.
Achievements 
• An NIHR call for surgical studies resulted in the 
award of some £28m of funding in 2014
• The number of patients entering surgical trials in the 
portfolio has doubled in the last year
• The Surgical Trials centres currently have 53 open 
trials, 26 trials in set up and 42 funding applications 
under review
• 156 new principal investigators are recruiting to 
surgical trials
• 53 new NHS trusts are now recruiting to trials.
Plans
Meetings
Centres continue to run regional meetings to engage 
existing and new investigators. Innovations for the coming 
year will include a greater emphasis on education and 
training of new researchers in trials methodologies, as well 
as the broader aspects of research including research ethics.
Evidence synthesis
The RCS is running seven systematic reviews for 
competitively selected projects. These are based in the 
Clinical Effectiveness Unit and they will inform the design of 
future funding applications for new trials.
Trials portfolio
A national portfolio of all trials being undertaken by the 
Surgical Trials Centres has been established and includes: 
trials closed to recruitment, open trials, trials in set up and 
trials submitted for funding. This document is a unique 
resource for investigators to access information and obtain 
contact details for surgical trials. 
The portfolio will also help investigators identify where there 
is a need for studies within their discipline. 
Technology Access Pathway
The NIHR and the RCS, together with partners (including 
NICE, MHRA, ABHI, CRUK, MRC, IDEAL) are developing 
a technology evaluation programme to facilitate easier 
THE RCS SURGICAL 
TRIALS INITIATIVE
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Oxford Surgical Trials launch day Professor Freddie Hamdy 
and David Beard (SITU Co-
Director) at SITU launch day
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access for industry, innovators and researchers to develop 
and evaluate new surgical medical devices and technologies. 
A combined RCS/NIHR infrastructure will provide a 
route to access specialist advice and build multidisciplinary 
partnerships to take new ideas and technologies forward, 
into early phase clinical studies as appropriate. It is hoped 
that a number of benefits will be realised: 
• A common and easily accessible pathway for innovators 
and companies should eliminate unnecessary barriers 
and speed up the adoption of new technologies 
• Early engagement of specialist clinical teams with 
researchers and specialist trials methodologists should 
lead to rapid feedback to the innovator or company
• Efficient development of the device or technology with 
safe, high quality evaluation for NHS and patient benefit.
International trials and a global surgical initiative
An International Trials Symposium will take place in 
November 2015 with a view to launching a trials programme 
across many countries. This will initially focus on Europe 
as a way of achieving faster recruitment to trials. This is 
only one strand in a wider RCS strategy to make a greater 
contribution to progress in global surgery.
But what do the people on the ground make of it?
The views of a specialty lead 
(Mr Abilash Jain, SSL appointed in 
conjunction with The British Society for 
Surgery of the Hand and The British 
Association of Plastic, Reconstructive and 
Aesthetic Surgeons)
Plastic surgery is a small surgical specialty covering hand 
surgery, trauma, congenital defects, burns and cancer. 
Plastic surgeons work with all other surgical specialties 
to undertake complex reconstructions. Much evidence is 
based on poorly conducted clinical research with only 3% 
of published work classified as randomized controlled trials 
(RCTs). While it is recognised that large scale research, 
undertaken as multicentre randomised controlled trials, 
generate the highest level of evidence on which to base best 
practice, in plastic surgery only 2–3 multi-centre RCTs are 
published globally each year.
Plastic and hand surgery were poorly represented on the 
clinical research landscape, with virtually no clinical trials 
or patients recruited to the NIHR portfolio. The reason 
for such poor clinical evidence was multifactorial but 
probably stemmed from the lack of a defined pathway that 
practising plastic surgeons could access to rigorously test the 
interventions they perform.
The RCS clinical trials initiative has changed this and has 
been embraced by the plastic and hand surgery community. 
Professors Dion Morton and Frank Smith at the Bristol launch Professor Iain Hutchison, Kate Law CRUK and Professor Hisham 
Mehanna at the launch of the Birmingham Surgical Trials Consortium
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It provides a mechanism to allow plastic and hand surgeons 
to directly access the expertise needed to undertake high 
quality clinical research with direct benefit to patient care. 
It has allowed us to develop a culture of clinical trials within 
plastic surgery and its sub-specialty, hand surgery, within the 
space of just 2 years.
I took up the role of RCS SSL in 2013 representing both 
the BSSH and BAPRAS and we have had a tremendous 
response from both associations, with over 260 members of 
the Reconstructive Surgery Trials Network (RSTN) set up 
to deliver clinical research. We have over 60 units involved 
providing us with representation across England, Wales, 
Scotland and Northern Ireland; we even have members in 
Italy, Australia and the USA.
We have run two very successful trials days at the RCS in 
which 160 surgeons have been taught on trials-related topics, 
trained in good clinical practice (GCP) and where they 
have had the opportunity to present their trial ideas. At the 
last winter BAPRAS meeting we had a hugely popular trials 
session and the next RSTN trials day is already booked for 6 
June 2015 at the RCS. 
Our first trial (NINJA – nail bed injuries) has ethical 
approval, will be adopted onto the NIHR Children’s 
portfolio and the pilot will start recruiting from four 
centres in the spring of 2015. A collaborative trial with the 
Association of Breast Surgeons has been awarded RfPB 
(Research for Patient Benefit) funding from the NIHR and 
plastic surgeons have recruited a third of the patients in 
total so far. There are five other trials at various stages of 
development and at least two will start to recruit this year. 
There are also two large multicentre audit projects that will 
be run nationally and, to inform future trials, plastic surgeons 
are also collaborating with the dermatologists and general 
surgeons on other projects. Further information is available on 
our website: http://reconstructivesurgerytrials.net
From a personal point of view this initiative has been very 
rewarding. As a relatively young academic surgeon I have 
learned from more experienced colleagues and have been able 
to approach them for advice and share the difficulties that 
inevitably occur. The process has taught me about a new area, 
research, as my background was in basic science. I have gained 
a lot of self-confidence and have a real pride in what has been 
achieved. The initiative has raised my profile not only nationally, 
but also internationally. I have learnt skills that have enhanced 
my clinical practice. Overall the future is looking very bright for 
clinical trial research in my specialty. While I have made rapid 
progress, it is clear that a national trials framework cannot be 
developed in just three years, which is the term of the current 
SSL position. I have enjoyed the process so much that I am keen 
to see through the initiatives that I have begun and continue as 
an SSL. I have no doubt that this initiative will act as a focus for a 
global shift towards high quality, evidence based plastic surgery 
clinical research, with its focus in the UK.
The views of a trials centre 
lead 
(Professor Jane Blazeby, co-lead for the Bristol 
Surgical Trials Centre)
The Royal College of Surgeons clinical trials initiative is 
changing the face of surgical research in the UK. Investment 
directly facilitates the centres to work with NHS, academic 
surgeons and registered clinical trials units to design high 
quality studies. The hall mark of approval from RCS attracts new 
and experienced investigators to work with the surgical trials 
centres. It creates a centre of attention for NHS trusts, deaneries 
and the CLRNs to be involved in RCTs in surgery. It provides 
a badge of authority for new and ongoing training courses 
in RCT methodology for trainees and NHS consultants. The 
initiative sets standards for a culture of collaboration between 
the five trials centres which underpins important discussions 
about working together on new and ongoing studies, rather than 
competing. 
The initiative is useful to write about in grant applications to 
demonstrate that the College is supporting surgeons to deliver 
high quality research and to show that there are administrative 
Professor Jane Blazeby presenting at the Reconstructive 
Surgery trials Network (RSTN) meeting at the RCS
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Bowel Disease Research Foundation (BDRF)
Breakthrough Breast Cancer
Breast Cancer Campaign
Cancer Research UK
Get A-Head Charitable Trust
George Drexler Foundation
Mary Kinross Charitable Trust
Henry Lumley Charitable Trust
The National Institute for Health Research (NIHR)
Orthopaedic Research UK
The Rosetrees Trust
The Enid Linder Foundation
The Facial Surgery Research Foundation – Saving Faces
staff in place to facilitate the proposed research and 
training. It has allowed us to consolidate our strategy to 
create an evidence base for surgery in the UK, invest in a 
new generation of surgeons to design, participate and lead 
new trials and gain further funding to sustain the work. 
The increasing number of funded trials that are recruiting 
on time and target because of this support has benefit 
for patients. These benefits apply both to those patients 
currently participating in trials as well as future patients. 
The close monitoring and follow up of trial patients along 
with access to trial staff are all additions to standard care. 
The research effort also facilitates partnership working, to 
identify future research topics of importance to patients and 
surgeons.
In Bristol, we are pleased and proud to be part of the 
initiative and look forward to continuing this endeavour on 
behalf of the College and those who supported the initiative.
With grateful thanks for the support of:
Association of Upper Gastrointestinal Surgeons of Great 
Britain and Ireland (AUGIS)
Association of Breast Surgeons (ABS)
British Association of Endocrine and Thyroid Surgeons 
(BAETS)
British Association of Plastic, Reconstructive and Aesthetic 
Surgeons (BAPRAS)
British Society for Surgery of the Hand (BSSH)
Triallists presenting their trials idea to the ‘dragons’ at the ‘dragon’s den’ style session at the Bristol Launch
Mr Jon Snow, Prof Jenny Donovan, Dr Jonathan 
Gower, Dr Andrew Cook and Prof Amar Rangan 
at the Orthopaedic Trials meeting at the RCS.
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To this end the Faculty provides 
training and examinations for dental 
specialties, advises the profession and 
the NHS on clinical guidelines and 
also produces a range of specialist 
publications. The Faculty also 
promotes and supports oral and 
dental surgery research in its broadest 
sense to a national and international 
audience.
Through our Research Committee, the 
Faculty offers two full-time fellowships 
for up to three years, to allow early career researchers to 
take time out of clinical training to undertake a PhD or to 
consolidate their research training. One of these fellowships 
is funded by the Wellcome Trust and is awarded jointly on an 
annual basis. The Faculty also offers up to five smaller research 
grants per year, which provide ‘consumables’ costs for clinical 
trainees beginning to establish a career in research. Since 2008, 
the Faculty has awarded 10 Fellowships and almost 30 small 
grants. Many of our successful awardees have now established 
themselves in successful clinical academic careers and in some 
cases are already professors in their chosen specialties.
The Faculty also organises national research symposia, which 
have been sponsored and are therefore provided free to over 
120 delegates on each occasion. These are held jointly with 
the Faculty of General Dental Practice and promote research 
opportunities for early career researchers and clinical academic 
trainees. We have particularly targeted the whole dental team, 
from both general practice and hospital settings, and promoted 
collaborative research and research in primary care. Speakers 
at the symposia are leaders in the field from NIHR (National 
Institute for Health Research) and the British Society for Oral 
and Dental research, as well as national figures covering topics 
including clinical trials, international collaborations, working 
with industry and research governance. As well as talks, the 
experts have run a number of hands-on workshops at each 
symposium.
Areas of oral and dental research which have been supported by 
the Faculty:
Oral cancer
Oral cancer affects over 6,000 people per year in the UK, of 
whom over 50% will die within 5 years of diagnosis. Against 
this background, our research priorities include early 
diagnosis and prevention and understanding mechanisms 
of disease progression, with the aim of developing new 
treatments. In line with this, the Faculty has funded several 
cancer research projects. These have included studies into 
the role the widespread human wart virus (papillomaviruses) 
in oropharyngeal cancer, as well as studies of the molecular 
mechanisms of cancer spread (metastasis) and public health 
approaches to reducing alcohol consumption.
Periodontal disease
Periodontal diseases are inflammatory diseases of the gums and 
supporting tissues of the teeth, which often lead to loss of bone 
and eventually the tooth or teeth. Over 90% of the population 
is affected by some form of gum disease, with 10% of the 
population affected by chronic periodontal disease. As well as 
the direct oral affects, these chronic inflammatory disorders 
can affect the whole body and are associated with diabetes and 
an increased risk of heart disease. Faculty funded projects in 
this area have included studies to investigate the relationships 
between periodontal disease and diabetes, inflammatory bowel 
disease and cardiovascular disease.
Craniofacial abnormalities
There are many inherited and acquired craniofacial anomalies 
that often have severe consequences for patients. The loss of 
function and poor facial appearance associated with many 
of these conditions often affects the sufferers self esteem and 
hence their ability to socialise and achieve their full potential. 
Research in this area has focussed on understanding the 
cause of facial anomalies and investigating approaches to 
management. The Faculty have funded a number of specific 
Faculty of Dental Surgery 
- Research Committee
The Faculty of Dental 
Surgery represents 
and supports dental 
specialists to achieve the 
highest possible standards 
of oral health care for 
patients and the public. 
Professor Paul Speight, 
Chair of the FDS 
Research Committee
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projects ranging from studies of the genetic mechanisms of 
cleft lip and palate, developing tissue engineering approaches 
to managing facial deformities, and exploring methods to 
engage patients in decisions about their management.
In June 2014, 
the Faculty of 
Dental Surgery 
held its second 
national research 
symposium in 
collaboration 
with the Faculty 
of General Dental 
Practice. This year 
the theme of the 
symposium was 
Collaborative 
Research and 
Opportunities for 
the Dental Team. The Faculty are keen to promote research 
for the whole dental team and the purpose of the symposium 
was to provide advice and encouragement, particularly to 
those who are just starting their research careers.
The invited speakers covered topics in three main areas: 
international collaborations, opportunities for Dental Care 
Professionals (DCPs) and working with industry. In all, 120 
delegates attended the day, including 42 general dental 
practitioners, 43 specialty registrars and academic trainees 
and 35 DCPs. The DCPs included hygienists and therapists, 
dental technicians, clinical dental technicians and dental 
nurses.
The morning session started with a talk from Drs 
James Fenton and Kieron Lee from the NIHR Trainees 
Coordinating Centre, who described all the various schemes 
available for funding research. They outlined the Integrated 
Academic training programme for academic fellows and 
lecturers, as well as opportunities for grant funding for PhD 
fellowships and career awards.
Following this, a series of renowned speakers covered 
the main themes. Professor Mike Curtis, Dean of the 
Institute of Dentistry, Barts and the London School of 
Medicine and Dentistry, described his own journey in 
developing international collaborations and highlighted 
the key attributes needed for successful partnerships – 
enthusiasm, trust and in depth knowledge of your subject 
area. Professor Paul Hatton, Professor of Biomaterials and 
Tissue Engineering, School of Clinical Dentistry, University 
of Sheffield, presented an overview of the European Union 
funding processes and outlined particular areas under FP7 
that would be of interest and relevance to dental research.
FDS Research Faculty and Speakers at the Symposium
Poster competition Runner-Up Miriam Khan.  
Are water pipe smokers aware that there are 
associated health risks with water pipe smoking?
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He gave a number of 
valuable tips on how 
to write proposals 
and win funding. 
Dr Anousheh Alavi, 
Scientific Affairs 
Manager at Colgate 
Palmolive, talked 
about working 
with industry and 
explained how our 
industrial colleagues 
are very keen and 
willing to collaborate and share ideas. She summarised how 
industrial research was managed and suggested ways in which 
researchers with good ideas can approach potential industrial 
partners.
Fiona Sandom, a Tutor Hygienist and Therapist from 
Cardiff and Postgraduate Tutor in North Wales, outlined 
opportunities for DCPs. Fiona had started from nothing 
except a good idea and had won a number of small grants 
to kick start her research. She inspired the audience with 
her tales of determination and enthusiasm to get grants and 
to undertake research in a difficult environment. During 
the meeting Professor Mike Lewis, President of the British 
Society for Oral and Dental Research (BSODR), gave a brief 
presentation outlining the benefits of membership and how 
the society can benefit and support early career researchers.
In the afternoon there were four research skills workshops, 
and each delegate had the opportunity to attend two. The 
choices were: How to write a grant and obtain funding 
(Professor Paul Hatton and Dr Kathryn Hurrell-Gillingham), 
101 Common mistakes which prevent your paper’s acceptance 
(Professor Ario Santini), Design of clinical trials (Professor 
Ivor Chestnutt) and Working with Industry (Dr Anousheh 
Alavai and Dr Mark Ide).
The day was free to all delegates and the Faculty are grateful 
to National Institute for Health Research (NIHR), Colgate 
Palmolive and the BSODR for funding the day.
In all, 120 delegates attended the day, including 42 general dental 
practitioners, 43 specialty registrars and academic trainees and 35 DCPs. 
The DCPs included hygienists and therapists, dental technicians, clinical 
dental technicians and dental nurses.
Poster competition winner Jennifer 
Hawarth.  Platelet interactive domains of 
Streptococcus gordonii surface protein PadA
Poster Competition Display Professor Paul Speight, Chair of FDS Research Committee
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Investigation of potential platelet interactive 
proteins expressed by infective endocarditis (IE) 
pathogen Streptococcus gordonii, and their possible 
role in the pathogenesis of IE
FELLOWSHIP/SPONSOR
FDS Research Fellowship
SITE OF WORK 
UCL Eastman Dental Institute 
Publications:  
Ciara Keane*; Helen J. Petersen*; Dorothea O. 
Tilley; Jennifer Haworth; Dermot Cox; Howard F. 
Jenkinson; Steve W. Kerrigan (2013) Multiple sites 
on Streptococcus gordonii surface protein PadA 
bind to platelet GPIIbIIIa. Journal of Thrombosis and 
Haemostasis doi:10.1160/TH13-07-0580 (*These 
authors contributed equally). Impact factor 6.081
Petersen HJ. Oral Bacteria; Masters of disguise and 
distant site invaders. Faculty of Dentistry Journal, 
Oct 2012
Presentations:                 
SGM annual meeting, York 2011, UCL Infection, 
Immunology and Inflammation Domain – London 2011
Prizes: 
1st Place, Research Presentation Prize, 
1st Place, Poster Competition,
Helen 
Petersen 
Infective endocarditis is a severe life-
threatening disease caused by bacterial 
infection of damaged heart valves. A well 
recognised cause is deposition of oral 
bacteria, which may get into the blood stream 
as a result of periodontal disease.  The 
purpose of this study was to identify proteins 
on the surface of oral bacteria, which may 
interact with platelets and promote adhesion 
to the surface of the heart.  Our results 
showed that oral bacterium (Streptococcus 
gordonii) a known endocarditis pathogen, 
expresses cell surface molecules that interact 
with adhesion molecules (integrins) on the 
surface of platelets. In vitro experiments 
showed that this interaction could facilitate 
platelet adhesion and spreading (activation). 
These results suggest that cell surface proteins on Streptococcus gordonii interact with platelets and likely contribute to the production 
of infected adhesions, which causes infective endocarditis. This raises the possibility of developing drugs to target these interactions 
for combating this disease. 
Reference; Keane C, Petersen HJ, Tilley DO, Haworth J, Cox D, Jenkinson HF, Kerrigan SW. Multiple sites on Streptococcus gordonii 
surface protein PadA bind to platelet GPIIbIIIa. Thromb Haemost. 2013 Dec;110(6):1278-87
Oral bacteria produce cell surface proteins that trick human platelets in to thinking they are areas of vascular damage in order 
to hide from the immune system. This may be a way that they can travel from the oral cavity to cause distant site infections.
A patient undergoing dental treatment
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Feasibility of alcohol screening and treatment 
interventions in dental settings
FELLOWSHIP/SPONSOR
FDS Research Fellowship
SUPERVISORS
Professor Simon Moore and Professor Jonathan Shepherd
SITE OF WORK 
Cardiff University School of Dentistry and Glynneath Dental Practice
PUBLICATIONS
1. Faculty Dental Journal, Volume 5, Number 3, July 2014, pp. 134–137.
2.  FDI World Dental Federation Oral Health Atlas, Second Edition due to be published September 2015.
PRESENTATIONS
1. Oral presentation 2014 British Association of Oral Surgery conference, RCS Edinburgh
2. Poster presentation 2014 British Association of Oral Surgery conference, RCS Edinburgh
PRIZES
First Prize DF2/SHO/Career Development Post category at the 2014 British Association of Oral Surgery conference 
Zairah 
Yusuf 
Roked
Alcohol misuse is a major risk factor for periodontal disease, dental caries, tooth erosion, mouth cancer and maxillofacial injury.
The aim of the study was to determine the 
feasibility of screening patients for alcohol 
misuse in a primary dental care setting and 
providing those identified as hazardous drinkers 
with a brief treatment intervention. This work 
was also designed to prepare the way for a large-
scale clinical trial. 
A randomised controlled trial was carried out 
in a general dental practice in South Wales. 
Patients aged 18–65 were approached and 
written consent received from those who agreed 
to participate. Patients were stratified according 
to appointment (with a dentist or hygienist) and 
screened using the Modified-Single Alcohol 
Screening Question, M-SASQ. Those scoring 
positively for alcohol misuse were randomly 
allocated to receive either a motivational 
interview from either the dentist or hygienist 
or usual care. The outcome assessor and patients were blind to allocations. The outcome measure at three months was M-SASQ 
score.
In total, a single hygiene patient and 106 dental patients were recruited. The hygiene patient did not score positively on the 
M-SASQ for alcohol misuse. Of the 106 dental patients recruited, 46 patients (43%) scored positively, with 26 allocated into the 
intervention group and 20 to the control. Follow-up data were available for 22 (48%) out of the 46 patients (12 in the intervention 
and 10 in the control group). M-SASQ scores changed from positive to negative for two patients in the intervention and five in the 
control group.
Alcohol misuse screening and treatment was feasible in a primary dental care setting. This suggests a new approach involving the 
dental team, which could potentially reduce burdens on specialist dental and medical services alike. Overall, the dentist was best 
placed to deliver the intervention rather than the hygienist. Contamination may have been a problem as more patients in the 
control group changed M-SASQ score. Building on these findings, a multi-centre, cluster randomised controlled trial is planned.
Zairah with a patient
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A study of shared decision making in orthognathic 
treatment
FELLOWSHIP/SPONSOR
FDS Research Fellowship
SUPERVISORS
Professors Susan J Cunningham, Nigel P Hunt & David 
R Moles
SITE OF WORK 
Eastman Dental Hospital, University College London 
Hospitals NHS Foundation Trust
Fiona
Ryan
The level of patient involvement in orthognathic consultations was relatively low at 22.55%.
Recently there has been increasing emphasis on shared 
decision-making (SDM) as the pinnacle of patient-centred 
care. There is evidence that SDM leads to improved outcomes, 
however, it remains to be widely adopted in healthcare to 
date. The aim of this study was to measure the extent of SDM 
in orthognathic consultations using the OPTION scale. 
This was a cross-sectional study involving pre-treatment 
orthognathic patients and the clinicians involved in their 
care. Multidisciplinary clinic consultations were audio 
recorded and rated by two independent raters using the 
OPTION scale. 
Consultations with 61 orthognathic patients were rated: 36% 
were male and 64% female. The mean age was 26 years and 
the mean consultation length was 12 minutes and 44 seconds. 
Agreement between the raters was acceptable, with an intra-
class correlation coefficient of 0.794 (95% confidence interval 
0.678 to 0.871). The mean OPTION score was 22.55% (range 
3–54%, SD 10.73%), indicating a low level of SDM.
The levels of SDM recorded in orthognathic consultations 
in this study were relatively low, although similar to other 
studies. It was felt that these results were largely due to 
patients attending a new ‘group information clinic’ one week 
prior to their MDT clinic appointment. This clinic is designed 
to provide detailed information of all general aspects of 
orthognathic treatment to patients and family members 
in a group. Thus, much of the information had already 
been provided and was not repeated at the second rated 
consultation.
The results of this study suggested that the extent of SDM 
in orthognathic consultations was relatively low but there 
are circumstances that are specific to this hospital that may 
account for this. This is the first study investigating SDM in 
the field of orthodontics. Improvements in SDM are necessary 
in order to ensure that patients are adequately involved in 
their treatment decisions.
Fiona and a patient engaged in shared decision-making
The Centre for Evidence in Transplantation (CET) is 
situated in the College’s Clinical Effectiveness Unit (CEU). 
The centre was established in 2005 to evaluate the quality 
of evidence available in solid organ transplantation (www.
transplantevidence.com).
The CET has been 
involved in a number 
of projects since its 
establishment, one 
of which has been to 
establish a registry 
of all randomised 
controlled trials in 
organ transplantation 
and to evaluate the 
methodological quality of 
those trials since January 
2004. This registry was published as a regular feature in the 
journal Transplantation, but from January 2008 this has been 
replaced by the Transplant Library.
The Transplant Library is an electronic library of all RCTs 
in solid organ transplantation from 1970 to the present and 
more recently includes systematic reviews that are regarded 
as of reasonable quality. The development of an electronic 
library has been a major project and includes all randomised 
controlled trials in solid organ transplantation. Through 
Ovid (a global provider of information for the healthcare 
industry) it became available to all members of the British 
Transplantation Society (BTS), Scottish NHS libraries and 
various other medical school libraries.
Evidentia Publishing has also taken on the library and is 
currently in the process of marketing and providing free trials 
to expand awareness of the Transplant Library, their current 
subscribers include the Canadian Transplantation Society, 
Brazilian Transplantation Society and the European Society of 
Transplantation (ESOT).
It is often asked why we need an electronic library in 
transplantation but if we remember that RCTs and systematic 
reviews/meta-analyses of RCTs are level-one evidence in any 
medical discipline then the aim was to develop a very easily 
searched and comprehensive library that could produce the 
relevant references in minutes rather than hours. Indeed, the 
great Archie Cochrane, after whom the Cochrane library is 
The Centre for Evidence 
in Transplantation
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named, predicted the need for specialist/subspecialist libraries of 
RCTs some 30 years ago: this is the first!
In an analysis of the methodology of randomised controlled trials 
in organ transplantation between 2004 and 2006 it was found that 
only around one third of those trials were methodologically sound 
in their design. A smaller sample of 91 RCTs published in 2004 
was evaluated for the quality of reporting of outcomes of RCTs 
and again we found significant defects in a majority of trials. As 
RCTs represent the highest level of available evidence this does 
detract from the value of the evidence available. On the basis of this 
information an agreement has been reached with ESOT that the 
CET would become the Knowledge Centre for ESOT and would 
offer advice in the design of RCTs, as well as provide assistance with 
the reporting of RCTs. Trials that were methodologically sound in 
design would be given ESOT/CET accreditation.
Some recent publications include, Antifungal Prophylaxis In Liver 
Transplantation: A Systematic Review And Network Meta-Analysis 
(Jonathan Evans), Social media and online attention as an early measure 
of the impact of research in solid organ transplantation (Simon Knight) 
and A systematic review of the use of rituximab for desensitisation in renal 
transplantation. (Philip Macklin) 
Within the past year Dr Liset 
Pengel, the CEO of the CET 
and a member of the staff of 
the Nuffield Department of 
Surgery, has been granted a 
distinction award by the NDS 
for her work with the CET. 
Peter Morris was inducted 
into the Research Hall of 
Fame at The Royal Melbourne 
Hospital. Neil Russell, who was the first Research Fellow at the 
CET, has finished his surgical training at Addenbrooke’s Hospital 
in Cambridge and has been appointed as a consultant abdominal 
transplant surgeon there. Nishanthi Talawila was promoted to a 
Research Associate in November 2013 after gaining her MSc in 
Public Health, and Katriona O’Donoghue joined the Centre for 
Evidence in Transplantation in April 2014 as a Research Assistant. 
John O’Callaghan has been awarded his DPhil and has produced a 
number of critically important papers arising from the work of his 
thesis which is devoted to organ preservation. 
The CET submitted four posters to the World transplant Congress 
in San Francisco in 2014 and all were given a distinction award. 
The CET team
Dr Liset Pengel teaching on the 
Evidence in Transplantation Course
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The Clinical Effectiveness 
Unit (CEU) is an academic 
collaboration between the 
College and the Department 
of Health Services Research 
and Policy within the London 
School of Hygiene and Tropical 
Medicine (LSHTM). Since its 
creation in 1998, it has become 
a national centre of expertise 
on conducting large-scale 
studies into the quality of 
surgical care. In undertaking 
these studies, it aims to provide 
timely comparative information 
to surgeons and hospitals about 
the process of care and patients 
outcomes. It is also involved in the RCS initiative to develop and 
implement a quality and outcomes strategy across the College 
and specialty associations.
The CEU is largely self-funded by obtaining external project 
grants and contracts, although it receives an annual contribution 
from the College’s research funds and the College underwrites 
five senior academic posts within the LSHTM. Its 16 staff 
members have a variety of backgrounds (eg health services 
research, epidemiology, medical statistics, clinical medicine, 
public health and social science) which gives it a multi-
disciplinary outlook and approach. Dr David Cromwell, Senior 
Lecturer at the LSHTM, has been the CEU Director since May 
2011.
CLINICAL EFFECTIVENESS UNIT
Audit and research
The core activity of the CEU is to conduct national clinical audits 
and research projects. Many of the national audits form part of 
the government’s National Clinical Audit and Patient Outcomes 
Programme (NCAPOP), which is playing an increasingly 
important role in the government’s strategy to improve the 
outcome of secondary care.
In April 2013, the CEU was commissioned to begin the National 
Prostate Cancer Audit (NPCA), which became the fifth national 
cancer audit within NCAPOP. The NPCA is designed to examine 
the treatment choices of men with newly diagnosed prostate 
cancer, and the outcomes of care including long term survival 
and quality of life. A challenge for the audit was to provide 
hospitals with information that would support continuous quality 
improvement for patients with early disease (who may simply 
require surveillance) as well as for patients with advanced disease 
(who are likely to require multi-modal therapy).
The NPCA represents the first of a new generation of national 
cancer audits. The core of its patient data will come from the 
English National Cancer Registration Service and the Welsh 
Cancer Information System, both of which will be linked to 
information on survival from the Office for National Statistics. 
This will keep the burden of data collection on staff to a 
minimum. This clinical data will be supplemented with data 
from patients, who will be asked to complete patient-reported 
outcomes (PROMS) and experience (PREM) questionnaires. 
The combination of clinical, PROMS and PREMS data is 
fundamental to understanding the many dimensions of quality 
health care for these patients, and it is a unique feature among 
current national cancer audits.
David Cromwell, Director 
of the CEU
Professor Ian Loftus, Professor Julian Scott and David 
Cromwell at the Vascular Society meeting in Manchester
CEU team at Vascular Society Meeting in Manchester
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The CEU was also commissioned in 2013 to run the 
National Vascular Registry, in collaboration with the 
Vascular Society of Great Britain and Ireland. The 
registry is another NCAPOP audit and was formed by the 
amalgamation of the National Vascular Database and 
UK Carotid Interventions Audit projects. These projects 
had been used by vascular surgical services in the UK 
to monitor their practice and outcomes since 2005, and 
were part of a broad quality improvement programme 
undertaken by the Vascular Society in collaboration with 
other organisations. The registry will evaluate the quality 
and outcomes of care for patients who undergo vascular 
surgery in England and Wales, and covers five main 
procedures: repair of abdominal aortic aneurysm (AAA); 
carotid endarterectomy; and lower-limb angioplasty 
/ stent, bypass and amputation among patients with 
peripheral arterial disease. While NCAPOP audits tend to 
cover just NHS hospitals in England and Wales, hospitals 
in Scotland and Northern Ireland are also encouraged 
to participate in the registry, so that work of the Vascular 
Society to improve the care provided by vascular services 
within the UK is still supported.
In its first year, the registry produced reports on the 
patterns of care for elective repair of infra-renal AAA 
and for carotid endarterectomy. The report on elective 
AAA repair continued the public reporting of outcomes 
on AAA begun by the Vascular Society, and updated 
the results from its 2012 report. This had examined the 
outcomes of 8,380 procedures between 1 October 2008 
and 30 September 2010 and found that the overall in-hospital 
mortality after surgery for that period had been 2.4%. The registry 
AAA report, published in November 2013, found that outcomes 
had continued to improve, with in-hospital mortality after surgery 
dropping to 1.8% for AAA repairs performed between January 
2010 and December 2012.
A brief description of other major CEU projects undertaken in 2013 
is given in Box 1.
CEU team meeting with American guest speaker Professor Dennis Scanlon from the Pennsylvania State University
Professor Sir Norman Williams and Dr Torsten Olbers from 
Sahlgrenska University Hospital in Gothenburg, Sweden
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Box 1: Other major CEU projects undertaken in 2013
• National Bowel Cancer Audit 
 The National Bowel Cancer Audit (NBCA) is funded 
by the Healthcare Quality Improvement Partnership 
(HQIP) and was developed by the Association 
of Coloproctology of Great Britain and Ireland 
(ACPGBI). The analyses for the 2013 Annual report 
were carried out by the CEU with support from the 
NHS Information Centre. It is managed by the Clinical 
Audit Support Unit within the NHS Information 
Centre.
• CRANE Database
 This is a registry of all children born with cleft lips 
and palates in England, Wales and Northern Ireland, 
their treatment and the outcomes. The CEU has 
been the host organisation for this registry since 
April 2005. CRANE is funded by the NHS – specialist 
commissioners involved in cleft care.
• Breast Cancer Outcomes project.
 This project is using national routine data to 
examine the patterns of care and outcomes of breast 
surgery among women with breast cancer. It is being 
carried out with the Association of Breast Surgeons, 
British Association of Plastic, Reconstructive and 
Aesthetic Surgeons (BAPRAS) and is part funded by 
Johnson & Johnson.
• National Oesophago-Gastric Cancer Audit
 This audit restarted in June 2011 and is being 
carried out in partnership with the Association 
of Upper Gastrointestinal Surgeons, the British 
Society of Gastroenterology, The Royal College 
of Radiology, and the National Clinical Audit 
Support Programme of the Health and Social Care 
Information Centre. The audit is funded by the 
Healthcare Quality Improvement Partnership. 
The publication of consultant-level surgical outcomes
As part of the NHS Commissioning Board’s publication 
Everyone Counts: Planning for Patients 2013/14, ten national 
clinical audits were asked to report on surgical outcomes by 
consultant in the summer of 2013. This initiative was part of 
NHS England’s drive to produce information that supports 
local clinicians to improve the outcomes of care and that 
provides more transparency for patients, and is seen as a 
complement to the NHS Outcomes Framework.
The CEU played an active role in producing the consultant-
level information for three of the ten national audits that 
participated in the Everyone Counts initiative, namely: the 
National Vascular Registry, the National Bowel Cancer Audit 
and the National Oesophago-gastric Cancer Audit. A challenge 
for the project teams was that the audits were designed 
primarily to support quality improvement at an organisational 
level, and not all captured the name of the consultant 
undertaking the surgery. Consequently, the months between 
the announcement of the policy in February 2013 and the 
publication on the figures in the summer became an extremely 
busy time for the CEU. Communicating with consultants and 
NHS organisations was a fundamental component of the task 
preparing the reports, and took a lot of organising. Preliminary 
information was circulated to surgeons for checking, which was 
followed by periods to allow for additional or corrected data to 
be returned to the audits. We were grateful for the incredible 
support we received from surgeons in this process, though it 
is fair to say that there was a wide range of opinions about the 
value of the exercise. 
Reporting the outcomes of specific procedures in a way that 
is accepted by the surgical profession and understood by the 
public is challenging. A particular issue concerns whether 
surgeons are performing sufficient procedures for poor 
performance to be detected reliably. We examined this issue 
for four procedures: adult cardiac surgery, curative resection 
for oesophago-gastric cancer; bowel cancer resection; and 
hip fracture surgery [Walker et al 2014]. We found that 
most cardiac surgeons do a sufficient number of operations 
for there to be a reasonable chance of detecting someone 
whose mortality rate is twice the national average. However, 
much fewer surgeons were performing the other procedures 
CEU team with Dr Torsten Olbers from Sahlgrenska 
University Hospital in Gothenburg, Sweden
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in sufficient numbers to identify this lower level of 
performance. Consequently, a potential risk of this policy 
is that the reporting of surgeon-level outcomes could 
lead to a false sense of security and could lead to inaction 
rather than support quality improvement. 
 
Teaching
The CEU runs a number of courses for surgeons and 
other health care professionals on statistics, clinical 
research methods and evidence-based surgery. The 
courses use a mixture of teaching methods ranging from 
lectures to interactive seminars and hands-on computer 
practicals. Course faculty often includes methodologists 
recruited from CEU staff as well as senior clinicians with 
a strong interest in research and audit.
Selected publications by CEU staff in 2013 and 2014
1. Callaghan CJ, Charman SC, Muiesan P, Powell JJ, 
Gimson AE, van der Meulen JH; UK Liver Transplant 
Audit. Outcomes of transplantation of livers from 
donation after circulatory death donors in the UK: a 
cohort study. BMJ Open 2013; 3: e003287.
2. Fitzsimons KJ, Copley LP, Deacon SA, van der Meulen JH. 
Hospital care of children with a cleft in England. Arch Dis 
Child 2013; 98: 970–74. 
3. Neuburger J, MacNeill F, Jeevan R, van der Meulen JH, 
Cromwell DA. Trends in the use of bilateral mastectomy in 
England from 2002 to 2011: retrospective analysis of hospital 
episode statistics. BMJ Open 2013; 3: e003179. 
4. Palser TR, Cromwell DA, Hardwick RH, Riley SA, Greenaway 
K, van der Meulen JH. National Oesophago-Gastric Cancer 
Audit. Impact of route to diagnosis on treatment intent and 
1-year survival in patients diagnosed with oesophagogastric 
cancer in England: a prospective cohort study. BMJ Open 2013; 
3: e002129.
5. Walker K. Neuburger J. Groene O, Cromwell DA, van der 
Meulen J. Public reporting of surgeon outcomes: low volumes 
lead to false complacency. Lancet 2013; 382: 1674–77.
6. Chadwick G, Groene O, Hoare J, Hardwick RH, Riley S, 
Crosby TD, Hanna GB, Cromwell DA. A population-based, 
retrospective, cohort study of esophageal cancer missed at 
endoscopy. Endoscopy 2014; 46: 553–60.
Research Fellows studying at a research methods course
77
7. Jeevan R, Cromwell DA, Browne JP, Caddy CM, Pereira J, 
Sheppard C, Greenaway K, van der Meulen JH. Findings 
of a national comparative audit of mastectomy and breast 
reconstruction surgery in England. J Plast Reconstr Aesthet 
Surg 2014; 67: 1333–44. 
8. Wallace D, Walker K, Kuryba A, Finan P, Scott N, van der 
Meulen J. Identifying patients at risk of emergency admission 
for colorectal cancer. Br J Cancer 2014; 111: 577–80.
9. Tovikkai C, Charman SC, Praseedom RK, Gimson AE, 
Watson CJ, Copley LP, van der Meulen J. Linkage of a 
national clinical liver transplant database with administrative 
hospital data: methods and validation. Transplantation 2014; 
98: 341–47.
10. Cathcart P, Nossiter J, Aggarwal A, Rashbass J, Lyratzopoulos 
Y, Payne H, Neal DE, van der Meulen J; National Prostate 
Cancer Audit group. The first national clinical audit of 
prostate cancer care. BJU Int 2013; 112: 883–84. 
David Cromwell teaching at a research methods course
The College is pleased to be able to 
offer a variety of awards as a result of 
the generous support of companies 
and individuals. These awards give 
surgeons the opportunity to work in an 
overseas institution to learn more about 
a particular surgical technique or area. 
The main benefit of the travelling awards 
is that the surgeon who benefits can 
translate the experience and know-how 
gained during the overseas fellowship 
to his or her own knowledge base, to 
benefit future patients in this country. 
The committees that decide the recipients 
of the travelling awards always include 
leading surgeons.
Rex & Jean Lawrie and Stefan 
& Anna Galeski Travelling 
Fellowships 2014
The College is most grateful to the Lawrie 
and Galeski families for supporting 
trainee surgeons to be part of the 
faculties which teach introduction to 
surgical skills workshops to trainees and 
medical students in Borneo, Sri Lanka, 
Algeria and Rwanda
Recipients 2014
Andrew Beamish
Aneel Bhangu
Andrew Cowie
Edward Fitzgerald
Kathryn Gash
Vimal Gokani
Rhiannon Harries
Sreelakshmi Mallappa
Jo Mennie 
William Muirhead
Oliver Old
Georgios Orfaniotis
Hew Torrance
Ethicon Foundation Fund
The Ethicon Foundation Fund was 
established by the generosity of 
Ethicon Limited. The fund provides 
financial assistance towards the cost 
of the travel to and from a research or 
training fellowship, thereby promoting 
international goodwill in surgery. 
Applicants should be sufficiently 
advanced in their training to benefit 
from such an experience or be within one 
year of their appointment as consultant 
surgeon.
Recipients October 2013
Mr Jonathan Hutt FRCS – 1 year 
Montreal, Canada
Mr Harry Powell FRCS – 9 months 
Sydney, Australia
Mr Paul Sutton MRCS – 5 weeks Mayo 
Clinic and Cleveland Clinic, USA
Mr Saket Tibrewal FRCS – 4 weeks 
Toronto, Canada
Mr Ewan Wilson FRCS – 1 month Texas, 
USA
Recipients May 2014
Mr Mathew Sewell FRCS – 1 year 
Brisbane, Australia
Mr Parag Jaiswal – 1 year Calgary, Canada
Mr Sammy Hanna FRCS – 1 year Ontario, 
Canada
Mr Amit Shah FRCS – 1 year Sydney, 
Australia 
Mr Vincent Tang FRCS – 1 year 
Melbourne, Australia
Mr Simon Thompson FRCS – 1 year 
Sydney, Australia
Mr Tim Halsey FRCS – 1 week France
Recipients October 2014
Mr Daniel Rolton FRCS – 1 year City 
Hospital, Auckland, New Zealand
Mr Hugh Sims–Williams MRCS – 5 
months CURE Children’s Hospital 
Uganda
Mr Nirav Patel FRCS – 1 year Rubin 
Institute for Advanced Orthopaedics, 
Sinai Hospital of Baltimore
Mr Prabhakar Rajan FRCS – 4 months 
Karolinska University Hospital, Solna, 
Stockholm, Sweden
Mr Khaled Sarraf FRCS – 6 months St 
Michaels’s Hospital, Toronto
Mr Iain McGraw FRCS – 1 month 
Shriners Hospital for Children and the 
Philadelphia Hand Center
Dr Alastair Hunter FRCS – 2 weeks 
Institut Kaplan, Barcelona, Spain
Colledge Family Memorial 
Fellowship Fund
The Colledge Memorial Travelling 
Fellowship was established by Miss Cecilia 
Colledge in 1979 in memory of her 
father, the distinguished surgeon Lionel 
Colledge and her brother Maule who 
died in active service during the Second 
World War. The fellowship was founded 
to promote and advance the study and 
knowledge of surgery, in particular 
head and neck surgery, for the benefit 
of patients. Applicants must be senior 
trainees or new consultants and plan to a 
study for a period overseas.
Recipients 2013:
Mr Jonathan Michael Bernstein FRCS
Mr Philip John Clamp FRCS
Mr Enyinnaya Ofo FRCS
Mr Harry Richard Franklin Powell FRCS
Recipients 2014:
Mr Jonathan Hughes FRCS 
Mr Rohit Kumar FRCS
Mr Sergios Georgiou Latis FRCS
Mr Joel Anthony Smith FRCS
Mr Joseph David Wasson FRCS
Sir Ratanji Dalal Research 
Scholarship 
This research scholarship was founded 
under the will of Sir Ratanji Dinshaw 
Dalal. It is awarded jointly by The Royal 
College of Surgeons of England and the 
Royal College of Physicians of London. 
Applications are invited for this research 
scholarship, which is intended to support 
a project in either tropical surgery or 
tropical medicine. The scholarship 
is tenable for one year and is open to 
all medical practitioners registered in 
any part of the commonwealth. It may 
be held in any institution in Britain or 
PRIZES & Travelling awards
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overseas that is approved by The Royal College 
of Surgeons of England and the Royal College of 
Physicians of London.
Recipients 2013:
Mr Glenn Kunnath Bonney MRCS
Mr Henry Guy Francis Burnand MRCS
Recipient 2014:
Dr Rachel Wake
H J Windsor Prize 
The H J Windsor Prize was established in 1975 
with a gift of £2,500 from the late Dr H J Windsor 
KSG CBE FRCS of Brisbane, Australia. The 
Prize is intended to ‘assist in the advancement 
of surgery by an annual prize or by such other 
means as the Council shall from time to time 
determine’.
Recipient 2014
Miss Charlotte Lucy Bendon MRCS
The Rosetrees Trust Prize
The Rosetrees Trust Prize was established in 
2009 and applicants are invited to submit an 
essay describing how their research project will 
contribute to improvements in patient care 
within the next five years.
2013 Winner
Mr Alexander Liddle MRCS, Understanding failure 
in uni-compartmental knee replacement
2013 Joint Runners Up
Mr Alexander Woollard MRCS, Nerve regeneration 
in facial construction
Mr James Chan MRCS, Accelerating fracture repair
2014 Joint Winners 
Miss Katherine Gash MRCS, Hitting cancer where 
it hurts
Miss Michelle Griffin MRCS, 3D-printing 
nanocomposite polymers for ear and nose reconstruction; 
the new generation of organ replacements
Mr Alexander 
Woollard MRCS
Mr James 
Chan MRCS
Joint runners up receiving their prize from Professor Sir Norman Williams
 
 Higher  Degrees  For  Intercalated
Medical 
Students
DANIEL BEDER 82
George Bethell 82
Oliver Brunckhorst 83
Alexandra Burke-Smith 83
Nick Cork 84
Nicolaas Jansen van Rensburg 84
Chia Yew Kong 85
Pedram Kordrostami 85
Catherine Elizabeth Lovegrove 86
Kyung-Hoon Moon 86
Chandni Nigam 87
Joon Faii Ong 87
Michael John Rice 88
Sayinthen Vivekanantham 88
Medical Students Grants are awarded to medical 
students wishing to undertake an intercalated Bachelor of 
Science degree related to surgery. This has come about 
in particular from the onset of the Modernising Medical 
Careers reforms and the demands placed on medical 
students who wish to consider a career in surgery. Owing 
to the variation in the ways students are funded or not 
funded for such degrees, students require additional 
support in areas such as bench fees, consumables 
or subsistence. Each award is worth up to £5,000. 
MEDICAL STUDENTS
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Stem-cell therapy for 
Hirschsprung's disease
George Bethell
Medical School:  University of Liverpool
Location of research:  Institute of Child Health
The RCS award allowed 
me to undertake 
lab-based research 
working towards an 
MPhil in Children’s 
Health. The research 
was based at the 
University of Liverpool 
in partnership with 
Alder Hey Children’s 
hospital and supervised 
by Simon Kenny and 
Professor David Edgar.
Following surgery for 
Hirschsprung’s disease 
10%–30% of children 
suffer from long-term 
faecal incontinence 
or constipation, which 
can worsen as the 
patient grows older. It is 
thought that stem-cell 
therapy could resolve 
these issues. My work 
involved collection of 
human gut samples to 
determine the location 
and identity of enteric 
nervous system stem 
cells that are present 
in the gut. As well as 
achieving this, I have had the opportunity to present at two 
international conferences and am currently preparing two 
papers for publication.
I am grateful to the RCS for their support, which has made 
this degree and the attendance at conferences possible for me.
An analysis of the current 
management practices of 
radically treatable non-
small cell lung cancer in St 
James's University Hospital
DANIEL BEDER 
Medical School:  University of Leeds
Location of research:  St James’s University Hospital (SJUH), Leeds
Non-small cell lung 
cancer (NSCLC) 
affects 42,000 
people each year 
in the UK but only 
a small proportion 
can be cured 
with surgery. We 
audited three areas 
where changes may 
improve patient 
care in St James’s 
University Hospital 
(SJUH), Leeds.
1) NSCLC commonly spreads to the brain and brain imaging 
may identify patients at risk of relapsing. We offered brain 
imaging to 5% of patients, and 2% actually developed 
brain metastases.
2) Complete lymph node removal during surgery greatly 
improves chances of achieving cure. We sample and 
remove important lymph nodes in every patient, and 
completely remove them in 42% of patients; this is higher 
compared with other institutions.
3) Follow-up aims to detect relapses early; we found that chest 
x-ray is performed routinely and that follow-up practices 
varied between specialties and needs streamlining.
In summary, we are doing well compared with other 
institutions but aim for continued improvement.
Daniel with his poster illustrating his audit findings at the 
annual British Thoracic Oncology Group conference in 
Dublin, March 2014
George presenting at the British Association 
of Paediatric Surgery Conference 2014
George using the flow cytometer in the lab
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Development and validation 
of a simulation-based 
ureteroscopy curriculum 
- a randomised controlled 
trial
Oliver Brunckhorst
Medical School:  King’s College London
Location of research:  Guy’s Hospital, London
Training the modern surgeon is increasingly difficult, with 
the evermore complicated procedures and the decreased 
training hours. Simulation-based training may offer a much-
needed adjunct to regular training pathways. However, 
surgery is much more than just learning technical skills, as 
non-technical skills such as communication are also vital.
We have therefore 
developed a 
curriculum for 
the common 
urological 
procedure of a 
ureteroscopy, 
using simulators 
and a simulated 
operating room 
environment 
to develop 
technical and 
non-technical 
skills together. 
Results have been 
positive, with 
both skills considerably improved in those that underwent 
the curriculum. This is significant, as little research has 
been conducted to demonstrate that teaching both skill 
sets together is feasible and is useful for the development of 
future surgical curricula.
I am extremely grateful to the College for their support, 
which has allowed me to conduct this project, introducing 
me to the world of surgical education research.
A comparison of 
non-invasive portable 
imaging modalities for the 
assessment of burn depth in 
adult burn injuries
Alexandra Burke-Smith
Medical School:  Imperial College London
Location of research:  Chelsea and Westminster Hospital, London
Thanks to the RCS grant during my Intercalated BSc in 
Surgery and Anaesthesia at Imperial College, I was able 
to purchase a thermal imaging camera for my clinical 
study at Chelsea 
and Westminster 
Hospital. I compared 
the current 
gold-standard 
laser Doppler 
imaging (LDI) 
with the currently 
unproven Infrared 
Thermography 
(IRT) and the 
Spectrophotometric Intracutaneous Analysis (SIA) for 
accurate early assessment of burn depth, recommended to 
support early appropriate surgery and timely healing.
Our initial results indicated SIA has the potential for 
becoming the new 
preferred scanning 
modality as it is of 
equal/greater accuracy, 
reduced cost, easier 
and quicker when 
compared with LDI. 
These results now need 
to be corroborated in a 
larger series, in parallel 
to developing the software to modify the representation 
of the images to improve ease of interpretation. I plan to 
continue this project myself and have applied for an MSc in 
order to do so.
Oliver with supervisors Professor Prokar Dasgupta 
(Consultant Urological Surgeon) and Kamran Ahmed 
(Urology Registrar) at Guy’s Hospital Theatres
Alexandra holding the infrared thermal imaging camera 
purchased with her RCS grant and standing next to 
the Chelsea and Westminster laser Doppler unit
Alexandra (right) with one of her 
clinical supervisors, Isabel Jones
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Developing an open-source-
based 3D printer and 
methods for fabrication of 
POSS-PCU tissue engineering 
scaffolds
Nicolaas Jansen van Rensburg
Medical School:  University College London
Location of research:  Royal Free Campus, London
During my IBSc year, 
the award allowed me to 
purchase the parts for 
the first 3D printer in 
our department. Using 
an open-source design, 
we built and modified 
a 3D printer and 
developed methods to 
produce patient-specific 
lab-grown tissues. Our 
research has enabled us 
to use standard patient 
imaging (eg CT, MRI 
scans), convert these into 
three-dimensional models and, finally, print accurate replicas 
using a novel nano-composite biopolymer developed at the lab.
The technique developed isn’t limited to the initial application 
of spinal fusion cages and has since been applied to 
maxillofacial reconstruction 
and refinement of a tissue-
engineered trachea. For the 
research conducted, I was 
awarded the Best Research 
Presentation and viva voce 
2013/14 Prize. I have also been 
offered the chance to continue 
the research, working towards 
a PhD. This year would not 
have been possible without the 
generous award from the RCS. 
Thank you.
3D model of mandible from CT scan
Contemporary issues in 
paediatric neurosurgery 
- improving outcomes in 
paediatric CNS tumours
Nick Cork
Medical School:  University of Bristol Medical School
Location of research:  Frenchay Hospital, Bristol
My year of research in the Department of Neurosurgery at 
Frenchay Hospital would not have been possible without this 
generous award from the College.
The grant supported 
me in conducting a 
retrospective study of 
children diagnosed 
with brain or spinal 
tumours in the South 
West region, with a 
view to streamline 
and quality improve 
the process. Our aim 
was to identify factors 
guiding successful 
surgery, improve safety 
and effectiveness 
through better 
presurgical screening, 
and enable earlier 
diagnosis.
I was also able to organise a personal education 
programme, observing post-mortems, learning the 
principles of neuropathological dissection and attending 
subspecialty teaching and multidisciplinary meetings. The 
opportunity to assist in theatre on elective and emergency 
neurosurgical cases was a particular highlight, confirming 
my interest in pursuing a career in academic neurosurgery.
My thanks again to The Royal College of Surgeons of 
England, and their funding partners, for facilitating this 
rare and invaluable opportunity.
Nick examining a newly dissected brain in the 
Neuropathology laboratory at Frenchay Hospital
Professor Alexander Seifalian and myself in front of 
our first 3D Printer. We now have four!
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The relationship 
between the tumour 
microenvironment and 
epithelial-mesenchymal 
transition
Chia Yew Kong
Medical School:  University of Glasgow
Location of research:  Wolfson Wohl Cancer Research Centre, Glasgow
I have had a fruitful and productive year gaining key skills in 
conducting medical research and successfully completed a 
research project at the Wolfson-Wohl Translational Cancer 
Research Centre.
My research project’s aim looked 
at the process named epithelial 
mesenchymal transition, which 
allows cancer cells to break off from 
the tumour and spread to distant 
sites of the body. We examined its 
interplay with factors within the 
microenvironment of the tumour 
(the area surrounding the tumour) 
– an example of which are the cells 
of the immune system surrounding 
the tumour, which have been shown 
to have a protective effect against it. We plan to present these 
results at scientific conferences and write a manuscript for 
publications.
I would like 
to thank the 
College for this 
generous grant. 
The year has 
further inspired 
me to continue 
to pursue my 
aspirations 
of becoming 
a surgeon–
scientist in the 
future.
Does TGF-Beta (TGF- )
signaling initiate and 
drive the progression of 
osteoarthritis?
Pedram Kordrostami
Medical School:  University of Bristol
Location of research:  Bristol University Centre for Comparative and 
  Clinical Anatomy
Osteoarthritis is the most common cause of disability in the 
elderly, affecting hundreds of millions of people worldwide. 
Currently, there are no drugs that reverse or slow down the 
progression of disease and medical management is limited to 
pain relief, physiotherapy and surgery. My research investigated 
the role of TGF-β in the initiation and/or progression of 
osteoarthritis. This growth factor has an integral role in the 
maintenance of healthy cartilage and is a potential target 
for the development of new disease-modifying therapy. The 
research I carried out adds to the current knowledge and 
provides a platform for future research in the area. 
I am very grateful to the College for its invaluable support 
towards my research project, which has given me the 
opportunity to experience laboratory techniques under expert 
supervision. I have developed a range of new skills that will 
undoubtedly benefit my future surgical training.
Chia Yew in the lab
Chia Yew (middle) with supervisors, James Park, Clinical Research 
Fellow in Surgery (left) and Campbell Roxburgh, Clinical Lecturer in 
General Surgery (right)
Pedram (right) with supervisor Mo Sharif
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Echocardiography during 
the endothermal ablation 
and mechanochemical 
ablation of varicose 
veins: Do bubbles cause 
neurological symptoms?
Kyung-Hoon Moon
Medical School:  Imperial College London
Location of research:  Charing Cross Hospital, London
With the generous financial support from The Royal College 
of Surgeons of England, I conducted a project within the 
academic section of vascular surgery at Charing Cross Hospital 
as a part of my intercalated BSc in Surgery and Anaesthesia at 
Imperial College.
The project investigated the safety of two types of varicose vein 
treatments: a radio-wave heat technique and a novel device 
that simultaneously uses chemical and mechanical irritation to 
close the diseased veins. The safety was assessed by monitoring 
patients’ hearts with ultrasound for any errant bubbles 
produced that have been linked to stroke-like symptoms with 
other varicose vein treatments.
The RCS grant helped fund accurate ultrasounds of the heart 
and subsequent data analysis. The study was successfully 
completed and results have shown that the two techniques 
have an equally safe profile and do not produce heart 
ultrasound findings linked to stroke.
Local Anaesthetic Varicose Veins Unit, Charing Cross Hospital
Development and 
validation of the RARP 
Assessment Score for 
training and assessment 
of Robot-Assisted Radical 
Prostatectomy (RARP)
Catherine Elizabeth Lovegrove
Medical School:  University of Edinburgh/King’s College London
Location of research:  King’s College London
During my intercalated year I undertook a project focused on 
Robot-Assisted Radical Prostatectomy (RARP). The rise in 
robot-assisted surgery has changed the treatment offered for 
prostate cancer. It is imperative that surgeons be well trained 
in robot-assisted surgery, which requires unique technical 
and non-technical skills.
My dissertation project, supported by the Royal College of 
Surgeons, sought to identify the hazards within RARP to 
create a safety checklist for the protection of patient safety. The 
observational, longitudinal, multi-institutional study undertook 
qualitative and quantitative analysis for eight months.
Information 
about 
identified 
hazards 
was applied 
to the 
training and 
assessment of 
17 surgeons 
across 
Europe 
who were 
undertaking 
a Robotic Surgery Fellowship with the European Association 
of Urology. Using an assessment score, their learning curve 
in a total of 145 RARP cases was considered. This is the first 
time that learning curves for procedural steps have been 
examined in the literature.
Kamran Ahmed, Catherine Lovegrove and Professor 
Prokar Dasgupta beside the new DaVinciXi
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Personalised phenotyping 
of axillary tissue: 
Identifying biomarkers 
for presence of axillary 
metastasis in breast cancer
Chandni Nigam
Medical School:  Imperial College London
Location of research:  Charing Cross Hospital, London
Breast cancer frequently 
spreads to the axilla 
(armpit), requiring surgical 
clearance of the local 
nodes. However, at present 
it is not always possible to 
determine the extent of this 
spread prior to surgery. My 
project aimed to develop a 
rapid intra-operative test 
for biomarkers of axillary 
metastasis using liquid 
chromatography-mass 
spectrometry (LC-MS)-
based analysis of axillary 
tissue, which could facilitate 
complete surgical resection of the primary tumour and its 
metastases in one operating session.
During the project, I worked 
with the research team at 
the world-class International 
Phenome Centre and become 
acquainted with state-of-the-
art analytical techniques that 
are currently at the forefront 
of cancer research. I wish to 
thank the College for their 
generous funding of this 
project. Preliminary results of 
this study are promising and 
we are currently awaiting more 
data for analysis and eventual 
publication.
Mesenchymal stem-cell 
immunosuppressant 
polymer microcarriers for 
local immunosuppression 
in vascular composite 
allografts
Joon Faii Ong
Medical School:  Imperial College London
Location of research:  Guy’s Hospital, King’s College London
I am deeply grateful to the RCS for supporting my surgical 
aspirations and one of the projects I had initiated at the Harvard-
MIT Health Sciences and Technology Division. This project seeks 
to develop a novel immunosuppression platform for transplant 
recipients. Given that medicine-free acceptance of complex face 
and limb transplants is still significantly in 
the future, patients now need intermediate 
platforms to reduce the quantity of immunity 
medication and the accompanying toxic side 
effects as much as possible.
With the award we have been able to 
complete a significant portion of the in 
vitro work and continue to work at King’s 
College London. We are still pursuing 
development of the platform.
Without the RCS it would have been exceedingly difficult to tie my 
experiences with the face and limb transplant group at Harvard 
Medical School with clinical and research work in the UK.
It is in no small part because of the support of the College that 
I have been fortunate to 
graduate with First Class 
Honours from King’s 
College London. This 
backing from the College 
provides a critical link 
between my research 
experience, graduate 
school and future 
innovations.
Chandni collecting intra-operative axillary 
samples at Charing Cross Hospital Joon Faii with Professor Lucy 
Di Silvio, teacher, mentor, 
friend and inspiration
Chandni conducting pre-analytical sample 
preparation of axillary tissue at Charing 
Cross Hospital Joon Faii with colleagues from the Karp Laboratory
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Falls in Parkinson's disease: 
Where is the pathology?
Sayinthen Vivekanantham
Medical School:  Imperial College London
Location of research:  Charing Cross Hospital, London
The RCS award 
supported me 
through my 
Intercalated 
BSc in 
Neuroscience 
and Mental 
Health at 
Imperial 
College 
London, 
allowing me 
to pursue 
my research 
interest in 
functional 
neurosurgery.
My research 
aimed to 
correlate the clinical presentation of falls with pathological 
changes in post-mortem tissue of Parkinson’s disease 
patients. The structure we focused on is currently being 
considered as a target for functional neurosurgery.
We found the area of tissue that we had sampled based on 
neuroanatomical atlases was incongruent with the tissue 
structures we were expecting to see. Moving forward, 
we plan to sample the post-mortem tissue in a slightly 
different location, where we suspect our structure of 
interest will be present.
The skills I have gained include writing and presenting 
my research coherently, effectively critiquing data to be 
presented and, most importantly, understanding research 
methods. These enable me to potentially solve the clinical 
problems I come across. I believe this strong foundation will 
stand me well in future research and clinical roles.
Sayinthen staining sections of brain tissue 
at Charing Cross Hospital
The role of hypoxia on 
neuroblastoma cell 
migration and invasion
Michael John Rice
Medical School:  The University of Liverpool
Location of research:  University of Liverpool Centre for Cell Imaging and  
  Alder Hey Children’s Hospital
During my intercalation year I used a bursary from the 
College to undertake a Master’s degree at the University 
of Liverpool Centre for Cell Imaging in partnership 
with Alder Hey Children’s Hospital. Working under the 
guidance of Professor Paul Losty, Violaine Sée and Diana 
Moss, I investigated the effects of oxygen starvation on the 
vicious children’s cancer neuroblastoma (NBL).
NBL is a common, highly lethal tumour with poor 
survival. Current management includes tumour biopsy, 
chemotherapy, surgery, radiotherapy and bone marrow 
transplantation. Previous research has shown oxygen 
deprivation is linked to the formation of more aggressive 
tumours, which can evade treatments and result in 
increased 
mortality.
Our 
research has 
confirmed: 
the chick 
embryo is 
a suitable 
model for 
the study of 
NBL, oxygen 
starvation 
results in 
increased 
tumour 
proliferation and metastasis of NBL, and exposure to 
hypoxia results in long-term changes on the cellular level. 
Using this work we hope to identify therapeutic targets 
associated with oxygen starvation in order to develop novel 
treatments that improve prognosis.
Lab team outside University of Liverpool (Back L–R Rosalie 
Richards, Michael Rice, Marco Marcello) (Front L–R Carol Fan, 
Violaine Sée, Anne Herrmann, Amelie Schober, Sarah Taylor)
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Can you ma
ke 
We need to develop our 
surgeons through training 
and research opportunities so 
that they excel and fulfill their 
potential and provide the highest 
standards of patient care. 
To provide these opportunities the College relies almost 
exclusively on legacies, gifts and donations.
Legacies do not need to be huge sums of money to make a 
difference. A gift, whatever the amount, will help us continue 
to advance surgical standards by developing and delivering 
world-leading training and research programmes.  
To ensure that our surgeons can meet the challenges of the 
future please consider supporting the College.  
For more information or an 
informal chat about a legacy to 
the College, please contact us 
at fundraising@rcseng.ac.uk 
or call 020 7869 6086. 
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ELECTIVE
PRIZE 
REPORTS
Clare Connelly 92
James Glasbey 92
Andrew Jenkinson 93
Rosalind Marshall 93
Clare Stephanie Halcro Morgan 94
Niovi Papalexopoulou 94
Cissy Sze Sze Yong 95
The Elective Prize in Surgery is awarded 
to clinical students at a UK medical school 
wishing to pursue a career in surgery 
and planning to undertake their elective 
attachment in surgery in the developing 
world. Each award is worth up to £500.
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Paediatric 
orthopaedics elective 
in Cape Town
PRIESKEL PRIZE WINNER
Clare Connelly
Medical School:  The University of Edinburgh
Site of work:  Red Cross War Memorial Children’s Hospital and  
 Maitland Cottage Home Hospital, Cape Town, 
 South Africa
The exposure both 
to trauma and 
elective paediatric 
surgery that I 
gained during my 
time in Cape Town 
was incredible. I 
was able to play an 
active role both in 
clinic and in theatre 
and my knowledge 
and skills improved 
exponentially. The 
team were incredible 
and extremely 
welcoming. The 
patients were so inspiring in the way they overcame their 
disabilities, and often numerous operations with lengthy 
hospital stays, with good humour and positive attitudes. 
From my time in Cape Town I have gained understanding 
of orthopaedics in a different culture and have renewed and 
increased my enthusiasm for the specialty.
A general surgical 
elective in a high-
volume, resource-
limited setting
PRIESKEL PRIZE WINNER
James Glasbey
Medical School:  Cardiff University School of Medicine
Site of work:   Chris Hani Baragwanath Academic Hospital, Soweto,  
  South Africa
I conducted my elective period 
working in the general surgery 
and trauma departments.
Working on a busy admissions 
unit I was able to develop 
confidence in the management 
of acutely unwell surgical patients 
and procedural skills under 
the tutelage of my surgical 
trainers. While in South Africa, 
I undertook feasibility testing 
of the GlobalSurg protocol 
(globalsurg.org) and developed 
regional networks to deliver data 
collection in Autumn 2014.
An elective at this centre, with its unique blend of world-
leading clinical practice and resource-limited facilities, would 
come highly recommended to all general surgical enthusiasts 
with an interest in global health.
James acting as primary operator 
for a lipoma excision as part 
of a weekly day-case list
Morning song on the trauma ward after a busy night’s intake
Clare with the team from the Red Cross
Clare assisting in theatre
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Facial reconstructive 
surgery in Ethiopia
PRIESKEL PRIZE WINNER
Andrew Jenkinson
Medical School:  Cardiff University
Site of work:   Yekatit 12 hospital, Addis Ababa, Ethiopia
I spent my elective period with a charity called Project 
Harar, who provide facial surgery for some of the poorest 
people in Ethiopia.
One of my roles was to see new referrals and prepare them 
for assessment by the surgical team. With limited resources 
and a remarkable mix of pathology, making a diagnosis was 
a hugely rewarding 
challenge. The 
cases ranged from 
Hyena bites to 
Noma, a gangrene 
which eats the 
facial tissues of the 
malnourished.
Caring for such a 
wonderful group 
of people was 
an inspirational 
experience, which I 
hope will stay with 
me throughout my 
career.
Plastic and 
reconstructive 
surgery in Borneo
Rosalind Marshall
Medical School:  Imperial College London
Site of work:   Kuching General Hospital, Sarawak, Malaysia
My elective experience in the Plastic and Reconstructive 
Surgery Department at Kuching General Hospital was 
absolutely fantastic. Serving the whole of Sarawak, the 
department gets referrals from all over the state, and cases 
ranged from reconstruction after hunting accidents to burns. 
I had many opportunities to scrub in and assist in surgery, 
and learnt how to harvest, prepare and apply split-skin grafts. 
I was also able to go on an outreach clinic with a charity, 
giving GP services to villages and longhouses deep in the 
Borneo rainforest. I thoroughly recommend this elective for 
anyone considering a career in plastic surgery.
Andrew with a patient who had his nose reconstructed following a hyena bite
A typical rural Ethiopian household 
living near my accommodation
Rosalind (far left) assisting in theatre with John Ranjit (second from right)
Rosalind (far right) with John Ranjit (second from right) and 
the rest of the team in the operating department
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Paediatric 
Orthopaedics in Malawi
Clare Stephanie Halcro Morgan
Medical School:  University of Aberdeen
Site of work:  Beit-CURE international Hospital, Blantyre, Malawi
I was made to feel part of the team at Beit-CURE and 
thoroughly enjoyed my stay. The hospital’s paediatric 
operations are funded using private patient income, so I 
saw an interesting cross-section of adult as well as paediatric 
cases. Assisting in theatre under careful supervision, 
allowed me to improve my basic surgical skills and my time 
in paediatric outpatient clinics was a great opportunity 
to experience working within a different culture. The 
challenges Malawian children with physical disabilities can 
face was highlighted to me during the study I was involved in. 
I am now keen to undertake further voluntary work.
Paediatric Surgery 
and Orthopaedics in 
Cape Town
Niovi Papalexopoulou
Medical School:  King’s College London Medical School
Site of work:   Red Cross Children’s Hospital/Maitland Cottage  
  Home, Cape Town, South Africa
My elective was in paediatric 
surgery and orthopaedics in 
Cape Town. I wished to compare 
the practice of surgery in the 
developing world and the UK. 
In general surgery I assisted 
in theatre and participated in 
patient management in the ward. 
In burns theatres I witnessed 
the massive impact on children’s 
health from unsafe housing in 
townships. During orthopaedics 
I appreciated the skill of knowing 
when to and when not to operate 
in order to improve function. 
It was a fantastic learning 
opportunity that allowed me to 
experience the dichotomy of 
South African society and how it 
reflects in healthcare.
Helping fit a child with a spica cast 
following surgical correction of 
developmental dysplasia of the hip
Hungry elective students waiting for a South African braai at Mzoli’s in the 
township of Gugulethu after a spinal defects clinic at a local school
Clare scrubbed up to assist with an 
operation to correct a club foot, a 
common part of the hospital’s workload
Clare with some of the surgical team
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An evaluation of secondary alveolar bone 
grafts in  patients with cleft lip and palate
PKK PRIZE WINNER
Cissy Sze Sze Yong
Medical School:  UCL Medical School
Site of work:   St John’s Medical College, Bangalore, India
This elective has afforded me invaluable 
experience in academic surgery in a 
developing country. Participating in ward 
rounds, assisting in theatre and attending 
night shifts have enabled unparalleled 
hands-on experience that will greatly 
enhance my development as an aspiring 
future surgeon. My research with the 
plastic surgery department enabled a better 
understanding of the clinical condition, 
the current literature and development of 
research skills, such as using software tools 
to facilitate and expedite data collection. 
Participating in this project serves as 
a reminder of the crucial importance 
research has in ensuring that optimal 
patient care is delivered at all times.
Cissy (second left) with some local village children
Cissy (left) with some local student nurses at St John’s hospital Cissy (left) taking a history from a patient with a corrected cleft lip and palate
LEctures Delivered in 2013-2014
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Hunterian, Arris & Gale, Arnott, Zachary Cope, Joseph Toynbee and  
Lionel Colledge Memorial Lectures
Hunterian Mr Daniel Carradice, Venous Forum at RSM, 25 April 2013
Lower limb venous insufficiency - assessing associated quality of life impairment and effectiveness of intervention
The Lionel Colledge
Memorial Lecture
Arnott Vikas Khanduja, British Orthopaedic Association (BOA), Birmingham, 3 October 2013
Arthroscopic Anatomy of the Hip Joint
Joseph Toynbee 
Memorial Lecture
Hunterian Mr Matthew Bown, Circulation Foundation, Manchester, 29 November 2013
Genomic insights into abdominal aortic aneurysms
Zachary Cope Memorial Lecture Professor Derek Alderson, SARS Annual Meeting, Cambridge, 9th January 2014 
How to get your work published
Arris & Gale Professor Michael Nicholson, British Thoracic Society (BTS) Annual Congress, Glasgow, 26 February 2014
Renal Transplantation after Ex-Vivo normothermic perfusion
Hunterian Mr Stuart Smith, The Society of British Neurological Surgeons (SBNS), London, 26 March 2014
Into the third dimension: surgically targeting blood vessel development in aggressive brain tumours
Hunterian Mr David James Dunaway, European Society of Plastic, Reconstructive and Aesthetic Surgery (ESPRAS), Edinburgh, 8 July 2014 
3D modelling and the craniofacial surgeon; how geometric morphometrics in the assessment of deformity aids reconstruction for 
both congenital and acquired abnormalities
Hunterian Mr Erlick Abilio Coelho Pereira, Society of British Neurological Surgeons (SBNS), Warwickshire, 17 September 2014 
Mapping dorsal to ventral streams and somatotopy in midbrain periaqueductal grey
Hunterian Mr Imran Ahmad, Société Internationale d’Urologie (SIU), 4 October 2014
The role of WNT signalling in urothelial cell carcinoma
Hunterian Professor Paul John Finan, Yorkshire Chapter meeting of the Association of Coloproctology and the Leeds Regional Surgical Club, 
St James Hospital Campus, 17 October 2014
Transferring the lessons of personal audit in colorectal cancer to the national arena – an ongoing challenge!
Professor Richard T Ramsden, The Royal Society of Medicine, 1 November 2013 
Consent – can it ever be truly informed?
Mr Dipan Mistry, ENT UK, 13 September 2013
My Year in the Ear in Halifax, Nova Scotia
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Fundraising in Focus
Funding Partnerships:
» Association of Coloproctology of 
Great Britain & Ireland
» Association of Upper 
Gastrointestinal Surgeons of Great 
Britain & Ireland
» Arthritis Research Trust 
» British Association of Plastic 
Reconstructive & Aesthetic 
Surgeons
» British Association of Endocrine & 
Thyroid Surgeons
» British Society of Surgery of the 
Hand
» Ballinger Charitable Trust 
» Cancer Research UK
» Cardy Beaver Foundation
» Dunhill Medical Trust
» Edwin George Robinson Charitable 
Trust
» Enid Linder Foundation
» Facial Surgery Research Foundation 
(Saving Faces)
» Family of the late Mr Stefan Galeski
» Frances & Augustus Newman 
Foundation
» Fullbright Commission
» George Drexler Foundation
» Golden Bottle Trust
» Freemasons’ Fund for Surgical 
Research
» Henry Lumley Charitable Trust
» Lord Leonard and Lady Estelle 
Wolfson Foundation
» Mary Kinross Charitable Trust
» Oakdale Trust
» Orthopaedic Research UK
» Philip King Charitable Settlement
» Rosetrees Charitable Trust
» Royal Arch Masonry
» Shears Foundation 
» Wyndham Charitable Trust
» W D Macpherson Trust
Endowments, restricted and 
legacy funds: 
» Anderson Reid Fund
» Barlow Research Fellowship
» Bernhard Baron Fund
» Blond McIndoe Fund
» Buckston Browne Gift
» Burghard Bequest
» Carol Rummey Legacy
» Cicely Fay Simpson Legacy 
» Dennis F Clark Legacy
» Doris K King Legacy
» Dr Shapurji H Modi Memorial ENT 
Research Fund
» Edward Lumley Fund
» Eleanor M Heslop Legacy
» Gwendoline Shrimpton Legacy
» Harold Bridges Bequest
» Harry S Morton Fund
» John L Williams Legacy
» Laming Evans Research Fund
» Lea Thomas Fund
» Lillian May Coleman Legacy
» Osman Hill Collection & Research
» Parks Visitorship
» Patricia Constance Curry Legacy
» Philip & Lydia Cutner Legacies
» Shirley M Kanaar Legacy
» Sir Arthur Sims Fund
» Sorab (Soli) Jamshed Lam Legacy
» Tudor Edwards Fellowship
» Vandervell Research Fund
Joint Fellowships:
» British Association of Endocrine and 
Thyroid Surgeons (BAETS)
» British Association of Paediatric 
Surgeons (BAPS)
» British Association of Plastic, 
Reconstructive and Aesthetic 
Surgeons (BAPRAS)
» British Association of Surgical 
Oncology (BASO)
» British Society for Surgery of the 
Hand (BSSH)
» Get-A-Head Charitable Trust
» Prostate Cancer UK
Research at the College relies exclusively on voluntary income that has been gifted through donations, legacies and grants. 
We need your help if this work is to continue and flourish. Future innovations in surgery will continue to be driven by re-
search and surgical research continues to provide significant advances in a wide range of areas including:
Currently we are unable to support 80% of those applying for research grants due to lack of funds. If you would like to make a donation 
or discuss a legacy, please contact the College’s Development Office on 0207 869 6086, or by email at fundraising@rcseng.ac.uk
Grants are not restricted to research fellowships and we are delighted to discuss opportunities to encourage and develop the potential 
of young surgeons through education, training and research by way of travel and educational grants or annual prizes and awards. 
 » cancer survival rates
 » less invasive surgery and quicker recovery
 » joint replacements
 » transplantation
 » prevention of strokes
 » surgery for trauma and war-wounded victims
 » operations to improve hearing and sight.
Make a donation or leave a legacy to Surgical Research
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Teaching surgical skills in Algeria, Sri Lanka and Tooting!
1. Research fellows Hew Torrance and Kathryn Gash teaching suturing at the University of Algiers
2. Miss Sue Hill in Bechar with local medical students at the opening of the first medical 
school in south west Sahara
3. Andrew Cowie with trainee in Anuradhapura workshop in Sri Lanka
4. Oliver Old teaching vein patches in Anuradhapura, Sri Lanka
5. Andrew Beamish teaching surgical skills to 6th formers at Graveney School, Tooting
6. Miss Sue Hill & the British Ambassador talking to Algerian trainees in Algiers
7. Sreelakshmi Mallappa, Oliver Old & Andrew Cowie on a ward round in Kandy Hospital, Sri Lanka
8. The skills workshop in Oran, Algeria
9. Sreelakshmi Mallappa teaching surgical skills in Kandy, Sri Lanka 
The research fellow selection process
10. Professor Rob Sayers questioning Bynvant Sandhu at poster vivas
11. The interview panel for military research fellows at the RCS
12. Dr John Williams of the Wellcome Trust in discussions with Professor Martin Birchall at the 
Academic & Research Committee meeting
13. Professor Jim McEwen, Professor Gus McGrowther & Professor Rob Sayers  interviewing 
candidates for the five joint RCS/Dunhill Medical Trust research fellowships
14. Lord Cadogan talking to research fellows Michelle Griffin, Tim Jones and Liza Osagie at 
the Freemasons’ HQ
15. Clare Marx with Professor Sir Norman Williams on the day of her election to President 
SARS Cambridge 2014 and Durham 2015
16. Professor Alun Davies & Professor Dion Morton at SARS, Cambridge
17. Olga Tucker, Matthew Bedford & Professor Derek Alderson at SARS, Cambridge
18. Derek Alderson & Charlie Knowles at SARS in Durham
19. RCS/Fulbright scholar Marc Bullock & Derek Alderson at SARS, Durham
20. Professor Andrew Bradley at the Academy of Medical Sciences stand at SARS, Durham
21. Patricia Hagan, Anne Bishop & Professor Howard Kynaston of BAUS at SARS, Cambridge
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